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Abstract 
Dupuytren’s Disease (DD) is a benign and heritable connective tissue fibrosis that affects 
the palmar fascia and typically results in permanent finger contracture(s). Similar to other 
fibroses, DD is characterized by increased fibroblast proliferation, myofibroblast 
differentiation and excess collagen deposition. Currently, there are no truly effective 
treatment options for connective tissue fibroses. 
Increased levels of β-catenin, an intracellular trans-regulator of gene transcription, have 
been previously reported in DD. Genes that are associated with, and therefore potentially 
transcriptionally regulated by, β-catenin during DD development were identified in this 
thesis. One of these gene targets, IGFBP6, was shown to consistently be associated with 
β-catenin in fibroblasts derived from phenotypically normal palmar fascia (PF cells) but 
not fibroblasts derived from diseased tissues (DD cells). β-catenin association with the 
IGFBP6 promoter in these cells was directly correlated with IGFBP6 expression levels 
and with the secretion of its protein product, Insulin-like Growth Factor Binding Protein-
6 (IGFBP-6). In addition, 1438 unique genes were shown to associate with β-catenin in 
DD cells but not PF cells derived from the same patients. 
The functional consequences of IGFBP-6 repression, and the increased availability of its 
primary ligand, IGF-II were also elucidated. Exogenous addition of IGFBP-6 attenuated 
the proliferation of DD and control fibroblasts, and inhibited IGF-II induced contraction 
of DD cells. IGF-II stimulated the proliferation of normal fibroblasts but not fibroblasts 
derived from patients with DD. The gene encoding IGF-II, IGF2, was found to be up 
regulated in DD cells, and potential mechanisms facilitating IGF2 overexpression were 
investigated.  Loss of imprinted expression of IGF2 was detected in a subset of patients 
and a corresponding loss of H19 expression, a non-coding RNA that is reciprocally 
expressed relative to IGF2, was observed. Aberrant IGF2 promoter usage was also 
identified in a subset of DD and PF cells. In combination, these disease-associated 
changes may explain the increased IGF2 expression in DD.  Identification of novel gene 
targets of β-catenin and the factors that regulate the expression of IGFBP6 or IGF2 
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during the development of this debilitating fibrosis may allow us to identify novel 
therapeutic targets. 
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Chapter 1  
1 General Introduction 
1.1 Connective Tissue 
The tissues of the human body can be divided into the four broad categories of nervous, 
epithelial, muscle, and connective tissues [1,2]. Of these, connective tissues are the most 
abundant and widely distributed, and they have essential structural and supportive 
functions to hold and connect the other tissues of the body together.  Connective tissue 
itself can be subdivided into the four main classes of blood, bone, cartilage and 
connective tissue proper [2,3], the latter encompassing loose (e.g. adipose, areolar, 
reticular) and dense (e.g. regular, irregular and elastic) tissues [2].  
Many connective tissues can be envisaged as relatively small numbers of cells embedded 
in a “sea” of extracellular matrix (ECM). While the constituents of the ECM vary 
considerably between the different classes, most consist of various fibres and components 
of “ground substance”, such as proteoglycans and hyaluronic acid, that allow these 
tissues to maintain a high water content [2]. The fibres secreted by connective tissue cells 
include collagens, reticular and elastic fibres [1–3]. While many different cell types make 
up the different classes of connective tissue, connective tissue proper is primarily 
populated by fibroblasts [3]. This poorly characterized and heterogeneous group of 
pleomorphic cells are of mesenchymal origin [3,4] and play central roles in secreting the 
ground substance, fibres and many other molecules that make up the ECM of these 
tissues  [2,3,5].  
1.2 Fibrosis 
The term “fibrosis” refers to a disease state of connective or other tissues that is 
characterized by abnormal remodelling of the ECM, which results in thickening and 
hardening of tissues [6]. Major organ fibroses, such as those of the kidney [7], liver [8], 
lungs [9,10], and heart [11] can result in catastrophic organ failure and death. Fibrosis has 
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a significant etiological role in nearly 45% of deaths in the Western world that are the 
result of loss of major organ function [12]. 
While the majority of connective tissue fibroses are not life threatening, they often cause 
long term and debilitating loss of function of the affected area(s) and decreased quality of 
life [13,14]. Fibroses can have variable etiologies and characteristics that are dependent 
on the affected tissues, however many similarities between different fibroses exist at the 
basic cellular and molecular levels.  These similarities include increased Transforming 
Growth Factor (TGF)-β1 signalling, excessive fibroproliferation, collagen deposition into 
the ECM, and the formation and persistence of contractile myofibroblasts that contract 
and remodel the ECM to increase tissue density [6,15–19].  
The primary effector cell type in virtually all fibroses is the myofibroblast [17,20–22]. 
This cell type was initially characterized in granulation tissue as an “activated” 
contractile form of dermal fibroblast that expresses α-smooth muscle actin (α-SMA) 
within stress fibres [17,23–25]. Stress fibres allow myofibroblasts to generate the 
contractile forces required to induce wound closure and tissue contraction [23]. These 
fibroblasts can be resident in, or derived from tissues adjacent to, any tissue undergoing 
fibrosis and their differentiation into myofibroblasts is central to fibrosis development 
[20]. The conversion from fibroblast to myofibroblast can be initiated by changes in 
mechanical tension, various growth factors such as TGF-β1, or a combination of these 
factors [23–25]. Generally, highly proliferative fibroblasts do not express α-SMA or have 
abundant stress fibres, whereas myofibroblasts invariably display α-SMA positive stress 
fibres and often display a reduced proliferative potential [26]. There is an intermediate 
form between the fibroblast and myofibroblast, the “protomyofibroblast”, that is thought 
to retain the enhanced proliferative potential of a fibroblast, express cytoplasmic β and γ, 
but not α-smooth muscle, actins in their stress fibres, and can generate an intermediate 
level of contractile force on the ECM [27,28]. However, fully differentiated  
myofibroblasts are the major source of the excessive collagen deposition,  ECM 
contraction and remodelling that are causal for the development of the dense collagenous 
tissue that characterizes fibroses [27]. Under non-pathological circumstances, 
myofibroblasts undergo apoptosis once wound contraction has been achieved. In fibroses,  
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hyper-contractile, collagen-depositing myofibroblasts can persist for months or years 
[29], and can continually activate ECM-associated latent TGF-β1 through a tension-
dependent mechanism [30].  As TGF-β1 signalling can inhibit myofibroblast apoptosis 
[31], these factors can act in combination to promote further fibrosis development. 
1.3 TGF-β1 activation and signalling 
TGF-β1 signalling is considered to be central to the development of virtually all fibroses 
[20] as it can induce the production of α-SMA-containing stress fibres and enhanced 
cellular contractility of myofibroblasts [23,32,33]. This cytokine is synthesized in an 
inactive (latent) form and must first be activated to signal through its cognate receptors 
[34,35]. Disulfide-linked dimers of Latency Associated Peptide (LAP) and TGF-β1 
associate non-covalently to form the small latent complex, and if Latent TGF-β Binding 
Protein (LTBP) is present in the ECM, it covalently binds LAP through two disulfide 
bonds to form the large latent complex [34]. Active TGF-β1 can be released from this 
complex by the actions of proteases [36] and, in the context of myofibroblast contraction, 
increased tension or tissue stiffness through integrin binding to ECM-associated LAP 
[30]. 
Once TGF-β1 has been released from the small- or large latent complex, it can transduce 
signals from the ECM. TGF-β1 signals through two membrane associated receptors, 
TGF-β Receptors I and II, to activate canonical SMAD (Sma/MAD) signalling [37,38].  
The receptor-associated SMADs, SMAD2 and 3, are phosphorylated by receptor 
activation and form a complex with SMAD4, allowing SMAD2 and SMAD3 to enter the 
nucleus and elicit effects on the transcription of target genes that feature SMAD binding 
elements, or they can interact with other transcription factors and trans-regulate gene 
expression [37–40]. TGF-β1 can also initiate many parallel downstream pathways which 
are not dependent on SMAD phosphorylation, such as the MAP kinase pathway [41].  
1.4 Other pathways that cross-talk with TGF-β1 
TGF-β1 signalling can induce diverse and, in some cell types, mutually exclusive 
outcomes that include fibroblast proliferation and myofibroblast differentiation. For 
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example, combined epidermal growth factor and TGF-β1 signalling can induce normal, 
quiescent murine fibroblasts to proliferate faster than either factor in isolation, while 
Insulin-like Growth Factor (IGF)-II and TGF-β1 signalling can induce the same 
fibroblast cell line to become non-proliferative and take on features of contractile 
myofibroblasts [42]. Both TGF-β1 and IGF signalling can induce β-catenin accumulation 
in cells, and this intracellular signalling molecule can induce fibroblast proliferation or 
migration [43–47]. As increased myofibroblast differentiation and fibroblast proliferation 
are characteristics of all fibroses, and TGF-β1 signalling can have direct or indirect roles 
in promoting these effects, many groups have attempted to target this cytokine to prevent 
fibrosis development [11,48,49]. Unfortunately, TGF-β1 has integral and essential roles 
in normal wound healing and the inflammatory response [50–52], which greatly 
complicates its usefulness for therapeutic interventions. More recently, researchers have 
opted for identifying and targeting molecules that are downstream of TGF-β1 signalling 
or activate parallel signalling pathways that cross-talk with TGF-β1 signalling, to 
promote pathological rather than normal tissue repair [53]. Further insights into the 
molecular mechanisms that drive fibrosis development are required in order to identify 
optimal targets for these approaches. 
1.5 Dupuytren’s Disease 
Our laboratory has focused on identifying these targets in Dupuytren’s Disease (DD). DD 
is a fibrosis of the palmar fascia, which is a thin layer of connective tissue below the skin 
in the palm of the hand. Like virtually all fibroses [15,21,54,55], DD is characterized by 
increased TGF-β1 signalling, fibroblast proliferation, myofibroblast differentiation and 
excess collagen deposition [56–59].  Patients with DD usually present to the clinic with 
permanent and irreversible finger contractures [60–62]. Clinically, this disease is initially 
evident as a nodule in the palm of the hand [63] consisting of proliferating myofibroblasts 
[64] (Figure 1-1). Over time, nodules can progress to the involutional phase of DD where 
a collagenous and contractile disease cord forms along the palmar fascia. This process is 
associated with an increase in  myofibroblasts that impose significant contractile forces 
on the palmar fascia [23] and induce permanent contracture of the associated finger(s). 
Once finger contracture has occurred, the disease typically enters the final residual phase  
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Figure 1-1: Clinical presentation of Dupuytren’s Disease. 
In the proliferative stage of DD, a nodule is formed in the palm (Stage A), which then 
progresses to a collagenous disease cord in the involutional stage (Stage B). Finally, in 
the residual phase of disease (Stage C), the cord tightens which results in permanent 
contracture of the affected finger(s) and onset of the residual phase. (Reprinted with 
permission from Rehman et al. [178]) 
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[64] where the contractile cord becomes a heterogeneous structure with regions of 
acellular tissue, which are very collagenous, interspersed with cell-rich nodules, referred 
to as the “nodule-cord unit” [64]. The abundance of apoptosis-resistant myofibroblasts in 
nodules and disease cords is considered both a distinguishing feature and functionally 
important component of DD development [65,66], and new therapeutic treatment 
strategies are aimed at inhibiting the proliferation and differentiation of myofibroblasts 
and/or inducing their apoptosis.  
DD is also known as Dupuytren’s Contracture or palmar fibromatosis, and is the most 
common inherited connective tissue disorder of Caucasian males over 60 years of age 
[67,68]. In Europe, DD prevalence can be as high as 20% over a broader age range 
[67,69], while in Western countries, the prevalence of the disease increases with age and 
has been estimated to be approximately 15% at 60 years of age and up to 30% at 75 years 
[70]. The incidence of DD in the general US population was estimated to be 3 new 
diagnosed cases per 10, 000 in 2007 [71]. While males and females have similar global 
disease prevalence up to age 45, thereafter males are afflicted 3 to 4 times more often 
than females [72]. Almost 40% of patients with DD report that a family member is also 
affected, suggesting a strong genetic predisposition to its development [73,74]. 
Despite being first described in 1831 by Guillaume Dupuytren, more than 150 years later 
the etiology of DD remains poorly understood and a cure remains elusive. Both genetic 
and environmental factors have a role in determining susceptibility to this disease, as 
evidenced by the occurrence of both familial and apparently sporadic cases [73,75,76]. 
Risk factors for DD have been described, including manual labour, trauma, smoking, 
alcohol, diabetes and epilepsy [74,77–80]. While the conclusions drawn from many of 
these studies are controversial, the association with diabetes appears to hold true [77], as 
the prevalence of DD can be as high as 40% when assessed within a diabetic population 
[81,82]. The Dupuytren’s “diathesis” i.e. the list of characteristics that identify an 
individual as likely to develop DD, includes palmar bilateral lesions, positive family 
history, lesions over the knuckle (Garrod’s pads), Caucasian ethnicity, male gender, and 
age at onset of less than 50 years. These factors predict the risk of DD recurrence after 
treatment to be more than 70% if the individual satisfies all of these criteria [74]. The 
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genetic basis of the Dupuytren’s diathesis remains unclear, and there is an obvious need 
to identify the genetic links in DD in order to develop effective treatment strategies for 
these patients. 
1.6 Treatments for DD 
Surgical resection of the disease cord is the current  “gold standard” treatment option for 
DD patients [71,83], despite this approach resulting in disease recurrence in at least one 
of every three patients [74,84,85]. This unsatisfactory outcome occurs despite extensive 
and expensive [86] post-operative rehabilitation that negatively impacts patient quality of 
life [13]. For some patients, continual recurrence of finger contractures after surgeries 
leads them to consider amputation as a final option to eliminate the risk of relapse [87]. 
Alternative non-surgical interventions have been gaining popularity in recent years, 
however these treatments are associated with disease recurrence rates of 50% or higher 
[88–90]. These treatments include needle aponeurotomy, where a needle is used to 
manually sever and dissect the cord within the hand, and injections of Clostridial 
collagenase, an enzyme that breaks down the type I and type III collagen in the cord 
[88,91]. In the context of the high disease recurrence rates, there are currently no truly 
effective treatment options for DD [92]. A detailed understanding of the molecular 
processes that regulate fibroblast proliferation and their subsequent differentiation into 
myofibroblasts, as well as the genetic basis of DD, is required to design rational and more 
effective molecular therapies.   
1.7 Genetics of DD 
The increased incidence of DD in the Northern European population and the disease 
heritability within families strongly implicates a genetic component to Dupuytren’s 
Disease [72,73].  This concept has gained considerable support following a recent study 
demonstrating that one twin in a monozygotic male pair is 37% more likely to be affected 
by DD if the other has this disease versus just 7% in fraternal male twins [93]. 
Inheritance of DD is suggested to follow an autosomal dominant inheritance pattern with 
variable penetrance [94] and, while numerous studies have sought to identify the 
specifics of these genetic links, relatively few insights have been achieved. Chromosome 
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instability was suggested to be part of the genetic susceptibility for DD [95] and 
comparative genomic hybridization studies were completed to assess the possibilities of 
gene copy number variations, however subsequent findings did not support this 
hypothesis [96]. Another study reported DNA copy number variations in chromosome 6 
near the HLA locus, and chromosome 7 and 14 near the T-cell receptors - γ  and -α, 
respectively, but the sample size was limited in both studies [97,98] and the general 
applicability of the findings are unclear. There has been one genetic linkage study 
performed thus far in a Swedish family which identified an association in 16q [94], but 
these results are yet to be confirmed. A genome wide association study performed on 
European DD patients identified 11 associated single nucleotide polymorphisms (SNPs),  
6 of which were located near or within Wnt-related genes [99]. However the effects of 
these SNPs on Wnt regulation have not been reported, nor have consistent changes in the 
expression of these Wnt genes been detected in some expression analyses of DD cells 
[100]. Dysregulated Wnt gene expression was implicated in an exon array study that 
compared fibroblasts derived from DD palmar fascia from mostly male patients to 
fibroblasts derived from the thigh of female patients unaffected by DD [101].  However, 
most of the dysregulated genes that are consistently identified in previous microarray 
analyses of DD cells and tissues [98,102–104] were not identified in this exon array 
analysis, making it difficult to interpret these results. In summary, while some of the most 
recent genetic and transcriptional analyses are consistent in identifying genes that encode 
Wnts and/or molecules associated with Wnt signalling as potential contributors to DD 
development, their contributions remain controversial and very poorly understood. 
1.8 Molecular mechanisms of DD development 
TGF-β1 signalling is increased in DD and has been shown to induce myofibroblast 
differentiation [58,105] and fibroproliferation [106] of fibroblasts derived from fibrotic 
DD tissues (DD cells). As described in 1.4, the concurrent activation of parallel signalling 
pathways can direct TGF-β1 signalling intermediates to induce either of these outcomes 
in other systems [42]. The Wnt/β-catenin signalling pathway implicated in recent genetic 
and transcriptional analyses of DD tissues and cells is one of these parallel signalling 
pathways, and cross-talk with TGF-β1 signalling has been shown to elicit effects on 
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proliferation and myofibroblast differentiation in other systems [45,107]. Total cellular β-
catenin levels are increased in fibrotic DD tissues relative to the adjacent, non-fibrotic 
palmar fascia [108] and β-catenin levels in primary DD cells are sensitive to fibrosis-
associated changes in ECM tension in vitro [44]. These findings suggest that a detailed 
understanding of interactions between the TGF-β1 and Wnt/β-catenin signalling 
pathways may provide valuable insights into the molecular mechanisms of DD 
development.  
1.9 β-catenin 
β-catenin is best recognized as a 90 kDa [109] protein intermediate in the canonical Wnt 
signalling pathway that has important and mutually exclusive cell signalling and 
structural roles [110,111]. Structurally, β-catenin is essential for adherens junction 
formation, where it can interact with γ-, α-catenins and E-cadherin to promote the cell-to-
cell contacts [112,113] required during embryonic differentiation [110]. In addition, 
nuclear localization of β-catenin can induce interactions with T cell factor/Lymphoid 
enhancer factors (TCF/Lef) or other transcription factors to regulate gene transcription 
[114,115]. β-catenin-mediated trans-regulation of gene transcription is required for 
mesoderm formation in embryonic stem cells and in mice [110,116], illustrating its 
central roles in development. In Homo sapiens, β-catenin consists of 781 amino acids and 
can be functionally divided into the N-terminal, central and C-terminal domains [109]. 
The N-terminal domain is required for β-catenin signalling, but it is the central domain, 
which contains 12 armadillo repeats in a rigid scaffold, that is most important for β-
catenin function [109]. Many β-catenin binding partners interact with the armadillo repeat 
region in β-catenin.  E-cadherin interacts with all 12 repeats [117] and TCF/Lef interacts 
with 8 of these repeats [118], thereby precluding the simultaneous binding of both 
partners [119]. Whether the same pool of β-catenin that is involved in cell-cell contacts is 
released to trans-regulate gene transcription in the presence of Wnt signalling is 
somewhat controversial, however recent evidence in other signalling pathways is 
supportive of this concept [120,121].  
Canonical Wnt signalling (Figure 1-2) is integral to cellular proliferation and 
differentiation during embryonic development (reviewed in [122,123]). β-catenin is a key  
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Figure 1-2: Canonical Wnt Signalling Pathway. 
Stimulation of the Frizzled receptor/LRP5/6 by Wnts results in phosphorylation of 
Dishevelled (Dvl), which in turn inactivates GSK-3β. Inactivation of GSK-3β allows β-
catenin to be released from the destruction complex (which facilitates its degradation in 
the absence of Wnts in an ubiquitin-mediated mechanism) and to accumulate within the 
cytoplasm, translocate to the nucleus and transactivate the Tcf/Lef transcription 
complex. (Reprinted with permission from Bowley et al. [139])
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effector molecule in these processes under the regulation of glycogen synthase kinase 
(GSK)-3β. In the absence of a Wnt signal, GSK-3β phosphorylates β-catenin on serine 
residues 33 and 37 [124–126] and, with other  components of the “destruction complex” 
including axin, adenomatous polyposis coli (APC) and casein-kinase 1, targets phospho-
β-catenin to the E3 ubiquitin ligase complex for degradation by the 26S proteasome 
[127,128]. Wnt activation of the Frizzled receptor and its co-receptor, low density 
lipoprotein receptor-related protein (LRP5/6), facilitates binding with the cytoplasmic 
protein Dishevelled [129], phosphorylation of LRP and subsequent inactivation of GSK-
3β [130]. When the destruction complex is destabilized by the loss of axin and GSK-3β 
activity [130] in the presence of Wnts, β-catenin accumulates in the cytoplasm and 
translocates to the nucleus to regulate its target genes. Consistent with its central role in 
β-catenin signalling, GSK-3β is believed to be the major point of convergence for the 
many of the signalling pathways that cross-talk with the Wnt signalling pathway [123]. 
1.10 β-catenin-mediated transcription 
The mechanisms that regulate the nuclear translocation of β-catenin are not clearly 
understood, as it does not contain a nuclear localization signal and the signals that induce 
nuclear localization appear to vary between different cell types and systems. β-catenin 
does not bind DNA, but rather interacts with DNA binding transcription factors in order 
to elicit repressive or activating effects on transcription [109,119]. While Wnt-dependent 
β-catenin transcription is mainly transduced through TCF/Lef transcription factors, β-
catenin can also interact with SMADs or c-Jun/AP-1, or other complexes to regulate 
target genes [131–133]. Numerous β-catenin target genes have been documented, 
including c-myc [134], cyclin D1 [135], axin2 [136] and epidermal growth factor 
receptor [137]. To our knowledge, the majority of the genes that are regulated by or 
associated with β-catenin have been identified in cancer cells, and there are currently very 
few reports of β-catenin regulated genes in non-malignant cells. 
1.11 β-catenin in fibrosis and DD 
Increased β-catenin levels and signalling have been reported in many diseases [138–140], 
with or without obvious changes in Wnt signalling [43], and activation of this signalling 
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pathway is thought to contribute to disease progression by regulating cellular 
proliferation. Mutations in the gene encoding β-catenin, CTNNB1, have been reported in 
numerous cancers [141–144]. These mutations typically delete or inhibit β-catenin 
phosphorylation sites, allowing β-catenin to avoid degradation, translocate to the nucleus 
and dysregulate gene transcription. Very little is known about the identities of the genes 
that are regulated by β-catenin or the consequences of β-catenin-mediated gene 
transcription in fibrosis. One of the few β-catenin gene targets that has been identified is 
IGFBP6, encoding Insulin-like Growth Factor Binding Protein (IGFBP)-6 [145].  
IGFBP6 expression is reported to be transcriptionally downregulated by β-catenin in 
aggressive fibromatosis, and by unknown interactions in DD [145,146].  As β-catenin 
levels are increased in DD [44,108], these reports led us to hypothesize that β-catenin has 
a similar role in attenuating IGFBP6 expression in DD.  
1.12 IGFBP-6 
IGFBP6 encodes IGFBP-6, one of the six Insulin-like Growth Factor Binding Proteins 
(IGFBP-1 to -6) that bind the peptide growth factors IGF-I and IGF-II with high affinity 
[147–149]. While many IGFBPs also have IGF-independent roles [150–153], a major 
function of these proteins is to regulate the availability of the IGFs to their primary 
signalling receptor, the type I IGF receptor (IGFIR) [147]. IGFBP-6 is the only IGFBP 
which displays a 20-100X preference for IGF-II over IGF-I [154–156], making it a 
relatively specific inhibitor of IGF-II signalling. Originally isolated from cerebrospinal 
fluid, where its levels are highest [157–159], IGFBP-6 is a 23 kDa protein in its native 
state, but 28-34 kDa when O-glycosylated in vivo [157]. IGFBP-6, like the other IGFBPs, 
consists of 3 distinct N, C and L domains, however it differs from other IGFBPs in 
lacking two otherwise conserved cysteine residues in the N-domain. The N and C 
domains are highly conserved between all IGFBPs, and the N domain contains the 
primary IGF binding site. However, the strong preferential binding affinity for IGF-II by 
IGFBP-6 is conferred by its C domain [154,155], a  region that is also involved in 
binding glycosaminoglycans (GAGs) [160]. IGF-II binding affinity is decreased upon 
GAG binding due to overlap between the binding sites in the C domain. There are 5 O-
glycosylation sites within the L domain of IGFBP-6 and its glycosylation confers stability 
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and protection from proteolysis [161]. Glycosylation also increases IGF-II binding 
affinity and inhibits GAG binding, rendering IGFBP-6 a very stable IGF-II signalling 
inhibitor [160,162].  
1.13 IGFBP6 gene characterization and regulation 
The IGFBP6 gene contains four exons spanning 4.7 kb and is found on the long arm of 
chromosome 12. The gene does not contain a TATA box or CAAT motifs, however basal 
promoter activity is evident within 158 bp of the transcriptional start site [163]. The 
IGFBP6 promoter region has a high GC ratio, and its expression can be epigenetically 
downregulated by methylation of CpG islands [164]. Retinoic acid is a potent inducer of 
IGFBP6 expression and secretion [157,165]  and IGFBP6 is considered a p53 responsive, 
pro-apoptotic gene in some cell types [166]. Cyclic AMP has been shown to decrease 
IGFBP6 expression, and TGF-β [157,167], glucocorticoids, and estradiol have all been 
shown to affect IGFBP-6 secretion [157].  Other than a single report in aggressive 
fibromatosis implicating roles for β-catenin in the transcriptional downregulation of 
IGFBP6 [145], very little is known about trans-regulation of its transcription. 
1.14 IGFBP-6 in disease and fibrosis 
IGFBP-6 has well documented roles as an inhibitor of cellular proliferation in numerous 
systems and cell types [168,169]. It has also been reported to induce apoptosis through 
various mechanisms including Ku80 binding [170] and activating early growth response-
1 (EGR1) expression [168]. Additionally, IGFBP-6 has been shown to inhibit osteoblast 
and myoblast differentiation [156,171]. While most reports of IGFBP-6 actions are IGF-
II dependent, IGF independent effects in promoting cell migration [172] and inhibiting 
angiogenesis [173] have been recently reported. 
IGFBP-6 levels are dysregulated in many cancer systems [174–176] and increased in the 
cerebrospinal fluid of Alzheimer’s patients [158]. The role of IGFBP-6 in fibrosis is not 
well characterized to date. IGFBP6 mRNA has been detected in hepatic stellate cells, the 
precursors of myofibroblasts in liver fibrosis, however IGFBP-6 protein levels were 
undetectable based on an IGF-I ligand blot [177]. Aside from this study, all that appears 
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to be known about IGFBP-6 in fibrosis is that IGFBP6 expression in aggressive 
fibromatosis and Dupuytren’s Disease is suppressed [145,146]. As IGFBP-6 consistently 
inhibits cell proliferation and/or viability in other systems, downregulated IGFBP6 
expression and IGFBP-6 levels in fibroses would be predicted to enhance fibroblast 
proliferation through IGF-II dependent and/or IGF-II independent processes.  
1.15 IGF-II and the IGF2 gene 
IGF-II is a 7.5 kDa peptide consisting of 67 amino acids [178], which signals through the 
Type I IGF Receptor to elicit effects on apoptosis, proliferation, differentiation, survival, 
invasion, migration and a host of other cell behaviours in a variety of systems [179–182]. 
The IGF2 gene spans 30 kb on chromosome region 11p15, and contains 10 exons with 
the functional peptide only encoded by the last 3 exons [183]. IGF2 transcription can be 
initiated from 4 distinct promoters, all encoding the same mature IGF-II peptide [183] 
(Figure 1-3). Additionally, IGF2 is genomically imprinted and expressed only from the 
paternally-derived allele in most mammalian tissues [184]. 
While the role of IGF-II in fibrosis is poorly understood, IGF-II has been shown to 
induce collagen and fibronectin production in pulmonary fibrosis [185], and to induce 
myofibroblast differentiation in combination with TGF-β in murine fibroblasts [42]. 
Thus, increased IGF-II bioavailability would be predicted to contribute to the increased 
myofibroblast differentiation and collagen deposition established in Dupuytren’s Disease. 
The possible role(s) of IGF-II in DD have not yet been elucidated. 
1.16 Summary and rationale 
Dupuytren’s Disease is characterized by excessive TGF-β1 signalling, fibroblast 
proliferation, collagen deposition and an abundance of apoptosis-resistant myofibroblasts 
[61]. TGF-β1 signalling has been shown to increase β-catenin levels in DD [44] and to 
repress IGFBP6 expression [157,167]. Additionally, β-catenin levels are upregulated 
while IGFBP-6 levels are downregulated in DD and aggressive fibromatoses 
[108,145,146]. β-catenin is reported to repress IGFBP6 expression [145] and to enhance 
fibroblast proliferation by activating the transcription of proliferation-inducing target  
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Figure 1-3: Simplified map of the human IGF2 gene. 
The human IGF2 gene consists of 10 exons with exons 8, 9 and 10 (shown in green) 
encoding mature IGF-II. Initiation of transcription can occur from any of 4 distinct 
promoters (P1-P4), the activity of which are both developmental stage- and tissue-
specific.  
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genes [135]. Decreased IGFBP-6 levels are predicted to increase IGF-II signalling, and 
IGF-II signalling can cross-talk with TGF-β1 signalling to induce myofibroblast 
differentiation [42]. Based on these data, the central hypothesis of this thesis is that 
increased levels of endogenous TGF-β1 signalling induce β-catenin accumulation and 
signalling to repress the expression of IGFBP6 and other genes, the dysregulation of 
which, promote DD development. The resulting decrease in IGFBP-6 levels will increase 
fibroblast proliferation and/or the differentiation of myofibroblasts through IGF-II 
dependent or independent mechanisms in DD. 
1.17 Specific objectives of this thesis 
The specific objectives of this thesis were: 
1) To investigate the interactions between β-catenin, the promoter of IGFBP6 and 
IGFBP6 transcription in in vitro models of DD. These studies were subsequently 
expanded to identify all of the genes that interact with β-catenin during DD development.  
2) To determine the functional consequences of restoring IGFBP-6 to normal 
physiological levels and of increasing the levels of IGF-II, the primary ligand of IGFBP-
6, in in vitro models of DD. 
3) To elucidate the mechanisms that dysregulate the expression of IGF2, encoding IGF-
II, in in vitro models of DD.   
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Chapter 2  
2 Identification of β-catenin gene targets in Dupuytren’s 
Disease patients 
2.1 Introduction 
β-catenin is a central mediator of the canonical Wnt signalling pathway that plays 
essential roles in embryonic development [1–3] and disease progression [4–8]. In the 
absence of Wnt stimulus, β-catenin is phosphorylated by glycogen synthase kinase 
(GSK)-3β, ubiquitinated and degraded by the 26S proteasome. This process prevents 
translocation of β-catenin to the nucleus, and the activity of T cell factor/ lymphoid 
enhancer factor (TCF/Lef) transcription factors are inhibited by Groucho/TLE co-
repressors and the recruitment of histone deacetylases [9]. In the presence of Wnts, GSK-
3β is phosphorylated and inactivated, allowing β-catenin to accumulate in the cytoplasm 
and subsequently translocate to the nucleus. Nuclear β-catenin can displace Groucho/TLE 
co-repressors, interact with TCF/Lef transcription factors and recruit transcriptional 
activators to its target genes [10]. 
β-catenin levels and associated trans-regulation of gene transcription can also be 
increased by factors other than Wnts.  One of these factors is Transforming Growth 
Factor (TGF)-β [11–13], which can activate pathways that intersect with the canonical 
Wnt signalling pathway to stabilize β-catenin levels, promote its nuclear translocation, 
and elicit effects on gene transcription to enhance proliferation [13]. TGF-β-induced 
fibroblast proliferation in wound healing and fibrosis is dependent on cytoplasmic 
stabilization, accumulation and nuclear transport of β-catenin [14]. Increased β-catenin 
signalling and/or levels are reported in aggressive fibromatosis [12], Dupuytren’s Disease 
[11,15], lung, kidney and liver fibroses [6,16,17], supporting the hypothesis that β-
catenin plays a central role in the hyper-proliferation of fibroblasts that subsequently 
differentiate into myofibroblasts in these conditions. 
Dupuytren’s Disease (DD) is a benign and heritable fibrosis that is characterized by the 
formation of collagenous and contractile disease cords that result in permanent finger 
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contracture(s) [18,19]. At a cellular level, excessive TGF-β signalling and the abundance 
of apoptosis-resistant myofibroblasts are considered distinguishing features of DD, as 
they are of other fibroses [20–22].  The proliferation and differentiation of fibroblasts 
within, or in close proximity to, the tissue undergoing fibrosis is considered to be a major 
source of myofibroblasts in these conditions, and these processes are potently induced by 
TGF-β [23–25]. TGF-β has been shown to increase β-catenin accumulation in 
Dupuytren’s Disease [15]; however the transcriptional consequences of the increased β-
catenin levels are yet to be reported. TGF-β typically signals through SMADs to elicit its 
effects through the TGF-β receptors I and II. SMAD2 and 3 are phosphorylated upon 
stimulation with TGF-β, allowing their interaction with SMAD4 to facilitate the entry of 
SMADs 2 and 3 into the nucleus to regulate gene transcription. SMAD3 and β-catenin 
have been reported to act in concert to induce gene expression [26] and in chondrocytes, 
SMAD3 and SMAD4 can act to stabilize β-catenin levels to prevent its degradation and 
facilitate nuclear translocation [27]. β-catenin does not bind DNA [28,29], so it must 
interact with transcription factors to elicit its actions. In addition to TCF/Lef, β-catenin 
can interact with Forkhead box O (FOXO) transcription factors, which prevents 
transcription of β-catenin-TCF-Lef target genes [30]. TGF-β signalling can phosphorylate 
FOXO3 [31], which leads to its exclusion from the nucleus and the enhanced 
transcription of β-catenin-TCF/Lef target genes [30].  
The β-catenin target genes identified to date have mostly been reported on an individual 
basis in cancer cell lines [32–35]. These gene targets include, amongst others, c-myc, 
cyclin D1 and epidermal growth factor receptor (EGFR) [32,34,36–38]. Advances in 
bioinformatics have made it feasible to simultaneously identify all of the genes in the 
human genome that associate with β-catenin by chromatin immunoprecipitation 
sequencing analyses (ChIP Seq). This approach has been used to identify genome-wide 
β-catenin associations in two independent studies on colon cancer cells, which were 
limited to a single tumour cell line in each case [38,39]. Approximately 2 200 β-catenin 
gene targets that could be regulated by interaction with either TCF/Lef or AP-1 sites were 
identified in one study, while the other study identified ~ 2 800 gene targets potentially 
regulated by TCF/Lef only [38,39]. The relevance of these findings to benign diseases is 
currently unclear. 
34 
 
 
 
Very few β-catenin gene targets have been previously identified in any fibrosis. One of 
them is IGFBP6, encoding Insulin-like Growth Factor Binding Protein (IGFBP)-6. 
IGFBP6 expression was reported to be decreased in aggressive fibromatosis and to be 
correlated with β-catenin interactions with TCF3 [12]. Interestingly, IGFBP6 expression 
is also significantly decreased in DD, and like aggressive fibromatosis, β-catenin levels 
are increased in DD [7,12,15,40]. These findings led to the hypothesis that β-catenin 
association with the IGFBP6 promoter region is inversely correlated with its expression, 
and that IGFBP6 was one of many other genes that might be differentially regulated by 
β-catenin associations during DD development. The aim of this study was to use IGFBP6 
as a model β-catenin target gene to gain a more detailed understanding of its 
transcriptional regulation in fibroblasts derived from fibrotic DD tissues (DD cells) and 
fibroblast from normal palmar fascia (CT cells). In addition, a third category of 
fibroblasts were derived from the phenotypically unaffected palmar fascia in a digit 
adjacent to DD. These fibroblasts (PF cells) are predicted to be genetically identical to 
the DD cells derived from the same patient, and to provide a uniquely powerful set of 
controls to identify β-catenin interactions with IGFBP6 and other genes in patients that 
may be pre-disposed to DD development. Using these cells as comparators, multi-patient 
genome-wide ChIP Seq analyses were performed to identify all of the genes that are 
differentially associated with β-catenin in each group. The identification and 
characterization of the genes regulated by β-catenin is predicted to yield potential 
molecular targets to inhibit fibroblast proliferation and differentiation in DD and 
conditions with similar molecular characteristics. 
2.2 Materials and Methods 
 Derivation of primary fibroblasts 2.2.1
Small palmar fascia tissue samples were resected from patients with Dupuytren’s Disease 
(DD) and from patients undergoing carpal tunnel release (CT) during surgery at the Roth 
| McFarlane Hand and Upper Limb clinic with the approval from the University of 
Western Ontario Research Ethics Board for Health Sciences Research involving Human 
Subjects (HSREB protocol # 08222E, Appendix C). Patient de-identification and 
confidentiality were achieved by assigning numbers to these samples prior to processing. 
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All patients received a letter of information and signed consent forms for their tissues to 
be used for research purposes. Primary fibroblasts were derived from the disease cord 
(DD cells), and from phenotypically normal adjacent palmar fascia of the same DD 
patient (PF cells), as genetically matched controls. Lastly, normal CT fibroblasts were 
derived from the palmar fascia of patients undergoing carpal tunnel release, with no prior 
history of Dupuytren’s Disease (CT cells). Patient demographics for the cell lines used in 
these analyses are listed in Table 2-1.  
Table 2-1: Patient demographics for cell lines used in the ChIP and ChIP Seq 
analyses 
Patient Cell Line Gender Age Application 
1 244PF/DD M 30 ChIP, ChIP Seq 
2 271PF/DD M 58 ChIP, ChIP Seq 
3 275PF/DD M 91 ChIP, ChIP Seq 
4 276PF/DD M 45 ChIP 
5 CT24 M 66 ChIP 
6 CT25 F 44 ChIP 
7 CT26 F 35 ChIP, ChIP Seq 
8 CT27 F 48 ChIP, ChIP Seq 
9 CT30 F 59 ChIP 
10 CT31 M 78 ChIP, ChIP Seq 
 
 Chromatin Extraction 2.2.2
DD, PF and CT cells (N = 4) were grown to confluence in 15 – T175 flasks up to passage 
3 in 20 ml α-minimal essential media (α-MEM). Chromatin immunoprecipitation was 
performed using the SimpleChIP Enzymatic Chromatin IP Kit as per the manufacturer’s 
protocol and with minor optimization (Cell Signalling Technologies, Beverly, MA). 
Media was aspirated and cells were collected into a 50 ml conical tube and incubated 
with 1% formaldehyde in PBS solution for 10 min with rotation. Glycine was added to 
the solution to inactivate the formaldehyde crosslinking reaction for 5 min with rotation, 
after which it was centrifuged for 5 min at 2000 rpm (Hettich Zentrifugen Universal 32). 
The cell solution was washed twice with cold PBS for 5 min with rotation and then 
centrifuged. To lyse the membranes, cells were incubated in 10 ml Buffer A (proprietary 
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buffer included in the SimpleChIP Kit) for 10 min on ice with inversion every 3 min. The 
nuclei were pelleted at 3000rpm for 5 min at 4°C and resuspended in 10 ml Buffer B 
(proprietary buffer included in the SimpleChIP Kit) for 10 min on ice for lysis. The 
centrifugation was repeated and the pellet was then resuspended in 1 ml Buffer B prior to 
nuclease digestion and sonication.  
The samples were incubated with 10 µl Micrococcal Nuclease (2000 gel units/µl) for 20 
min at 37°C with frequent mixing to digest DNA to ~150-200 bp. The enzymatic reaction 
was halted by placing the sample on ice and adding 100 µl 0.05 M EDTA. The nuclei 
were pelleted at 13 000 rpm for 1 min at 4°C and the pellet was resuspended into 1 ml 
ChIP Buffer (proprietary buffer included in the SimpleChIP Kit) supplemented with 
protease inhibitors and phenylmethylsulfonyl fluoride (PMSF). The nuclear suspension 
was split into 2 x 500 µl samples and incubated on ice for 10 min. The crude chromatin 
extract was sonicated on ice twice per sample with the following settings: 1 sec pulse on, 
1 sec pulse off, amplitude = 30, duration = 30 sec. Lysates were centrifuged at 10 000 
rpm for 10 min at 4°C to obtain the chromatin preparation and pellets were discarded.  
A small sample from the chromatin extraction was used to confirm DNA concentration 
and fragment sizes of 150-200 bp, after the DNA was purified on the spin columns 
included with the SimpleChIP Kit as per the manufacturer’s protocol. The purified ChIP 
DNA was loaded in a 1% agarose gel to determine fragment size by electrophoresis. To 
determine DNA concentration, 1 µl of each sample was loaded onto the NanoDrop 
Spectrophotometer ND-1000 and quantified. 
 Immunoprecipitation 2.2.3
For each immunoprecipitation, 15-20 µg of chromatin was diluted into 500 µl samples in 
1X ChIP Buffer supplemented with Protease Inhibitor Cocktail. Ten µg of rabbit 
monoclonal Histone H3 antibody, 10 µg of rabbit polyclonal β-catenin antibody, 10 µg 
rabbit polyclonal SMAD2/3 antibody (all from Cell Signalling Technologies, Beverly, 
MA), 4 µg mouse monoclonal RNA Polymerase II antibody (Upstate Biotechnology, 
Etobicoke, ON Canada), and 2.5 µg rabbit or mouse IgG were added to each tube and 
rotated overnight at 4°C. Thirty µl of ChIP grade Protein G Magnetic Beads were added 
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to each sample and rotated at 4°C for 2 hours. Immunoprecipitated (IP) samples were 
washed according to the manufacturer’s protocol 3X in a low salt buffer wash, and once 
in a high salt buffer containing 5M NaCl. The supernatant was carefully removed and 1X 
ChIP Elution buffer was added to each IP sample prior to elution at 65°C for 30 minutes 
in a water bath with gentle mixing every 5 minutes. The magnetic beads were discarded 
and the supernatant was transferred to a new tube. Proteinase K and NaCl were added to 
each eluted chromatin sample and the inputs (containing no antibody) and incubated for 2 
hours at 65°C. ChIP DNA was isolated according to the manufacturer’s protocol in the 
supplied spin columns. Briefly, DNA Binding Buffer was added to each sample and 
transferred to a DNA spin column. Samples were centrifuged for 30 sec at 14 000 rpm 
and washed in DNA Wash Buffer and spun down again, discarding the liquid in the 
collection tube each time. Fifty µl of DNA Elution Buffer was added and spun at 14 000 
rpm for 30 sec. Samples were stored at -20°C until further analysis. For ChIP Seq 
analysis specifically, the DNA from 3 individual IPs were isolated in one DNA spin 
column in order to achieve enough DNA for the library preparation.  
 Real Time PCR Analysis 2.2.4
Primers were designed to amplify regions of the IGFBP6 promoter surrounding each of 
the TCF sites by real-time PCR after DNA isolation from the ChIP experiments. TCF1_F 
5’-TGCTGACAATGAGGTTCGTAT-3’ and TCF1_R 5’-
GTTATGCAACAGGGACCATC-3’ were used for the TCF1 site located at -1210 to -
1204 from the start site in the IGFBP6 promoter. For the TCF2 site, at -155 to -148, the 
following primers were used: TCF2_F 5’-CATACACACTAAGTGGATTGC-3’, and 
TCF2_R 5’-CTCCCTTTCCAGTTTCTGTT-3’. The PCR procedure employed iQ SYBR 
Green Supermix chemistry (Bio-Rad Laboratories Ltd., Mississauga, ON, Canada) and 
the following program was run:  50°C for 2 min, 95°C for 10 min, followed by 45 cycles 
of 95°C for 15 sec, and 60°C for 1 min on the Bio-Rad CFX384 Real Time System.  
 Library Preparation 2.2.5
ChIP DNA was quantified using the Qubit Fluorometer High Sensitivity DNA assay 
(Invitrogen Corporation, Carlsbad, CA). Ten ng of DNA was required for the library 
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preparation using the NEBNext ChIP-Seq Library Prep Master Mix Set for Illumina 
(New England Biolabs) and the manufacturer’s protocol was followed with size selection 
using AmpureXP Beads. Briefly, ChIP DNA was end-repaired, after which a series of 
deoxy-adenosines were added to the DNA.  Adaptors compatible with the Illumina 
platform were purchased in a NEBNext Multiplex Oligos for Illumina kit (New England 
Biolabs) and ligated to the dA-tailed DNA. This ligated DNA-adaptor was enriched by 
PCR using the following program: Initial denaturation at 98°C for 30 sec, 15 cycles of 
denaturation at 98°C for 10 sec, annealing at 65°C for 30 sec, and extension at 72°C for 
30 sec, and lastly, final extension at 72°C for 5 min. These library preparations were then 
sent to The Centre for Applied Genomics at the Sick Children’s Hospital in Toronto for 
quality control and sequencing. One patient sample did not pass quality control analyses 
on the Bioanalyzer, and thus it was excluded from the sequencing run. Thus sequencing 
was performed once on 3 different primary cell lines per group (N = 3, n = 1, CT, PF and 
DD), corresponding to 6 different patients. 
 ChIP Sequencing Analysis 2.2.6
All libraries were sequenced on the Illumina HiSeq 2500 across 3 lanes, using v3 
chemistry in a multiplex paired end protocol (2x100-bases). Base calling was performed 
with the Illumina pipeline 1.8.1. Raw sequence data files (referred to as reads) were 
merged and aligned to the hg19 human genome using a PERL script written in-house by 
Dr. Greg Gloor (See Appendix D). The aligned reads data were uploaded to the Galaxy 
Browser (http://usegalaxy.org) [41–43] where further downstream analysis was 
performed. Peaks were called using Model-based Analysis of ChIP Seq (MACS) v1.0.1 
[44] using an MFOLD enrichment factor of 5, tag size = 100, bandwidth = 150 and p < 
0.05 for forward and reverse read files separately for each sample. The intersect tool in 
the BEDtools package [45] available on Galaxy was used to retain only peaks common 
between forward and reverse datasets (ie. overlapping). From these, only those peaks that 
were common to all 3 patient samples within each group were retained as consistent -
catenin associations within the human genomes of that group. These peaks were then 
intersected with RefSeq files to determine their location within the genome. Peaks that 
fell within a gene region were mapped back to the RefSeq file using another PERL script 
39 
 
 
 
(See Appendix E) which isolated the RefSeq accession numbers from each association in 
order to obtain a gene identity using NCBI Batch Entrez.  
 Ingenuity Pathway Analysis 2.2.7
Networks, and disease and biological function associations between the genes isolated 
from the ChIP Seq analysis were generated with QIAGEN’s Ingenuity Pathway Analysis 
(IPA, QIAGEN, Redwood City, www.qiagen.com/ingenuity). P values were determined 
using a right-tailed Fisher Exact test, which calculates the probability that the observed 
gene associations to each category are due to random chance. In general, p < 0.05 
indicates a non-random association. 
2.3 Results 
 Chromatin Immunoprecipitation (ChIP) Experiments 2.3.1
Increased β-catenin and decreased IGFBP6 levels have been independently reported in 
Dupuytren’s Disease (DD) and aggressive fibromatosis [12,15,40].  Denys et al. reported 
that the downregulated expression of IGFBP6 in aggressive fibromatosis was due to β-
catenin interactions with TCF3, a member of the TCF/Lef  transcription factor family, in 
the IGFBP6 promoter [12]. To determine whether β-catenin had a role in repressing 
IGFBP6 transcription in DD, ChIP analyses were performed on untreated DD, PF and CT 
cells as described in the methods. Histone H3 and IgG antibodies were included as 
positive and negative controls, respectively, in addition to a no-antibody (input) control. 
DNA was isolated from the pull-downs and primers specific to each TCF binding site 
within the IGFBP6 promoter were used in the real-time PCR analysis. Two consensus 
TCF binding sites have been reported within the IGFBP6 promoter region; the site 
designated “TCF1” is located at -1210 to -1204bp and the “TCF2 site” is located from -
155 to -148bp from the transcriptional start site of IGFBP6 (Figure 2-1) [12]. As shown 
in Figure 2-2A, ChIP analyses revealed similar levels of β-catenin association with the 
TCF1 and TCF2 sites in the IGFBP6 promoter of PF cells; however these differences 
were not significant (p > 0.05). While β-catenin interaction at the TCF2 site was detected 
in CT and PF cells, (compared to the TCF1 site where β-catenin association with IGFBP6 
was detected only in PF cells), there were no significant differences in the levels of  
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Figure 2-1: Locations of the TCF sites in the IGFBP6 promoter region. 
There are 2 TCF sites located within the IGFBP6 promoter region as identified 
previously [12]. TCF1 is located at -1210 to -1204 and TCF2 is located at -155 to 
-148 from the ATG start site. 
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associations. β-catenin association with the TCF sites in the IGFBP6 promoter was 
variable across the 4 PF/DD patients (Figure 2-3A & B). Assessed overall, β-catenin 
association with the IGFBP6 promoter was lowest in DD cells relative to PF cells and CT 
cells, directly correlating with IGFBP6 expression levels in these cells. Histone H3 was 
utilized as a positive control for these analyses and found to be highly associated with 
exon 3 of RPL30 in DD, PF and CT cells (Figure 2-2B). 
TGF-β1 treatment simultaneously represses IGFBP6 levels and enhances cytoplasmic β-
catenin accumulation in both DD and aggressive fibromatosis [11,12]. TGF-β signalling 
through SMADs can negatively regulate gene transcription [46,47] by recruiting histone 
methyltransferases or histone deacetylases to target genes [48,49]. As the IGFBP6 
promoter contains multiple SMAD binding elements (CAGA sequences) [26], it was of 
interest to determine if SMAD interactions with the IGFBP6 promoter correlated with β-
catenin interactions with this gene. Additional ChIP experiments were performed using a 
SMAD2/3 antibody to detect either SMAD2 or SMAD3 associations with the IGFBP6 
promoter.  As shown in Figure 2-2C, little to no SMAD2/3 was shown to associate with 
the IGFBP6 promoters of untreated DD cells at the TCF2 site and CT cells at the TCF1 
site. SMAD2/3 association with the IGFBP6 promoter was more detectable at the TCF1 
site in PF/DD cells and in contrast, more detectable in the control PF and CT cells at the 
TCF2 site. These differences in the levels of association did not reach statistical 
significance. ChIP experiments were also performed with an RNA Polymerase II 
antibody to correlate RNA Polymerase II association with IGFBP6 and IGFBP6 
expression in DD and PF cells. As IGFBP6 lacks an obvious TATA box, primers were 
designed to span 250 bp upstream of the transcriptional start site based on a report of 
basal promoter activity being maintained within 153 bp from the ATG [50]. RNA 
Polymerase II was found to be more highly associated with the IGFBP6 promoter of PF 
cells than with DD cells (Figure 2-2D), correlating with IGFBP6 expression levels in 
these cells. PF cells, which are genetically identical to the DD cells, appear to have β-
catenin, SMAD2/3 and RNA Polymerase II located within the IGFBP6 promoter region, 
while little or no interactions of these proteins were evident in genetically identical, 
patient-matched DD cells.  
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Figure 2-2: Association of A) β-catenin, B) Histone H3, C) SMAD2/3, 
and D) RNA Polymerase II in CT, PF and DD cells by chromatin 
immunoprecipitation. 
Chromatin was extracted from primary CT (white bars), PF (grey bars) and 
DD (black bars) fibroblasts. Immunoprecipitations were performed using β-
catenin (N = 4, n = 1), SMAD2/3 (N = 4, n = 1), and RNA Polymerase II (N 
= 2, n = 1) antibodies with Histone H3 (N = 2, n = 1) and species-specific 
IgG as a control. β-catenin and SMAD2/3 association with the IGFBP6 
promoter was examined at the 2 TCF sites (Figure 2-1). Histone H3 
association was assessed within exon 3 of Human RPL30. Mean association 
was plotted normalized to IgG (dotted line, below 1 signifies background 
noise) with standard error of the mean.  
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Figure 2-3: β-catenin association with the A) TCF1 and B) TCF2 sites in the 
IGFBP6 promoter by patient. 
ChIP experiments were performed to assess β-catenin association with the IGFBP6 
promoter region in CT (white bars), PF (grey bars) and DD (black bars) cells. β-
catenin association with the IGFBP6 promoter in each patient is plotted relative to 
rabbit IgG (dotted line) background at 1. 
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 ChIP Seq preparation 2.3.2
Having confirmed that the levels of β-catenin association with the IGFBP6 promoter 
varied between DD, PF and CT cells, ChIP Sequencing (ChIP Seq) studies were 
performed to identify all of the other β-catenin gene targets that varied between these 
groups. β-catenin and input ChIP samples were used in this analysis as recommended by 
technical reviews of this procedure [51]. In order to prepare the ChIP samples for 
sequencing, separate libraries were created for each DD, PF and CT sample (β-catenin IP 
and input samples) using commercially available kits compatible with the Illumina 
platform. Briefly, 10 ng of DNA for each sample was end repaired, dA-tailed and ligated 
to Illumina adaptors to facilitate complementarity for downstream sequencing and for 
PCR amplification. The quality of each DNA library was confirmed on a Bioanalyzer (N 
= 3 per group, done once n = 1) prior to paired-end multiplex (2x101 bp) sequencing on 
the Illumina HiSeq 2500. Approximately 40 million reads were obtained per sample in 
the forward and reverse directions, with approximately 80% of these reads aligning 
exactly once to the genome. These reads were aligned with the human hg19 genome and 
peaks were called using Model-based Analysis of ChIP Seq (MACS) [44].  
 Selecting peak calling parameters 2.3.3
To our knowledge, there are no previous reports of ChIP Seq analyses of trans-activators 
of transcription in samples derived from multiple patients. For this reason, it was 
necessary to carefully design de novo parameters for the peak calling portion of the 
workflow. As β-catenin association with IGFBP6 in PF cells was previously confirmed 
by ChIP, these interactions were used as a baseline parameter in the ChIP Seq analysis. 
Peaks were identified in the IGFBP6 promoter in 2 out of 3 PF samples from the forward 
analysis, and 1 out of 3 from the reverse analysis (Table 2-2) using a model-fold 
(MFOLD) enrichment factor of 5 and a p-value < 0.05, demonstrating a low overall 
enrichment in the study. Using these interactions as a baseline measure, these parameters 
were stringently applied in the final study to call only those overlapping peaks that 
appeared in all 3 patients and in both forward and reverse analyses.  
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Figure 2-4: A) Peak numbers and B) overlaps identified during MACS 
analysis in CT, PF and DD cells. 
Peak calling was performed using MACS, with an MFOLD enrichment = 5 and 
p < 0.05. A) Only peaks or β-catenin associations common between forward 
and reverse analyses and across all 3 primary cell lines per group (CT, PF and 
DD), corresponding to 6 different patients (PF and DD are from the same 
patient) were used in downstream ChIP Seq analysis. B) Peak overlaps were 
assessed between cell groups using the Intersect tool available with the 
BEDtools package in Galaxy. 
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Table 2-2: Peaks located within the IGFBP6 promoter region that correspond to the 
TCF2 site where β-catenin associates as identified in ChIP analysis 
Patient Forward or 
Reverse 
Peak Start Peak End Position from 
IGFBP6 gene* 
P-value 
244 PF F 53 490 823 53 491 223 -397 0.0109 
275 PF F 53 490 730 53 491 112 -490 0.0365 
244 PF R 53 490 735 53 491 096 -485 0.0158 
*Relative to IGFBP6 gene position at chr12: 53 491 220 
 
 Peaks identified by MACS 2.3.4
MACS analysis identified an average of ~400 000 peaks in each CT sample, ~350 000 
peaks in each PF sample and ~630 000 peaks in each DD sample. However, when both 
the forward and reverse analyses were assessed across all 3 patients in each group, only 
1.13%, 0.68% and 1.84% of CT, PF and DD peaks respectively were retained for further 
analysis (Figure 2-4A). There were almost 5 times as many β-catenin associations with 
chromosomal regions of DD cells than with PF cells, and almost 2.5 times more 
associations with DD cells than with CT cells. No peaks were identified at this level of 
stringency that overlapped between all three cell types, in all 3 patients, in both forward 
and reverse analyses (Figure 2-4B). There was minimal peak overlap between the three 
cells types: 51 overlapping peaks were identified between DD and PF cells, 12 between 
CT and DD and only 1 between CT and PF.  
Interestingly, only 32.4% of the peaks of β-catenin associations with the genomes of the 
DD samples, 33.5% of the PF samples, and 43.6% in CT samples fell within a gene or 
within 10 kb of a gene (Figure 2-5). The identities of the genes within 10 kb of the 
regions of β catenin association were obtained by mapping the peak locations back to the 
RefSeq Genebase and a selection are listed in Tables 2-3 (CT cells), 2-4 (PF cells) and 2-
5 (DD cells). These analyses can be interpreted to indicate that more than 65% of the β-
catenin associations in DD and PF cells and 55% of the β-catenin associations in CT cells 
were with regions of the genome where there are no known genes. The majority of the β-
catenin associations with regions of the genome that contain protein encoding genes were  
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Figure 2-5: Peak locations within the human hg19 genome by cell type. 
Overlapping peaks common across all patients were mapped back to the RefSeq genome to 
determine locations of peaks using the Intersect tool in BEDtools. β-catenin associations within 
10 kb, introns or exons of a gene were identified. Most of the β-catenin associations are within 
regions with no known RefSeq genes. 
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Table 2-3: Select β-catenin associations within 10 kb of a gene in CT cells. 
RefSeq 
Accession 
Number 
Gene Symbol Gene Description 
Chromosomal 
Location 
NC_000012.12 ABCD2 
ATP-binding cassette, sub-family D (ALD), member 
2 
12q12 
NC_000008.11 ADAMDEC1 ADAM-like, decysin 1 8p21.2 
NC_000002.12 ADCY3 adenylate cyclase 3 2p23.3 
NC_000005.10 ARHGEF28 Rho guanine nucleotide exchange factor (GEF) 28 5q13.2 
NC_000017.11 CCL1 chemokine (C-C motif) ligand 1 17q12 
NC_000003.12 CCR2 chemokine (C-C motif) receptor 2 3p21.31 
NC_000012.12 CD163 CD163 molecule 12p13.3 
NC_000003.12 COL6A5 collagen, type VI, alpha 5 3q22.1 
NC_000007.14 EGFR epidermal growth factor receptor 7p12 
NC_000007.14 ELFN1 
extracellular leucine-rich repeat and fibronectin type 
III domain containing 1 
7p22.3 
NC_000008.11 EPHX2 epoxide hydrolase 2, cytoplasmic 8p21 
NC_000012.12 EPS8 epidermal growth factor receptor pathway substrate 8 12p12.3 
NC_000001.11 FAM110D family with sequence similarity 110, member D 1p36.11 
NC_000011.10 FAT3 FAT atypical cadherin 3 11q14.3 
NC_000014.9 FBLN5 fibulin 5 14q32.1 
NC_000009.12 FCN1 ficolin (collagen/fibrinogen domain containing) 1 9q34 
NC_000004.12 FNIP2 folliculin interacting protein 2 4q32.1 
NC_000016.10 FOXL1 forkhead box L1 16q24 
NC_000006.12 GPR110 G protein-coupled receptor 110 6p12.3 
NC_000013.11 GPR183 G protein-coupled receptor 183 13q32.3 
NC_000014.9 GSKIP GSK3B interacting protein 14q32.2 
NC_000001.11 HHAT hedgehog acyltransferase 1q32 
NC_000006.12 HIST1H1C histone cluster 1, H1c 6p21.3 
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NC_000006.12 HLA-DMA major histocompatibility complex, class II, DM alpha 6p21.3 
NC_000006.12 HLA-DOB major histocompatibility complex, class II, DO beta 6p21.3 
NC_000001.11 IFI16 interferon, gamma-inducible protein 16 1q22 
NC_000001.11 MACF1 microtubule-actin crosslinking factor 1 1p32-p31 
NC_000015.10 MAP2K1 mitogen-activated protein kinase kinase 1 
15q22.1-
q22.33 
NC_000001.11 MIR197 microRNA 197 1p13.3 
NC_000004.12 MIR577 microRNA 577 4q26 
NC_000017.11 MIR634 microRNA 634 17q24.2 
NC_000019.10 MIR643 microRNA 643 19q13.41 
NC_000009.12 MIR873 microRNA 873 9p21.1 
NC_000020.11 MMP24 matrix metallopeptidase 24 (membrane-inserted) 20q11.2 
NC_000006.12 NKAPL NFKB activating protein-like 6p22.1 
NC_000008.11 NRG1 neuregulin 1 8p12 
NC_000005.10 PCDHGA4 protocadherin gamma subfamily A, 4 5q31 
NC_000002.12 PDE11A phosphodiesterase 11A 2q31.2 
NC_000005.10 PDE4D phosphodiesterase 4D, cAMP-specific 5q12 
NC_000011.10 PGR progesterone receptor 11q22-q23 
NC_000014.9 PRKCH protein kinase C, eta 14q23.1 
NC_000001.11 PTPN22 
protein tyrosine phosphatase, non-receptor type 22 
(lymphoid) 
1p13.2 
NC_000015.10 RASGRP1 
RAS guanyl releasing protein 1 (calcium and DAG-
regulated) 
15q14 
NC_000014.9 RNASE9 ribonuclease, RNase A family, 9 (non-active) 14q11.2 
NC_000001.11 S1PR1 sphingosine-1-phosphate receptor 1 1p21 
NC_000018.10 TCEB3B 
transcription elongation factor B polypeptide 3B 
(elongin A2) 
18q21.1 
NC_000002.12 TCF7L1 
transcription factor 7-like 1 (T-cell specific, HMG-
box) 
2p11.2 
NC_000006.12 TJAP1 tight junction associated protein 1 (peripheral) 6p21.1 
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NC_000022.11 TTLL12 tubulin tyrosine ligase-like family, member 12 22q13.31 
NC_000013.11 TUBGCP3 tubulin, gamma complex associated protein 3 13q34 
NC_000017.11 USP32 ubiquitin specific peptidase 32 17q23.3 
NC_000017.11 VTN Vitronectin 17q11 
NC_000001.11 WNT3A 
wingless-type MMTV integration site family, 
member 3A 
1q42 
NC_000022.11 WNT7B 
wingless-type MMTV integration site family, 
member 7B 
22q13 
 
Table 2-4: Select β-catenin associations within 10 kb of a gene in PF cells. 
RefSeq 
Accession 
Number 
Gene Symbol Gene Description 
Chromosomal 
Location 
NC_000001.11 ACTN2 actinin, alpha 2 1q42-q43 
NC_000010.11 ANXA2P3 annexin A2 pseudogene 3 10q21.3 
NC_000004.12 ARAP2 
ArfGAP with RhoGAP domain, ankyrin repeat and 
PH domain 2 
4p14 
NC_000001.11 ASPM 
asp (abnormal spindle) homolog, microcephaly 
associated (Drosophila) 
1q31 
NC_000020.11 CDH4 cadherin 4, type 1, R-cadherin (retinal) 20q13.3 
NC_000020.11 DEFB119 defensin, beta 119 20q11.21 
NC_000007.14 EGFR-AS1 EGFR antisense RNA 1  
NC_000001.11 ELAVL4 ELAV like neuron-specific RNA binding protein 4 1p34 
NC_000022.11 FAM19A5 
family with sequence similarity 19 (chemokine (C-
C motif)-like), member A5 
22q13.32 
NC_000001.11 FCRL5 Fc receptor-like 5 1q21 
NC_000011.10 GAS2 growth arrest-specific 2 11p14.3 
NC_000004.12 GNRHR gonadotropin-releasing hormone receptor 4q21.2 
NC_000003.12 GPR15 G protein-coupled receptor 15 3q11.2-q13.1 
NC_000006.12 GPR63 G protein-coupled receptor 63 6q16.1-q16.3 
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NC_000011.10 GRIK4 glutamate receptor, ionotropic, kainate 4 11q22.3 
NC_000003.12 GRM7 glutamate receptor, metabotropic 7 3p26.1-p25.1 
NC_000003.12 KCNH8 
potassium voltage-gated channel, subfamily H (eag-
related), member 8 
3p24.3 
NC_000003.12 LINC00879 long intergenic non-protein coding RNA 879 3q11.2 
NC_000004.12 LINC01098 long intergenic non-protein coding RNA 1098 4q34.3 
NC_000016.10 LOC390705 
protein phosphatase 2, regulatory subunit B'', beta 
pseudogene 
16p11.2 
NC_000010.11 MBL2 mannose-binding lectin (protein C) 2, soluble 10q11.2 
NC_000018.10 METTL4 methyltransferase like 4 18p11.32 
NC_000003.12 MIR1324 microRNA 1324  
NC_000021.9 MIR155HG MIR155 host gene (non-protein coding) 
NC_000012.12 MIR3612 microRNA 3612  
NC_000019.10 MIR371A microRNA 371a 19q13.42 
NC_000019.10 MIR372 microRNA 372 19q13.42 
NC_000003.12 MIR3919 microRNA 3919  
NC_000009.12 MIR4290 microRNA 4290  
NC_000011.10 MRGPRX1 MAS-related GPR, member X1 11 
NC_000002.12 NRXN1 neurexin 1 2p16.3 
NC_000011.10 OR10G7 
olfactory receptor, family 10, subfamily G, member 
7 
11q24.2 
NC_000012.12 PDE1B phosphodiesterase 1B, calmodulin-dependent 12q13 
NC_000004.12 PGRMC2 progesterone receptor membrane component 2 4q26 
NC_000001.11 PPIH peptidylprolyl isomerase H (cyclophilin H) 1p34.1 
NC_000013.11 PRR20A proline rich 20A 13q21.1 
NC_000010.11 PTPRE protein tyrosine phosphatase, receptor type, E 10q26 
NC_000008.11 REXO1L2P 
REX1, RNA exonuclease 1 homolog (S. 
cerevisiae)-like 2 (pseudogene) 
8q21.2 
NC_000017.11 RHOT1 ras homolog family member T1 17q11.2 
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NC_000008.11 RIMS2 regulating synaptic membrane exocytosis 2 8q22.3 
NC_000001.11 S100A9 S100 calcium binding protein A9 1q21 
NC_000011.10 SCN3B 
sodium channel, voltage-gated, type III, beta 
subunit 
11q23.3 
NC_000015.10 SEMA7A 
semaphorin 7A, GPI membrane anchor (John 
Milton Hagen blood group) 
15q22.3-q23 
NC_000011.10 SPON1 spondin 1, extracellular matrix protein 11p15.2 
NC_000018.10 TCEB3CL 
transcription elongation factor B polypeptide 3C-
like 
18q21.1 
NC_000018.10 TCEB3CL2 
transcription elongation factor B polypeptide 3C-
like 2 
18q21.1 
NC_000013.11 TPTE2 
transmembrane phosphoinositide 3-phosphatase and 
tensin homolog 2 
13q12.11 
NC_000004.12 USP17L30 
ubiquitin specific peptidase 17-like family member 
30 
4p16.1 
NC_000015.10 WDR72 WD repeat domain 72 15q21.3 
NC_000019.10 ZNF285 zinc finger protein 285  
 
Table 2-5: Select β-catenin associations within 10 kb of a gene in DD cells. 
RefSeq 
Accession 
Number 
Gene Symbol Gene Description 
Chromosomal 
Location 
NC_000007.14 ADAM22 ADAM metallopeptidase domain 22 7q21 
NC_000002.12 APOB apolipoprotein B 2p24-p23 
NC_000017.11 CCL23 chemokine (C-C motif) ligand 23 17q12 
NC_000001.11 CD1C CD1c molecule 1q23.1 
NC_000019.10 CD33 CD33 molecule 19q13.3 
NC_000001.11 CD58 CD58 molecule 1p13 
NC_000001.11 CD84 CD84 molecule 1q24 
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NC_000003.12 CD86 CD86 molecule 3q21 
NC_000003.12 CNTN4 contactin 4 3p26.3 
NC_000004.12 CXCL13 chemokine (C-X-C motif) ligand 13 4q21 
NC_000008.11 DEFB105A defensin, beta 105A 8p23.1 
NC_000019.10 FCGBP Fc fragment of IgG binding protein 19q13.1 
NC_000012.12 FGF6 fibroblast growth factor 6 12p13 
NC_000005.10 FGFR4 fibroblast growth factor receptor 4 5q35.2 
NC_000002.10 FSIP2 fibrous sheath interacting protein 2 2q32.1 
NC_000004.12 GABRG1 
gamma-aminobutyric acid (GABA) A receptor, 
gamma 1 
4p12 
NC_000001.11 GBP7 guanylate binding protein 7 1p22.2 
NC_000005.10 GHR growth hormone receptor 5p13-p12 
NC_000020.11 GHRH growth hormone releasing hormone 20q11.2 
NC_000001.11 GJA5 gap junction protein, alpha 5, 40kDa 1q21.1 
NC_000001.11 GJA8 gap junction protein, alpha 8, 50kDa 1q21.1 
NC_000001.11 GJB5 gap junction protein, beta 5, 31.1kDa 1p35.1 
NC_000006.12 GPR63 G protein-coupled receptor 63 6q16.1-q16.3 
NC_000006.12 GPRC6A 
G protein-coupled receptor, class C, group 6, 
member A 
6q22.1 
NC_000021.9 GRIK1 glutamate receptor, ionotropic, kainate 1 21q22.11 
NC_000002.12 ICA1L islet cell autoantigen 1,69kDa-like 2q33.2 
NC_000009.12 IFNA10 interferon, alpha 10 9p22 
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NC_000009.12 IFNA7 interferon, alpha 7 9p22 
NC_000004.12 IL2 interleukin 2 4q26-q27 
NC_000016.10 ITGAX 
integrin, alpha X (complement component 3 
receptor 4 subunit) 
16p11.2 
NC_000009.12 LOC642929 general transcription factor II, i pseudogene 9p11.2 
NC_000018.10 MIR187 microRNA 187 18q12.2 
NC_000013.11 MIR320D1 microRNA 320d-1 13q14.11 
NC_000002.12 MIR548F2 microRNA 548f-2 2q34 
NC_000020.11 MIR646HG MIR646 host gene (non-protein coding) 20q13.33 
NC_000013.11 MTUS2 
microtubule associated tumor suppressor candidate 
2 
13q12.3 
NC_000006.12 NKAIN2 Na+/K+ transporting ATPase interacting 2 6q21 
NC_000011.10 OR4C45 
olfactory receptor, family 4, subfamily C, member 
45 
11p11.12 
NC_000011.10 OR51I1 
olfactory receptor, family 51, subfamily I, member 
1 
11p15.4 
NC_000003.12 OR5H1 
olfactory receptor, family 5, subfamily H, member 
1 
3q11.2 
NC_000006.12 PKIB 
protein kinase (cAMP-dependent, catalytic) 
inhibitor beta 
6q22.31 
NC_000008.11 POTEA POTE ankyrin domain family, member A 8p11.1 
NC_000005.10 PPP2R2B protein phosphatase 2, regulatory subunit B, beta 5q32 
NC_000013.11 PRR20A proline rich 20A 13q21.1 
NC_000001.11 S100A7A S100 calcium binding protein A7A 1q21.3 
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NC_000015.10 SNORD109A small nucleolar RNA, C/D box 109A 15q11.2 
NC_000015.10 
SNORD116-
17 
small nucleolar RNA, C/D box 116-17 15q11.2 
NC_000002.12 SOX11 SRY (sex determining region Y)-box 11 2p25 
NC_000018.10 TCEB3CL 
transcription elongation factor B polypeptide 3C-
like 
18q21.1 
NC_000018.10 TCEB3CL2 
transcription elongation factor B polypeptide 3C-
like 2 
18q21.1 
NC_000019.10 TPM4 tropomyosin 4 19p13.1 
NC_000004.12 USP17L13 
ubiquitin specific peptidase 17-like family member 
13 
4p16.1 
NC_000004.12 USP17L15 
ubiquitin specific peptidase 17-like family member 
15 
4p16.1 
NC_000004.12 USP17L21 
ubiquitin specific peptidase 17-like family member 
21 
4p16.1 
NC_000004.12 USP17L30 
ubiquitin specific peptidase 17-like family member 
30 
4p16.1 
 
located within the intronic regions of those genes rather than their promoters or other 
locations.  
 Vertical analyses: β-catenin associations within each patient 2.3.5
Each set of PF and DD cells derived from the same patient are predicted to be genetically 
identical, as Dupuytren’s Disease is a benign fibromatosis and any germline mutations 
that predispose patients to DD are predicted to be evident in fibroblasts irrespective of 
their disease state. Therefore it was appropriate to perform vertical analyses of the peaks 
isolated from each matching PF and DD sample for each of the 3 patients. The amount of 
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overlap within each patient cell line differed, further complicating the ability to derive 
common features from the analyses. Specifically, patients # 244, 271 and 275 displayed 
4.3%, 16.1% and 8.7% overlap between β-catenin associations in PF and DD cells 
respectively. When all 3 DD cell lines were assessed relative to their corresponding PF 
cells, there were 8 805 regions of β-catenin association in all 3 DD patients, but not their 
corresponding PF samples, which translated to 2 792 gene associations within genes or 
within 10 kb upstream of a gene. There were 1 544 regions or 547 genes where β-catenin 
associated within a gene or within 10 kb upstream of a gene that were specific to all PF 
cells assessed relative to all DD cells assessed. From these, 1 438 and 497 unique genes 
were identified in DD and PF cells, respectively. Only 51 regions of β-catenin association 
were common between PF and DD cells. A selection of the genes identified from the β-
catenin associations within intronic regions from these analyses are listed in Appendices 
F and G. 
Table 2-6: Separating β-catenin associations according to presence within PF cells, 
DD cells or both, within each patient. 
Patient# Both DD and PF PF only DD only 
#244 48 388 250 000 810 000 
#271 250 000 500 000 800 000 
#275 59 753 310 000 320 000 
 
 
 Ingenuity Pathway Analysis of β-catenin associations within 2.3.6
10 kb of a gene 
To determine the networks, diseases and signalling pathways associated with the genes 
that had β-catenin associations within 10 kb of their location, Ingenuity Core Analyses 
were conducted on the complete lists of genes used to generate Tables 2-3, 2-4 and 2-5. 
The top disease and biological function association for all 3 cell types was identified as 
“cancer” (Figure 2-6). Other prominent disease and biological function associations in PF 
and CT cells were “cell growth”, “proliferation”, “morphology” and “development”. 
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Interestingly, the genes identified in DD cells were mostly categorized as contributing to 
pathological, rather than normal or developmental, processes.  
2.4 Discussion 
β-catenin was shown to associate with the IGFBP6 promoter in both PF and CT cells, 
while little to no association of β-catenin with IGFBP6 was evident in DD cells. These 
data suggest that there is a direct correlation between β-catenin association with the 
IGFBP6 promoter and IGFBP6 mRNA levels in DD, PF and CT cells, and that loss of β-
catenin at the IGFBP6 promoter leads to its transcriptional downregulation.  This 
interpretation is consistent with RNA Polymerase II association with the IGFBP6 
promoters in PF cells, but not DD cells, despite these cells being derived from the same 
hand of the same patient. Additional patients would have to be assessed to confirm β-
catenin association levels with the IGFBP6 promoter, as the results in this study did not 
achieve statistical significance, likely due to the small patient sample size. Experiments 
confirming whether β-catenin is an absolute requirement for IGFBP6 expression in DD 
will be a focus of future studies.  
These findings are in direct contrast to a previous report in aggressive fibromatosis 
indicating an inverse correlation between β-catenin association and IGFBP6 transcription 
[12]. As PF cells are derived from the non-fibrotic palmar fascia of patients with DD, 
they might represent “pre-DD” fibroblasts that are somewhere between normal and 
diseased at the level of β-catenin interactions with target genes. Changes in β-catenin 
association with IGFBP6 or other genes between CT, PF and DD cells may provide 
insights into the processes that lead to the eventual downregulation of IGFBP6 
transcription in DD cells. TGF-β can further repress IGFBP6 expression in DD and PF 
cells, and future studies will focus on elucidating its ability to regulate β-catenin and 
RNA Polymerase II association with the IGFBP6 promoter.  
The association of SMAD2/3 with the IGFBP6 promoter region demonstrated in this 
report may provide some insight into the possible roles of TGF-β in this process. SMADs 
may repress gene transcription by recruiting histone methyltransferases or histone  
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Figure 2-6: Disease and biological function categories determined by Ingenuity Pathway 
Core Analysis of β-catenin associated genes of CT, PF and DD cells. 
Genes identified from the β-catenin associations within 10 kb of a gene were input into IPA 
(QIAGEN, Redwood City, www.qiagen.com/ingenuity) to determine indirect and direct 
relationships between the genes. These genes were then allocated to specific biological 
function or disease categories using a right-tailed Fisher’s Exact statistical test to determine a 
threshold for significance. 
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deacetylases to target genes, and the recruitment of histone deacetylases by TCF/Lef 
factors to inhibit transcription has been previously documented [9,48,49]. Preliminary 
studies in our laboratory using chaetocin, a histone methyltransferase inhibitor [52], 
indicated that treatment markedly induced IGFBP6 expression in DD and PF cells, but 
only mildly in CT cells, consistent with differing levels of histone methylation at the 
IGFBP6 locus in these cells. 
Genome-wide associations of β-catenin were identified in this study by ChIP sequencing 
across the genomes of 9 different cell lines derived from 6 different patients. This is the 
first study, to our knowledge, to report β-catenin associations with genes in human cells 
derived from multiple patients with any fibrosis, or indeed for any disease of any kind.  
The β-catenin gene associations identified in the genomes of PF and DD cells may 
provide insight into the processes that drive Dupuytren’s Disease progression. During the 
vertical analyses, the overlapping regions between PF and DD cells were removed, such 
that the peaks that remained were specifically associated in PF cells or in DD cells. 
Identical genes within these DD and PF lists are present because β-catenin is associating 
with different regions of the gene in these 2 cell types, which could be due to β-catenin 
transactivation of different transcription factors or the same transcription factor binding 
another area. In addition, overlap was evident between β-catenin association with genes 
encoding related, but different factors in DD, PF and CT cells. For example, while 
FGF14 was identified as a β-catenin associated gene in all 3 cell types, FGF12 was 
specifically identified in DD cells and CT cells, while FGF10 was identified only in CT 
cells. Interestingly, FGF10 expression has been shown to attenuate fibrosis in mice [53], 
which would suggest that β-catenin is required for its expression in CT cells, and that it 
may be transcriptionally downregulated in DD in a similar manner to IGFBP6. Different 
fibroblast growth factors may have distinct temporal roles in the fibroproliferation in DD 
and each may contribute uniquely to disease progression. The potential for different 
FGFs to perform distinct functions is yet to be explored in DD. Interestingly, β-catenin 
associated with many different genes encoding cadherins in DD cells, while β-catenin 
associated more often with genes encoding protocadherins in PF and CT cells (See 
Appendices F and G). Additionally, β-catenin associations with numerous collagen genes 
were identified in these analyses, supporting previous suggestions that β-catenin may 
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have a role in regulating collagen expression [54–56]. As excess collagen deposition is 
characteristic of essentially all fibroses including Dupuytren’s Disease, it is feasible that 
β-catenin may transactivate expression of these genes. Previous microarray data reports 
for DD indicate that COL18A1 and COL6A1 are upregulated in DD nodule tissue relative 
to external control tissue [40], consistent with the hypothesis that β-catenin might 
promote the transcriptional activation of these collagen genes.  
β-catenin has been reported to associate with a variety of genes in many cell types, the 
majority of which were derived from cancers or other diseased tissues. This is the first 
study to our knowledge to identify the genes that β-catenin associates with in normal (in 
this case, palmar fascia-derived) fibroblasts. CT cells were shown to exhibit intermediate 
levels of β-catenin association with various genes relative to the levels of interactions 
evident in DD and PF cells. Remarkably, no overlapping peaks of β-catenin association 
were identified in all 3 cell types. This implies that β-catenin association with genes is 
distinct in normal palmar fascia fibroblasts derived from patients without DD, and normal 
palmar fascia fibroblasts derived from patients with DD in an adjacent digit. These 
findings may suggest that the development of DD is incremental, and that normal 
fibroblasts (CT cells) progress to fibroblasts that are “primed” for disease development 
(PF cells) to diseased fibroblasts (DD cells). β-catenin interactions may contribute to this 
intricate process by trans-regulating gene expression in a specific manner. The single 
peak overlap between PF and CT cells suggests that it might be possible to identify 
genetic biomarkers that distinguish an individual who is genetically predisposed to 
disease development from an individual who is not.  
The majority of β-catenin gene associations identified in this study were localized within 
intronic regions. Introns have been shown to regulate gene expression in a variety of 
systems [57], and in some cases may have more influence on gene expression than the 
promoter [58]. This has been definitively demonstrated for Arabidopsis profilin genes, 
where swapping intron 1 of vegetative profilin-2  with intron 1 of reproductive profilin-5 
led profilin-5 to express a more vegetative profilin-2 pattern [58]. These findings have 
contributed to the acceptance of introns playing more important roles in mediating gene 
expression in humans than was previously thought [57]. For example, IGFBP6 
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expression can be induced by retinoid X receptor activation of an AP-1 site within its first 
intron [59] and Ubiquitin C expression can be enhanced by Yin Yang 1 trans-activation 
within its first intron [60]. Interestingly, when this intronic region is moved upstream of 
the promoter, Yin Yang 1 can no longer affect Ubiquitin C expression, indicating a 
spatial dependence for intron-mediated enhancement of transcription. Additionally, 
removal of regulatory regions for splicing can diminish gene expression, demonstrating 
that splicing is also required for optimal gene expression [60]. As such, intronic regions 
also function as areas where splicing is regulated, and this may be another reason for β-
catenin association within these regions. While most of the β-catenin gene associations 
were within intronic regions, more than 50% were located in regions of the genome with 
no known genes, the significance of which is currently unknown. 
The Ingenuity pathway analysis provided further insight into the types of genes being 
regulated by DD, PF and CT cells. In all 3 cell types, cancer was the top 
disease/biological function category which was identified based on the β-catenin gene 
associations. While these gene associations may truly reflect a similar disease mechanism 
between DD and cancer, this can also be the result of the bias in the literature towards 
cancer research and development, as IPA creates its categories based on the research 
available in multiple databases. Nonetheless, associations between DD and cancer 
development have been identified in a few studies [61,62]. Interestingly, despite the 
minimal overlap in peaks between PF and CT cells, the biological function categories 
determined from the gene lists were similar, identifying cell proliferation, morphology 
and development as significant, which confirms previous reports listing β-catenin as a 
mediator of cell proliferation [7,30,63]. In contrast, the top 10 categories in DD cells 
were all pathological processes, supporting the concept that molecular therapies must 
achieve normal homeostasis in the palmar fascia, rather than just the absence of disease, 
to prevent DD progression. 
While many previous studies have identified specific TCF/Lef targets, only 2 studies in 
human colon cancer cells have looked specifically for β-catenin gene targets throughout 
the human genome [38,39]. In HCT116 cells, 2 168 β-catenin gene targets were 
identified, while 2 794 were identified in SW480 cells, both of which are comparable to 
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the 2 792 β-catenin gene targets identified in this study of DD cells [38,39]. While there 
was little overlap between the genes identified in SW480 and DD cells, this could be due 
to the adenomatous polyposis coli mutation in SW480 cells which stabilizes β-catenin, 
and may in turn affect β-catenin-mediated gene transcription. Surprisingly, there were 
only 168 genes which overlapped between the two studies on HCT116 and SW480 cells 
[39], which may be the result of the additional transcription factor, AP-1 possibly playing 
a role in mediating β-catenin effects on transcription in HCT116 cells [38], but not 
SW480 cells. Many Wnt genes were identified as β-catenin gene targets in SW480 cells 
[39]. In the current study, Wnt-associated genes were identified mostly in CT cells, which 
might suggest that the Wnt pathway is turned off in DD cells, since our lab was unable to 
detect any consistent changes in Wnt gene expression in DD cells relative to non-fibrotic 
cells [64]. Lack of Wnt involvement in DD may also be the result of SNPs located within 
Wnt genes, as identified in a genome wide association study of DD cells where 6/11 
SNPs were reportedly within Wnt genes. Based on these data, it was hypothesized that 
SNPs in Wnt genes may pre-dispose patients to DD [65].  
In contrast, considerable overlap was evident between the HCT116 study and this study 
in terms of the gene families that were identified, although the specific members of those 
gene families differed. For example, ADAM 12, ADAM19 and ADAMTS16  were 
identified as β-catenin gene targets in colon cancer while ADAMs 2, 5, 18, 19, 22, 29, 32, 
TS16, TS18, TS19 and TS20 were identified as β-catenin gene targets in DD. ADAM12 is 
a highly up-regulated gene in DD [40,66] where it is believed to function as an adhesion 
molecule and an IGFBP protease [67]. It is currently unclear if the up-regulated 
expression of ADAM12 in colon cancer and DD is the result of distinct mechanisms, or if 
the association between β-catenin and ADAM12 in DD was excluded due to the 
stringency of peak calling parameters implemented that required peaks to be identified in 
all 3 patients in forward and reverse analyses.  
Currently, there is a lack of standards and guidelines for assessing ChIP sequencing data 
derived from multiple patients. Many algorithms for analyzing multiple datasets focus on 
integrating ChIP Seq studies performed by various groups [68–70].  Unfortunately, peak 
calling can be achieved through multiple approaches that can vary between analyses, 
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adding an additional layer of complexity to an integrative analysis of multiple studies. In 
this study, each patient was assessed individually and the data was compared after peak 
calling was complete. Between-patient variability made this a very difficult and complex 
process, as each patient displayed different levels of β-catenin association within their 
genome despite beginning the analyses with similar numbers of reads. β-catenin 
association was much higher in the DD cells derived from two of the three DD patients 
assessed, while the levels of β-catenin association was comparable between the PF and 
DD cells derived from the third patient (Table 2-6). A recent publication identified 
jMOSAiCS (joint model-based one- and two-sample analysis and inference for ChIP) as 
a new ChIP Seq software specifically designed to analyze multiple datasets by controlling 
for the different amount of enrichment between samples [71]. It has also been optimized 
to work for trans-acting transcriptional regulators, such as β-catenin. Current algorithms 
are optimized either for cis-acting transcription factors or for histone modifications, as 
the nature of the peaks derived from each analysis differ (sharp peaks for transcription 
factor interactions versus broad peaks for histone marks) [72]. It is unclear if a trans-
acting factor like -catenin would be expected to generate sharp or broad peaks, making 
it difficult to select an optimal program. While jMOSAiCs does seem to address many 
issues that are faced by researchers analyzing ChIP Seq data derived from clinical 
isolates, it is best equipped to handle two different datasets, making it less than ideal for 
this study.  
A limitation of the current study is that β-catenin enrichment was low, which made it 
difficult to identify significant peaks over background input “noise”. Increasing DNA 
concentration, and/or testing more β-catenin antibodies for use with ChIP Seq would be 
required to optimize the enrichment [73]. It is important to note that this study was 
limited to identifying significant levels of association between β-catenin and the human 
genomes derived from the various cell types. These analyses did not address the 
consequences of these interactions in terms of gene transcription. Additional studies will 
be required to independently confirm the associations reported in this analysis and to test 
the effects of β-catenin association with the expression of specific candidate genes of 
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interest. Confirmatory ChIP and the corresponding PCR analyses for a selection of the 
genes identified in this study will be the focus of future studies. 
In summary, β-catenin-mediated trans-regulation of gene transcription is likely to 
contribute to the development of Dupuytren’s Disease, as it does many other diseases 
[7,74]. IGFBP6 was confirmed as a target of β-catenin interactions in PF and CT cells, 
which display relatively robust IGFBP6 expression, whereas this association was 
attenuated in DD cells.  The lack of β-catenin interactions with the IGFBP6 promoter in 
DD cells is likely to contribute to the down-regulated IGFBP6 expression in these cells. 
A large number of additional β-catenin target genes were identified that were specific to 
DD cells, and detailed analyses of their transcriptional regulation are likely to provide 
novel insights into their contribution to fibrosis development. These genes may also have 
potential as biomarkers to distinguish individuals predisposed to developing DD from the 
non-predisposed population. Chapter 3 will focus on elucidating the functional 
consequences of IGFBP-6 downregulation and subsequent increased IGF-II signalling in 
DD.  
  
65 
 
 
 
2.5 References 
[1] W. Kim, M. Kim, E. Jho, Wnt/β-catenin signalling: from plasma membrane to 
nucleus, Biochem. J., 450 (2013) 9–21. 
[2] T. Valenta, G. Hausmann, K. Basler, The many faces and functions of β-catenin, 
EMBO J., 31 (2012) 2714–2736. 
[3] B.T. MacDonald, K. Tamai, X. He, Wnt/Beta-Catenin Signalling: Components, 
Mechanisms, and Diseases, Dev. Cell, 17 (2009) 9–26. 
[4] C.-H. Lee, H.-W. Hung, P.-H. Hung, Y.-S. Shieh, Epidermal growth factor 
receptor regulates beta-catenin location, stability, and transcriptional activity in 
oral cancer, Mol. Cancer, 9 (2010) 64. 
[5] S. Tejpar, C. Li, C. Yu, R. Poon, H. Denys, R. Sciot, E. Van Cutsem, J.J. 
Cassiman, B. a Alman, Tcf-3 expression and beta-catenin mediated transcriptional 
activation in aggressive fibromatosis (desmoid tumour), Br. J. Cancer, 85 (2001) 
98–101. 
[6] W.-S. Ge, Y.-J. Wang, J.-X. Wu, J.-G. Fan, Y.-W. Chen, L. Zhu, β-catenin is 
overexpressed in hepatic fibrosis and blockage of Wnt/β-catenin signalling inhibits 
hepatic stellate cell activation, Mol. Med. Rep., 9 (2014) 2145–51. 
[7] E. Bowley, D.B. O’Gorman, B.S. Gan, Beta-catenin signalling in fibroproliferative 
disease, J. Surg. Res., 138 (2007) 141–50. 
[8] J.H. Heaton, M. a Wood, A.C. Kim, L.O. Lima, F.M. Barlaskar, M.Q. Almeida, 
M.C.B. V Fragoso, R. Kuick, A.M. Lerario, D.P. Simon, I.C. Soares, E. Starnes, 
D.G. Thomas, A.C. Latronico, T.J. Giordano, G.D. Hammer, Progression to 
adrenocortical tumorigenesis in mice and humans through insulin-like growth 
factor 2 and β-catenin, Am. J. Pathol., 181 (2012) 1017–33. 
[9] D.L. Daniels, W.I. Weis, Beta-catenin directly displaces Groucho/TLE repressors 
from Tcf/Lef in Wnt-mediated transcription activation, Nat. Struct. Mol. Biol., 12 
(2005) 364–71. 
[10]  a Hecht, K. Vleminckx, M.P. Stemmler, F. van Roy, R. Kemler, The p300/CBP 
acetyltransferases function as transcriptional coactivators of beta-catenin in 
vertebrates, EMBO J., 19 (2000) 1839–50. 
[11] L. Vi, A. Njarlangattil, Y. Wu, B.S. Gan, D.B. O’Gorman, Type-1 Collagen 
differentially alters beta-catenin accumulation in primary Dupuytren’s Disease 
cord and adjacent palmar fascia cells, BMC Musculoskelet. Disord., 10 (2009) 72. 
[12] H. Denys, A. Jadidizadeh, S. Amini Nik, K. Van Dam, S. Aerts, B. a Alman, J.-J. 
Cassiman, S. Tejpar, Identification of IGFBP-6 as a significantly downregulated 
gene by beta-catenin in desmoid tumors, Oncogene, 23 (2004) 654–64. 
66 
 
 
 
[13] S. Amini Nik, R.P. Ebrahim, K. Van Dam, J.-J. Cassiman, S. Tejpar, TGF-beta 
modulates beta-Catenin stability and signalling in mesenchymal proliferations, 
Exp. Cell Res., 313 (2007) 2887–95. 
[14] S.S. Cheon, Q. Wei, A. Gurung, A. Youn, T. Bright, R. Poon, H. Whetstone, A. 
Guha, B. a Alman, Beta-catenin regulates wound size and mediates the effect of 
TGF-beta in cutaneous healing, FASEB J., 20 (2006) 692–701. 
[15] V.M. Varallo, B.S. Gan, S. Seney, D.C. Ross, J.H. Roth, R.S. Richards, R.M. 
McFarlane, B. Alman, J.C. Howard, Beta-catenin expression in Dupuytren’s 
disease: potential role for cell-matrix interactions in modulating beta-catenin levels 
in vivo and in vitro, Oncogene, 22 (2003) 3680–4. 
[16] H. Xue, Z. Xiao, J. Zhang, J. Wen, Y. Wang, Z. Chang, J. Zhao, X. Gao, J. Du, Y.-
G. Chen, Disruption of the Dapper3 gene aggravates ureteral obstruction-mediated 
renal fibrosis by amplifying Wnt/β-catenin signalling, J. Biol. Chem., 288 (2013) 
15006–14. 
[17] Z. Sun, C. Wang, C. Shi, F. Sun, X. Xu, W. Qian, S. Nie, X. Han, Activated Wnt 
signalling induces myofibroblast differentiation of mesenchymal stem cells, 
contributing to pulmonary fibrosis, Int. J. Mol. Med., 33 (2014) 1097–109. 
[18] A.P. Saboeiro, J.J. Porkorny, S.I. Shehadi, K.S. Virgo, F.E. Johnson, Racial 
distribution of Dupuytren’s disease in Department of Veterans Affairs patients, 
Plast. Reconstr. Surg., 106 (2000) 71–5. 
[19] J.D. Saar, P.C. Grothaus, Dupuytren’s disease: an overview, Plast. Reconstr. Surg., 
106 (2000) 125–34; quiz 135–6. 
[20] C. Krause, P. Kloen, P. Ten Dijke, Elevated transforming growth factor β and 
mitogen-activated protein kinase pathways mediate fibrotic traits of Dupuytren’s 
disease fibroblasts, Fibrogenesis Tissue Repair, 4 (2011) 14. 
[21] G. Gabbiani, G. Majno, Dupuytren’s contracture: fibroblast contraction? An 
ultrastructural study, Am. J. Pathol., 66 (1972) 131–46. 
[22] W.D. James, R.B. Odom, The role of the myofibroblast in Dupuytren’s 
contracture, Arch. Dermatol., 116 (1980) 807–11. 
[23] M.B. Vaughan, E.W. Howard, J.J. Tomasek, Transforming growth factor-beta1 
promotes the morphological and functional differentiation of the myofibroblast, 
Exp. Cell Res., 257 (2000) 180–9. 
[24] B. Hinz, Formation and function of the myofibroblast during tissue repair, J. 
Invest. Dermatol., 127 (2007) 526–37. 
[25] A. Desmoulière, Factors influencing myofibroblast differentiation during wound 
healing and fibrosis, Cell Biol. Int., 19 (1995) 471–6. 
67 
 
 
 
[26] S. Dennler, S. Itoh, D. Vivien, P. ten Dijke, S. Huet, J.M. Gauthier, Direct binding 
of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of 
human plasminogen activator inhibitor-type 1 gene, EMBO J., 17 (1998) 3091–
3100. 
[27] M. Zhang, M. Wang, X. Tan, T.-F. Li, Y.E. Zhang, D. Chen, Smad3 prevents beta-
catenin degradation and facilitates beta-catenin nuclear translocation in 
chondrocytes, J. Biol. Chem., 285 (2010) 8703–10. 
[28] A.H. Huber, W.J. Nelson, W.I. Weis, Three-dimensional structure of the armadillo 
repeat region of beta-catenin, Cell, 90 (1997) 871–882. 
[29] Y. Xing, K.-I. Takemaru, J. Liu, J.D. Berndt, J.J. Zheng, R.T. Moon, W. Xu, 
Crystal structure of a full-length beta-catenin, Structure, 16 (2008) 478–487. 
[30] T. Jin, I. George Fantus, J. Sun, Wnt and beyond Wnt: multiple mechanisms 
control the transcriptional property of beta-catenin, Cell. Signal., 20 (2008) 1697–
704. 
[31] K. Naka, T. Hoshii, T. Muraguchi, Y. Tadokoro, T. Ooshio, Y. Kondo, S. Nakao, 
N. Motoyama, A. Hirao, TGF-beta-FOXO signalling maintains leukaemia-
initiating cells in chronic myeloid leukaemia, Nature, 463 (2010) 676–680. 
[32] O. Tetsu, F. McCormick, Beta-catenin regulates expression of cyclin D1 in colon 
carcinoma cells, Nature, 398 (1999) 422–6. 
[33] X. Ding, Y. Yang, B. Han, C. Du, N. Xu, H. Huang, T. Cai, A. Zhang, Z.-G. Han, 
W. Zhou, L. Chen, Transcriptomic Characterization of Hepatocellular Carcinoma 
with CTNNB1 Mutation, PLoS One, 9 (2014) e95307. 
[34] K.K.N. Guturi, T. Mandal, A. Chatterjee, M. Sarkar, S. Bhattacharya, U. 
Chatterjee, M.K. Ghosh, Mechanism of β-catenin-mediated transcriptional 
regulation of epidermal growth factor receptor expression in glycogen synthase 
kinase 3 β-inactivated prostate cancer cells, J. Biol. Chem., 287 (2012) 18287–96. 
[35] E.J. Sawyer, A.M. Hanby, R. Poulsom, R. Jeffery, C.E. Gillett, I.O. Ellis, P. Ellis, 
I.P.M. Tomlinson, Beta-catenin abnormalities and associated insulin-like growth 
factor overexpression are important in phyllodes tumours and fibroadenomas of 
the breast, J. Pathol., 200 (2003) 627–32. 
[36] T. Sasaki, H. Suzuki, K. Yagi, M. Furuhashi, R. Yao, S. Susa, T. Noda, Y. Arai, K. 
Miyazono, M. Kato, Lymphoid enhancer factor 1 makes cells resistant to 
transforming growth factor beta-induced repression of c-myc, Cancer Res., 63 
(2003) 801–6. 
[37] J.Y. Leung, F.T. Kolligs, R. Wu, Y. Zhai, R. Kuick, S. Hanash, K.R. Cho, E.R. 
Fearon, Activation of AXIN2 expression by beta-catenin-T cell factor A feedback 
68 
 
 
 
repressor pathway regulating Wnt signalling, J. Biol. Chem., 277 (2002) 21657–
65. 
[38] D. Bottomly, S.L. Kyler, S.K. McWeeney, G.S. Yochum, Identification of {beta}-
catenin binding regions in colon cancer cells using ChIP-Seq, Nucleic Acids Res., 
38 (2010) 5735–45. 
[39] K. Watanabe, J. Biesinger, M.L. Salmans, B.S. Roberts, W.T. Arthur, M. Cleary, 
B. Andersen, X. Xie, X. Dai, Integrative ChIP-seq/microarray analysis identifies a 
CTNNB1 target signature enriched in intestinal stem cells and colon cancer, PLoS 
One, 9 (2014) e92317. 
[40] S. Rehman, F. Salway, J.K. Stanley, W.E.R. Ollier, P. Day, A. Bayat, Molecular 
phenotypic descriptors of Dupuytren’s disease defined using informatics analysis 
of the transcriptome, J. Hand Surg. Am., 33 (2008) 359–72. 
[41] J. Goecks, A. Nekrutenko, J. Taylor, Galaxy: a comprehensive approach for 
supporting accessible, reproducible, and transparent computational research in the 
life sciences, Genome Biol., 11 (2010) R86. 
[42] B. Giardine, C. Riemer, R.C. Hardison, R. Burhans, L. Elnitski, P. Shah, Y. Zhang, 
D. Blankenberg, I. Albert, J. Taylor, W. Miller, W.J. Kent, A. Nekrutenko, 
Galaxy: a platform for interactive large-scale genome analysis, Genome Res., 15 
(2005) 1451–1455. 
[43] D. Blankenberg, G. Von Kuster, N. Coraor, G. Ananda, R. Lazarus, M. Mangan, 
A. Nekrutenko, J. Taylor, Galaxy: A web-based genome analysis tool for 
experimentalists, Curr. Protoc. Mol. Biol., (2010). 
[44] Y. Zhang, T. Liu, C. a Meyer, J. Eeckhoute, D.S. Johnson, B.E. Bernstein, C. 
Nusbaum, R.M. Myers, M. Brown, W. Li, X.S. Liu, Model-based analysis of 
ChIP-Seq (MACS), Genome Biol., 9 (2008) R137. 
[45] A.R. Quinlan, I.M. Hall, BEDTools: A flexible suite of utilities for comparing 
genomic features, Bioinformatics, 26 (2010) 841–842. 
[46] P. ten Dijke, C.S. Hill, New insights into TGF-beta-Smad signalling, Trends 
Biochem. Sci., 29 (2004) 265–73. 
[47] C.H. Heldin, K. Miyazono, P. ten Dijke, TGF-beta signalling from cell membrane 
to nucleus through SMAD proteins, Nature, 390 (1997) 465–71. 
[48] Y. Wakabayashi, T. Tamiya, I. Takada, T. Fukaya, Y. Sugiyama, N. Inoue, A. 
Kimura, R. Morita, I. Kashiwagi, T. Takimoto, M. Nomura, A. Yoshimura, 
Histone 3 lysine 9 (H3K9) methyltransferase recruitment to the interleukin-2 (IL-
2) promoter is a mechanism of suppression of IL-2 transcription by the 
transforming growth factor-β-Smad pathway, J. Biol. Chem., 286 (2011) 35456–
65. 
69 
 
 
 
[49] J.S. Kang, T. Alliston, R. Delston, R. Derynck, Repression of Runx2 function by 
TGF-beta through recruitment of class II histone deacetylases by Smad3, EMBO 
J., 24 (2005) 2543–55. 
[50] Y.P. Dailly, Y. Zhou, T.A. Linkhart, D.J. Baylink, D.D. Strong, Structure and 
characterization of the human insulin-like growth factor binding protein (IGFBP)-
6 promoter: identification of a functional retinoid response element, Biochim. 
Biophys. Acta, 1518 (2001) 145–51. 
[51] B.L. Kidder, G. Hu, K. Zhao, ChIP-Seq: technical considerations for obtaining 
high-quality data, Nat. Immunol., 12 (2011) 918–922. 
[52] D. Greiner, T. Bonaldi, R. Eskeland, E. Roemer, A. Imhof, Identification of a 
specific inhibitor of the histone methyltransferase SU(VAR)3-9, Nat. Chem. Biol., 
1 (2005) 143–5. 
[53] V. V Gupte, S.K. Ramasamy, R. Reddy, J. Lee, P.H. Weinreb, S.M. Violette, A. 
Guenther, D. Warburton, B. Driscoll, P. Minoo, S. Bellusci, Overexpression of 
fibroblast growth factor-10 during both inflammatory and fibrotic phases 
attenuates bleomycin-induced pulmonary fibrosis in mice, Am. J. Respir. Crit. 
Care Med., 180 (2009) 424–36. 
[54] B.M. Jackson, P. Abete-Luzi, M.W. Krause, D.M. Eisenmann, Use of an Activated 
Beta-Catenin to Identify Wnt Pathway Target Genes in Caenorhabditis elegans, 
Including a Subset of Collagen Genes Expressed in Late Larval Development, G3 
(Bethesda)., 4 (2014) 733–47. 
[55] J. Rhee, J.-H. Ryu, J.-H. Kim, C.-H. Chun, J.-S. Chun, α-Catenin Inhibits β-
Catenin-T-cell Factor/Lymphoid Enhancing Factor Transcriptional Activity and 
Collagen Type II Expression in Articular Chondrocytes through Formation of 
Gli3R-α-Catenin-β-Catenin Ternary Complex, J. Biol. Chem., 287 (2012) 11751–
11760. 
[56] W. Han, W. Wang, K.A. Mohammed, Y. Su, Alpha-defensins increase lung 
fibroblast proliferation and collagen synthesis via the beta-catenin signalling 
pathway, FEBS J., 276 (2009) 6603–6614. 
[57] A.B. Rose, Intron-mediated regulation of gene expression, Curr. Top. Microbiol. 
Immunol., 326 (2008) 277–290. 
[58] Y. Jeong, J. Mun, I. Lee, J.C. Woo, C.B. Hong, S. Kim, Distinct roles of the first 
introns on the expression of Arabidopsis profilin gene family members, Plant 
Physiol., 140 (2006) 196–209. 
[59] I.P. Uray, Q. Shen, H.-S. Seo, H. Kim, W.W. Lamph, R.P. Bissonnette, P.H. 
Brown, Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent 
permissive cooperation of retinoid receptors and AP-1, J. Biol. Chem., 284 (2009) 
345–53. 
70 
 
 
 
[60] M. Bianchi, R. Crinelli, E. Giacomini, E. Carloni, L. Radici, M. Magnani, Yin 
Yang 1 intronic binding sequences and splicing elicit intron-mediated 
enhancement of ubiquitin C gene expression, PLoS One, 8 (2013) e65932. 
[61] S. Wilbrand, A. Ekbom, B. Gerdin, Dupuytren’s contracture and sarcoma, J. Hand 
Surg. Br., 27B (2002) 50–2. 
[62] S. Wilbrand, A. Ekbom, B. Gerdin, Cancer incidence in patients treated surgically 
for Dupuytren’s contracture, J. Hand Surg. Br., 25 (2000) 283–7. 
[63] C. Soler, C. Grangeasse, L.G. Baggetto, O. Damour, Dermal fibroblast 
proliferation is improved by beta-catenin overexpression and inhibited by E-
cadherin expression, FEBS Lett., 442 (1999) 178–182. 
[64] D.B. O’Gorman, Y. Wu, S. Seney, R.D. Zhu, B.S. Gan, Wnt expression is not 
correlated with beta-catenin dysregulation in Dupuytren’s Disease, J. Negat. 
Results Biomed., 5 (2006) 13. 
[65] G.H. Dolmans, P.M. Werker, H.C. Hennies, D. Furniss, E.A. Festen, L. Franke, K. 
Becker, P. van der Vlies, B.H. Wolffenbuttel, S. Tinschert, M.R. Toliat, M. 
Nothnagel, A. Franke, N. Klopp, H.-E. Wichmann, P. Nürnberg, H. Giele, R.A. 
Ophoff, C. Wijmenga, Wnt signalling and Dupuytren’s disease, N. Engl. J. Med., 
365 (2011) 307–17. 
[66] B. Shih, D. Wijeratne, D.J. Armstrong, T. Lindau, P. Day, A. Bayat, Identification 
of biomarkers in Dupuytren’s disease by comparative analysis of fibroblasts versus 
tissue biopsies in disease-specific phenotypes, J. Hand Surg. Am., 34 (2009) 124–
36. 
[67] S. Mochizuki, Y. Okada, ADAMs in cancer cell proliferation and progression, 
Cancer Sci., 98 (2007) 621–8. 
[68] A.E. Handel, G.K. Sandve, G. Disanto, L. Handunnetthi, G. Giovannoni, S. V 
Ramagopalan, Integrating multiple oestrogen receptor alpha ChIP studies: overlap 
with disease susceptibility regions, DNase I hypersensitivity peaks and gene 
expression, BMC Med. Genomics, 6 (2013) 45. 
[69] A.H. Wagner, K.R. Taylor, A.P. DeLuca, T.L. Casavant, R.F. Mullins, E.M. 
Stone, T.E. Scheetz, T. a Braun, Prioritization of retinal disease genes: an 
integrative approach, Hum. Mutat., 34 (2013) 853–9. 
[70] Y. Li, D.M. Umbach, L. Li, T-KDE: a method for genome-wide identification of 
constitutive protein binding sites from multiple ChIP-seq data sets, BMC 
Genomics, 15 (2014) 27. 
[71] X. Zeng, R. Sanalkumar, E.H. Bresnick, H. Li, Q. Chang, S. Keleş, jMOSAiCS: 
joint analysis of multiple ChIP-seq datasets, Genome Biol., 14 (2013) R38. 
71 
 
 
 
[72] J. Wang, V. V. Lunyak, I. King Jordan, BroadPeak: A novel algorithm for 
identifying broad peaks in diffuse ChIP-seq datasets, Bioinformatics, 29 (2013) 
492–493. 
[73] P.J. Park, ChIP-seq: advantages and challenges of a maturing technology, Nat. 
Rev. Genet., 10 (2009) 669–680. 
[74] H. Clevers, R. Nusse, Wnt/β-catenin signalling and disease, Cell, 149 (2012) 
1192–205.  
 
 
 
72 
 
 
 
Chapter 3  
The following chapter is adapted from C. Raykha, J. Crawford, B.S. Gan, P. Fu, L.A. 
Bach, D.B. O’Gorman, IGF-II and IGFBP-6 regulate cellular contractility and 
proliferation in Dupuytren’s disease, Biochim. Biophys. Acta, 1832 (2013) 1511–9. 
3 IGF-II and IGFBP-6 regulate cellular contractility and 
proliferation in Dupuytren’s Disease 
3.1 Introduction 
Dupuytren's Disease (DD) is a debilitating condition of the hand [1,2] characterized by 
the formation of collagenous cords in the palmar and/or digital fascia and permanent 
finger contractures.  Despite being amongst the most common inherited connective tissue 
diseases [1–4], the etiopathology of DD has remained elusive since its description in the 
1830s [5]. While microsurgical excision [6] of the contractile cord tissue can temporarily 
restore dexterity, this and other treatment approaches fail to prevent disease recurrence in 
more than 30% of patients [7–10]. There is a clear need for a better understanding of the 
molecular pathology of DD to achieve more effective therapeutic approaches.  
Due to the unique physiology of the palmar fascia and the lack of understanding of DD at 
a molecular level, there are no established animal or immortalized cell models in which 
to study DD development. We take the approach of comparing primary fibroblasts 
derived from surgically resected DD contracture (cord) tissue (DD cells) to fibroblasts 
derived from the palmar fascia of the adjacent, phenotypically unaffected digit exposed 
during surgery (PF cells). While DD may be associated with increased cancer mortality in 
some populations [11,12], patients with a family history of finger contractures do not 
display any major chromosomal rearrangements or deletions [13] and DD is considered a 
benign, heritable fibrosis [4]. Single nucleotide polymorphisms (SNPs) have been 
identified as potential markers of this heritability [14], and these polymorphisms are 
predicted to be present in all somatic tissues in these patients rather than limited to 
diseased tissues. PF cells can therefore be viewed as genetically matched “latent disease” 
cells that carry the same predisposing SNPs as DD cells, making them the ideal controls 
73 
 
 
 
for studies of the molecular mechanisms that promote disease development in this 
population. In addition, we derive a second control group of palmar fascia fibroblasts (CT 
cells) from patients with no history of DD who are undergoing surgeries for unrelated 
reasons, such as carpal tunnel release. We consider CT cells to be normal controls and 
useful comparators to patient matched PF/DD cells in studies designed to identify 
characteristics that are specific to cells predisposed to DD development [15,16].  
Using these unique cell models, we have focused on identifying molecules that regulate 
the proliferation and differentiation of palmar fascia fibroblasts into myofibroblasts, the 
hyper-contractile cell type that remodels the palmar fascia to induce finger contractures in 
DD. Several research groups have previously reported gene expression analyses of DD 
tissues or cells with the aim of identifying dysregulated genes with potential roles in 
myofibroblast development [13,16–20]. Our previous studies have focused on TGF-β1, 
encoding transforming growth factor-β1 (TGF-β1) and TGF-β-induced genes such as 
periostin [21]. In parallel, we and others [19] have identified IGFBP6 as a significantly 
downregulated transcript in DD tissue. The relevance of downregulated IGFBP6 
expression to the proliferation and differentiation of palmar fascia fibroblasts into DD 
myofibroblasts has not been previously explored.  
IGFBP6 encodes insulin-like growth factor binding protein (IGFBP)-6, one of a family of 
six secreted proteins that bind insulin-like growth factors (IGFs)-I and -II with high 
affinity and regulate their bioavailability [22]. While most IGFBPs can regulate the 
availability of both IGF-I and IGF-II under normal physiological conditions, IGFBP-6 is 
unique in displaying a 50 fold higher affinity for IGF-II [23,24], identifying it as an IGF-
II-specific binding protein under normal physiological conditions [23].  
In this study, we demonstrate that IGFBP6 mRNA and IGFBP-6 protein levels are 
downregulated components of DD cells, and that IGF2 mRNA and IGF-II peptide levels 
are upregulated in DD cells relative to controls. Recombinant IGFBP-6 was found to 
attenuate the proliferation of DD, PF and CT cells, and co-treatment with IGF-II was 
ineffective at neutralizing these effects. IGF-II significantly enhanced DD cell 
contractility and this effect could be abrogated by IGFBP-6. Overall, these findings 
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implicate IGFBP-6 and IGF-II as previously unrecognized regulators of DD cell 
proliferation and contractility that may have potential as therapeutic targets in this and 
related fibrocontractile diseases. 
3.2 Materials and Methods 
 Clinical specimen collection 3.2.1
Surgically resected Dupuytren's disease cords were collected from patients undergoing 
primary surgical resections at St Joseph's Hospital, London, Ontario. Samples of 
phenotypically normal palmar fascia tissue exposed during surgery were collected from 
an adjacent, visually unaffected digit for comparative analyses. None of these patients 
were being treated for recurrent disease. In addition, small samples of palmar fascia were 
collected from patients without Dupuytren's disease who are undergoing hand surgery for 
unrelated reasons, such as carpal tunnel release, in which the palmar fascia was 
phenotypically unaffected. All subjects provided written informed consent and specimens 
were collected with the approval of the University of Western Ontario Research Ethics 
Board for Health Sciences Research involving Human Subjects (HSREB protocol # 
08222E). 
 Immunohistochemistry 3.2.2
Surgically resected DD cord and patient matched, phenotypically normal palmar fascia 
samples were fixed in 10% formalin prior to dehydration, paraffin embedding and 
microtome sectioning. Paraffin-embedded specimens were sectioned (5 μm), dewaxed, 
rehydrated and treated with a 3% hydrogen peroxide solution to quench endogenous 
peroxidase activity. Slides were treated with a serum-free blocking reagent (Background 
Sniper, Biocare Medical, Concord, CA) for 10 min and rinsed in PBS prior to incubation 
with rabbit polyclonal IGFBP-6 (Austral Biologicals, San Ramon, CA) overnight at 4 °C. 
After a wash in PBS, the slides were incubated (30 min, 22 °C) with a biotinylated 
secondary anti-rabbit antibody (Vector Labs, Burlington ON), washed briefly in PBS, and 
incubated (30 min, 22 °C) with avidin/biotin/HRP complex (Vector elite PK-6100, 
Vector Labs, Burlington ON). Finally, the slides were washed with PBS, and incubated 
(1 min) in an enhanced diaminobenzidine (Cardassian DAB; Biocare Medical, Concord, 
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CA). Sections were counterstained with methyl green (10 min), dehydrated, cleared, and 
mounted with Permount (Fisher Scientific, Ottawa, ON).  
 Primary cell culture 3.2.3
Primary fibroblasts were isolated from surgically resected DD cord tissues (DD cells), 
phenotypically normal (non-fibrotic) palmar fascia tissue from an adjacent, visually 
unaffected digit (PF cells) and normal palmar fascia (CT cells) as previously described 
[25]. The cultures were maintained in α-MEM-medium supplemented with 10% fetal 
bovine serum (FBS, Invitrogen Corporation, Carlsbad, CA) and 1% antibiotic–
antimycotic solution (Sigma-Aldrich, St. Louis, MO). All primary cell lines (DD, PF and 
CT cells) were assessed at the lowest passage number achievable up to a maximum of 6 
passages, after which the cells were discarded. No changes in cell morphology, 
growth/viability or contractility attributable to serial passage were evident in these cells.  
 Real time PCR 3.2.4
Total RNA samples from primary DD, PF and CT cells were assessed for quality on an 
Agilent 2100 Bioanalyzer. 2 μg of high quality total RNA was reverse transcribed into 
cDNA first strand using the High-Capacity cDNA Archive Kit (Applied Biosystems) in 
accordance with the manufacturer's instructions. TaqMan gene expression assays were 
used to measure IGFBP6, IGF2 and IGF1 expressions. IGFBP6 (Hs00181853_m1) and 
IGF2 (Hs01005963_m1) expressions were measured relative to the RPLP0 endogenous 
control (Hs99999902_m1), and IGF1 (Hs01547656_m1) was measured relative to 
GAPDH (Hs99999905_m1) using the ΔΔCT method after confirmation of parallel PCR 
amplification efficiencies on a Real-Time PCR ABI Prism 7500. PCR reactions were 
carried out under the following conditions: Initial denaturation at 95 °C for 5 min 
followed by cycles of denaturation (95 °C for 15 s), primer annealing (60 °C for 1 min) 
and transcript extension (50 °C for 2 min) for 45 cycles. 
 Western immunoblotting 3.2.5
Surgically resected tissues were snap-frozen in liquid nitrogen and protein extracts were 
prepared using a tissue bio-pulverizer and PhosphoSafe Protein Extraction Buffer (VWR, 
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Mississauga, ON). Cultured cells were lysed in RIPA Cell Lysis Buffer (Teknova Inc., 
Hollister, CA) supplemented with protease inhibitor cocktail (Sigma-Aldrich, St. Louis, 
MO), 0.1 M NaF, 10 mM PMSF and 10 mM sodium orthovanadate and placed on ice for 
30 min after needle aspiration. After centrifugation to remove insoluble material, total 
protein concentrations were determined by BCA analysis. Gel electrophoresis on a 15% 
polyacrylamide gel and Western immunoblotting were performed using standard 
procedures, and proteins were visualized using enhanced chemiluminescence (ECL). The 
primary antibodies utilized were mouse monoclonal IGF-II (Upstate Biotechnology, 
Etobicoke, ON) and mouse monoclonal β-actin (Santa Cruz Biotechnology, Dallas, TX). 
Total protein levels were assessed by Ponceau S staining (Sigma Aldrich, Oakville, ON, 
Canada). 
 Quantitative IGFBP-6 immunoassay 3.2.6
The levels of secreted IGFBP-6 in DD and PF cell conditioned media were assessed 
using the Luminex xMAP fluorescent bead-based technology (Luminex Corporation, 
Austin, TX) and the Bio-Plex 200 readout system according to the manufacturer's 
instructions (Bio-Rad Laboratories Inc., Hercules, CA). IGFBP-6 levels were calculated 
from standard curves of recombinant IGFBP-6 in a solution using Bio-Plex Manager 
software (v.4.1.1, Bio-Rad). 
 WST-1 cell proliferation assay 3.2.7
The WST-1 assay (Roche, Mississauga, ON, Canada) was adapted to measure changes in 
the proliferation of primary fibroblasts grown on type-1 collagen, the most abundant 
protein component of palmar fascia. We have included type-1 collagen substrates in all 
our assays to more closely replicate in vivo conditions. In brief, 2 × 10
3
 cells were plated 
in α-MEM/2% FBS in 4 × 96 well trays pre-coated with 60 μl of type-1 collagen (1.8 
mg/ml), treatments or vehicles were added, and the trays were incubated at 37 °C for 7 
days. WST-1 reagent was added to the wells on days 1, 3, 5 and 7 to allow cleavage of 
the tetrazolium salt to formazan by cellular mitochondrial dehydrogenases. Equal 
volumes of supernatant were transferred to additional 96 well trays and absorbance 
measurements were taken at 450 nm and 650 nm (reference wavelength). This assay 
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measures electron transport across the plasma membrane of dividing cells, and thus 
functions as an indirect measure of viable cell proliferation. We interpret the outputs as 
net proliferation (total cell number changes due to the combined effects of mitogenesis 
and apoptosis). All experiments were performed at least three times on a minimum of 4 
DD, PF and CT cell lines, each assessed in triplicate. 
 Fibroblast populated collagen lattice assays 3.2.8
Collagen contraction assays were carried out using modified versions of Bell et al. [26] 
and Tomasek and Rayan [27]. In brief, the contractility of DD, PF and CT cells at low 
passage (≤6) was assessed in three-dimensional fibroblast populated collagen lattices 
(FPCLs). Collagen lattices were cast in 24-well tissue culture trays with each well 
containing 400 μl collagen (final collagen concentration of 1.8 mg/ml), 100 μl 
neutralization solution, treatment or vehicle, and 1 × 10
5
 cells. FPCLs were maintained in 
α-MEM supplemented with 2% FBS and 1% antibiotic–antimycotic solution at 37 °C in 
5% CO2. For “relaxed” FPCLs (rFPCLs), lattices were allowed to polymerize for 1 h 
before being gently released from the sides and bottoms of the wells using a metal rod. 
Relaxed FPCLs typically undergo gradual lattice contraction over 24 h in tissue culture 
media. Floating lattices for rFPCLs were digitally scanned at 24.0 h only. For “stressed” 
FPCLs (sFPCLs), the collagen lattices remained attached to the wells for 72 h to allow 
the cells to induce (and respond to) stress within the lattice and differentiate toward a 
contractile myofibroblast phenotype [28]. Lattices were released after 72 h, typically 
resulting in rapid contraction over 6 h. Floating lattices for sFPCLs were digitally 
scanned at release (0 h), 0.5 h, 1.0 h, 2.0 h and 6.0 h. The areas of individual lattices in 
rFPCLs and sFPCLs were determined using the freehand tool in ImageJ software. 
Sequential area calculations were then normalized to the area of the lattice (i.e. the area 
of the well in which the lattice was cast) prior to release. All experiments were performed 
on a minimum of 3 and a maximum of 10 DD, PF and CT cell lines, each assessed in 3 
separate experiments, in triplicate. 
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 Statistical analyses 3.2.9
Statistical analysis was conducted using SPSS v. 17 and Microsoft Excel 2007 statistical 
software. For sFPCL data, repeated measures analysis of variance analyses were used to 
assess the significance of treatment effects and treatment/time interactions to distinguish 
overall treatment-induced changes in contractility from treatment induced changes in 
contractility that became significant over time. Significant treatment/time interactions 
were further assessed with simple main effects analyses to determine at which time point 
a treatment had a significant effect. Paired t-tests were used to determine significant 
changes in contractility at 24 h in rFPCLs and in proliferation by change score analysis 
between day 7 and day 1. Results were deemed significant when p < 0.05. 
3.3 Results 
 IGFBP6 mRNA and IGFBP-6 levels are attenuated in 3.3.1
Dupuytren's disease tissues and in DD cells 
While IGFBP6 has been identified as a significantly downregulated gene transcript in 
gene array studies comparing DD tissues to phenotypically unaffected palmar fascia 
[19,20], corresponding changes in IGFBP-6 levels have not been reported. As shown in 
Figure 3-1A, decreased IGFBP-6 immunoreactivity was evident in paraffin-embedded 
sections of DD cord relative to visibly unaffected palmar fascia tissue from an adjacent 
digit in the same patient (Figure 3-1B). This decrease in IGFBP-6 immunoreactivity in 
DD tissue was despite an inverse disparity in the number of palmar fascia cells (stained 
with methyl green in Figure 3-1A and B) in DD cord tissues and the adjacent palmar 
fascia. To confirm the cellular source of IGFBP-6 in DD tissues, we assessed IGFBP6 
expression in primary fibroblasts derived from diseased palmar fascia (DD cells) relative 
to primary fibroblasts derived from the adjacent, phenotypically unaffected palmar fascia 
of the same patients (PF cells). As shown in Figure 3-1C, IGFBP6 mRNA levels were 
significantly lower in DD cells than in genetically matched PF cells. We also assessed 
IGFBP-6 secretion in DD and PF cells, and compared these levels to primary fibroblasts 
derived from normal palmar fascia from unrelated patients undergoing treatment for 
unrelated conditions (CT cells). IGFBP-6 secretion was significantly reduced in DD cells  
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Figure 3-1: IGFBP6 expression and IGFBP-6 secretion are downregulated in 
Dupuytren's disease (DD). 
Sections of paraffin embedded phenotypically normal, unaffected palmar fascia 
tissue (A) and DD “cord” tissue (B) from the same patient were assessed for 
IGFBP-6 immunoreactivity, evident as brown (diaminobenzidine, DAB) staining. 
Palmar fascia fibroblasts were counter-stained with methyl green. C) QPCR 
analysis of IGFBP6 mRNA levels in primary fibroblasts derived from 
phenotypically unaffected palmar fascia (PF cells) and DD cord tissue (DD cells) 
from the same patients (* = p < 0.05 for DD vs PF samples, N = 3, n = 3). D) 
IGFBP-6 secretion by normal palmar fascia fibroblasts (CT cells), PF cells and DD 
cells in serum free media over 48 h (* = p < 0.05 for DD vs CT samples, N = 3, n = 
1). 
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Figure 3-2: IGF2 expression and IGF-II levels are upregulated in DD. 
A) QPCR analysis of IGF2 mRNA levels in CT, PF and DD cells (* = p < 0.05 for 
DD vs CT samples, N = 6, n = 1). B) QPCR analyses of IGF1 and IGF2 mRNA 
levels in primary PF cells (grey bars) and DD cells (black bars) (* = p < 0.05 for 
DD vs PF samples, N = 6, n = 1). C) Representative Western immunoblotting 
analyses of DD and PF cell lysates and normal palmar fascia tissue (CT) and DD 
cord tissue lysates with an IGF-II antibody. Molecular weight (MW) markers are 
indicated in kDa. Immunoblotting for β-actin and Ponceau S staining for total 
protein (the major protein band at 67 kDa, albumin, is shown) confirmed equal 
protein loading. Tissue culture media samples with or without recombinant IGF-II 
(rIGF-II) were included as negative and positive controls. 
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relative to PF cells and CT cells over 48 h when cultured under identical serum free 
conditions (Figure 3-1D). 
 IGF2 mRNA and IGF-II levels are increased in DD cells 3.3.2
As IGFBP-6 has been reported to elicit effects by sequestering IGF-II, we assessed basal 
IGF2 expression in DD and PF cells. IGF2 mRNA levels were consistently (n = 6 
patients) and significantly (p < 0.05) increased in DD cells relative to patient-matched PF 
cell controls and non-patient-matched CT cells (Figure 3-2A). In contrast to IGF2, the 
expression of IGF1, encoding Insulin-like Growth Factor-I, was unchanged between DD 
and PF cells (Figure 3-2B). To determine if increased IGF2 expression resulted in 
increased IGF-II secretion, we assessed IGF-II levels in DD cord tissue and DD cell 
lysates. As shown in Figure 3-2C, IGF-II immunoreactivity was increased in DD tissue 
and cell lysates relative to normal palmar fascia tissue and PF cell lysates. Multiple bands 
correlating with precursor forms of IGF-II, including “big” IGF-II and variably 
glycosylated pro-IGF-II previously reported in human serum [29] were evident in all cell 
lysates. As our findings indicated reciprocal changes in IGFBP6 and IGF2 mRNA levels 
and IGFBP-6 and IGF-II protein levels in DD cells relative to controls, we compared the 
effects of recombinant IGFBP-6 and recombinant IGF-II, individually and in 
combination, with or without TGF-β1, on the net proliferation and contractility of DD 
and PF cells. 
 IGFBP-6 attenuates DD cell proliferation in an IGF-II 3.3.3
independent manner 
Based on our analyses of IGFBP-6 secretion by CT cells (Figure 3-1D) and previous 
studies in tumor cells [30], we chose to assess the effects of 400 ng/ml of recombinant 
IGFBP-6 on net cellular proliferation. As shown in Figure 3-3A, a single treatment with 
400 ng/ml of recombinant IGFBP-6 on day 0 induced a significant reduction in DD (p < 
0.01), PF and CT (each p < 0.05) cell proliferation. As TGF-β1 is an established 
component of DD [31], and has been shown to deplete IGFBP-6 secretion in human 
fibroblasts [32], the effects of TGF-β1 on proliferation of CT, PF and DD cells were also  
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Figure 3-3: IGFBP-6 attenuates the proliferation of DD, PF and CT cells. 
Net proliferation (growth and/or apoptosis) of CT (white bars, N = 3 patients, n = 
3), PF (grey bars, N = 4 patients, n = 3) and DD (black bars, N = 4 patients, n = 3) 
cells cultured on type-I collagen substrates was assessed using the WST-1 assay. 
Data are shown as change scores (absorbance on day 7 minus absorbance on day 1). 
Significant effects of treatment vs vehicle are indicated as * p < 0.05 and ** p < 
0.01, ns = not significant. Treatments were the following: A) IGFBP-6 treatment 
(400 ng/ml) or IGF-II treatment (100 ng/ml) or TGF-β1 (12.5 ng/ml) vs vehicle, B) 
IGF-II + IGFBP-6 treatment (100 ng/ml and 400 ng/ml respectively) vs vehicle, and 
C) mIGFBP-6 (400 ng/ml) or IGFBP-6 (400 ng/ml) vs vehicle. 
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assessed. A single treatment with 12.5 ng/ml of recombinant TGF-β1, as previously 
demonstrated [33] in DD and PF (each p < 0.05), and CT (p < 0.01), attenuated 
proliferation over the subsequent 7 days relative to vehicle treated cells. To assess the 
effects of IGF-II on cellular proliferation, DD, PF and CT cells were treated with a single 
dose of recombinant IGF-II at 100 ng/ml, as previously described [34,35]. While 
treatment with recombinant IGF-II at 100 ng/ml significantly enhanced CT cell 
proliferation over 7 days (p < 0.05), no significant effects of IGF-II treatment on the 
proliferation of DD or PF cells were detected (Figure 3-3A). As shown in Figure 3-3B, 
co-incubation of cells with IGFBP-6 and IGF-II at equimolar concentrations did not 
rescue the inhibitory effects of IGFBP-6 treatment. To confirm IGF-II independence of 
these effects on cell proliferation, DD, PF and CT cells were treated with a single dose of 
a non-IGF-II binding IGFBP-6 analog (mIGFBP-6) [36] at 400 ng/ml. IGFBP-6 and 
mIGFBP-6 had similar inhibitory effects on the proliferation of PF cells (p < 0.05, Figure 
3-3C) and CT cells (p < 0.01, data not shown). Unlike in PF and CT cells, mIGFBP-6 
was significantly (p < 0.05) less effective at inhibiting DD cell proliferation than IGFBP-
6, although both treatments had statistically significant negative effects relative to vehicle 
treated cells (p < 0.01). 
 IGF-II enhances DD cell contraction of collagen lattices 3.3.4
To assess the effects of IGF-II and IGFBP-6 on DD and PF cell contractility, we utilized 
two types of fibroblast populated collagen lattice assays, relaxed FPCLs (rFPCLs) 
[28,37–39] and stressed FPCLs (sFPCLs) [21,40,41]. The 72 h incubation period in the 
presence of treatments in the sFPCL protocol allowed us to distinguish the effects of 
treatment-induced myofibroblast differentiation [42] from the immediate effects of 
treatment that are measured in rFPCLs [38]. 
DD cells were more contractile than PF cells in rFPCL assays in the absence of treatment 
(Figure 3-4A). IGFBP-6 (400 ng/ml) did not significantly affect the contractility of DD, 
PF or CT cells in rFPCLs (data not shown). IGF-II (100 ng/ml) significantly enhanced 
rFPCL contraction by DD cells (p < 0.05) but did not significantly affect PF (Figure 3-
4A) or CT cell (data not shown) contractility. Platelet derived growth factor (PDGF), an 
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established inducer of fibroblast contractility in rFPCLs [38], enhanced both DD and PF 
cell contractility in these assays. IGFBP-6 (400 ng/ml) did not significantly affect the 
contractility of DD, PF or CT cells in sFPCLs (data not shown). IGF-II treatment 
significantly enhanced both PF (p < 0.05) and DD (p < 0.001) cell contractility over 6 h 
after lattice release (Figure 3-4C and D respectively). In addition to treatment effects, 
significant IGF-II treatment/time interactions were evident for both cell types (p < 0.01). 
While IGF-II significantly induced DD cell contraction at all time points after release, the 
level of significance increased from p < 0.01 at release to p < 0.001 6 h after release. 
Significant effects of IGF-II treatment were only evident 2 h after release in PF cells (p < 
0.05). TGF-β1 treatment (12.5 ng/ml) significantly enhanced DD cell (p < 0.01) 
contractility in these assays, whereas a significant TGF-β1 treatment/time interaction was 
evident in PF cells (p < 0.01) 6 h after lattice release (p < 0.01) (Figure 3-4B). IGF-II did 
not significantly affect sFPCL contraction by CT cells (data not shown). Co-treatments 
with equimolar IGFBP-6 and IGF-II abrogated the IGF-II induced contractility of both 
DD and PF cells (Figure 3-5A). 
As TGF-β1 signaling intermediates and IGF-II have been reported to elicit combinatorial 
effects on myofibroblast differentiation in murine fibroblasts [43], we assessed the effects 
of treating PF and DD cells with both growth factors in combination (Figure 3-5B). 
While TGF-β1 and IGF-II treatments significantly enhanced the contractility of PF and 
DD cells relative to vehicle treated controls, no significant combinatorial treatment 
effects were detected over treatment with either factor in isolation. 
3.4 Discussion 
In this study, we have identified IGFBP6 and IGF2 as reciprocally dysregulated genes in 
DD cells relative to PF cells. Previous studies have reported increased TGF-β1 
expression and sensitivity, enhanced contractility, α smooth muscle actin (αSMA) 
expression and myofibroblast differentiation in DD cells [44–46], features shared with 
primary myofibroblast-like cells derived from other fibroses [47–49]. Other than TGF-β1, 
very few of the dysregulated genes in DD cells have been functionally linked to the main 
characteristics of DD development, namely fibroblast proliferation and palmar fascia 
contraction by myofibroblasts. Based on our findings, we hypothesize that downregulated  
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  Figure 3-4: IGF-II enhances DD cell contraction of collagen lattices. 
The effects of IGF-II on PF (grey bars) and DD (black bars) cell contractility were 
assessed in relaxed fibroblast populated collagen lattice assays (rFPCLs) over 24 h 
(A) and stressed FPCLs (sFPCLs) over 6 h (B, C and D) as described in the 
Methods section. Significant treatment effects are denoted as * p < 0.05, ** p < 0.01 
and *** p < 0.001. The effects of treatment vs vehicle on rFPCL contraction were 
assessed by t-test analyses at 24 h (N = 4 patients, n = 3). The effects of treatment 
vs vehicle on sFPCL contraction were assessed by ANOVA of repeated measures 
analyses and, where treatment/time interactions were detected, by simple main 
effects analyses (N = 10 patients, n = 3). Treatments were the following: A) IGF-II 
(100 ng/ml) or PDGF (100 ng/ml) in rFPCLs and B) IGF-II (100 ng/ml) or TGF-β1 
(12.5 ng/ml) in sFPCLs. C) Contraction curves for PF cells from 0.5 h to 6 h after 
lattice release with vehicle, TGF-β1 or IGF-II treatment. D) Contraction curves for 
DD cells from 0.5 h to 6 h after lattice release with vehicle, TGF-β1 or IGF-II 
treatment. Significant treatment/time interactions are denoted as * p < 0.05 and ** p 
< 0.01. 
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Figure 3-5: IGF-II-induced PF and DD cell contractility is attenuated by 
IGFBP-6, but not enhanced by TGF-β1. 
The effects of co-treatment with IGF-II and IGFBP-6 (N = 3 patients, n = 3), and 
IGF-II and TGF-β1 (N = 6 patients, n = 3) were assessed on PF (grey bars) and DD 
(black bars) cell contractility in stressed fibroblast populated collagen lattice assays 
(sFPCLs) over 6 h. Significant effects of treatment vs vehicle on sFPCL contraction 
were detected by ANOVA of repeated measures analyses. Statistically significant 
treatment effects are denoted as * p < 0.05 and *** p < 0.001, ns = not significant. 
Treatments were the following: A) IGFBP-6 (400 ng/ml) and IGF-II (100 ng/ml) 
and B) TGF-β1 (12.5 ng/ml) and IGF-II (100 ng/ml). 
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IGFBP6 expression and upregulated IGF2 expression jointly contribute to DD 
progression by promoting fibroblast proliferation, contractility and palmar fascia 
contraction in DD.  
As IGFBP-6 is a high affinity IGF-II binding protein [23], we hypothesized that 
attenuation of IGFBP6 expression and IGFBP-6 protein levels in DD would enhance 
IGF-II availability and signaling. IGF-II signaling can promote mitogenesis [50–53] and 
inhibit apoptosis [54,55], and IGFBP-6 can antagonize these effects by sequestering and 
inhibiting IGF-II signaling [30,56–58].  However, co-treatment with equimolar IGFBP-6 
and IGF-II elicited similar negative effects on the net proliferation compared to cells 
treated with IGFBP-6 alone. Consistent with these findings, an IGFBP-6 analog with 
attenuated IGF-II binding capacity (mIGFBP-6) exhibited similar effects on PF cell 
proliferation to native IGFBP-6. These data suggest that IGFBP-6 attenuates PF cell 
proliferation through mechanisms that are independent of IGF-II sequestration, consistent 
with a subset of reports of IGFBP-6 actions in other diseases [36,59,60].  In contrast to 
PF and CT cells, mIGFBP-6 was significantly less effective at decreasing DD cell 
proliferation than native IGFBP-6. IGF2 expression is enhanced in DD cells relative to 
PF and CT cells, and exogenous IGF-II treatment did not promote DD cell proliferation 
(Figure 3-3A). We speculate that increased endogenous IGF-II expression in DD may be 
one of the (potentially several) factors that enhance DD cell survival (rather than 
proliferation) in a low IGFBP-6 environment. The identification and elucidation of the 
IGF-II dependent and independent mechanisms activated by IGFBP-6 in DD cells will be 
a focus of future studies.  
In contrast to its inhibitory effects on cellular proliferation, IGFBP-6 treatment did not 
significantly inhibit cellular contractility. However, IGFBP-6 was effective at attenuating 
the increase in PF and DD cell contractility induced by IGF-II treatment (Figure 3-5A). 
Overall, our data imply two distinct consequences of IGFBP-6 depletion in DD that are 
likely to enhance disease progression; the induction of IGF-II dependent and/or 
independent processes that increase the net proliferation of palmar fascia cells, and the 
enhancement of IGF-II induced cellular contractility.  
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In contrast to a previous study in nodule-derived DD cells cultured on tissue culture 
plastic where TGF-β1 was shown to be growth-stimulatory [44], TGF-β1 consistently 
inhibited the proliferation of DD, PF and CT cells cultured on type-1 collagen culture 
substrates (Figure 3-3A). This may reflect the effects of differing culture substrates 
(tissue culture plastic vs type-1 collagen in this study) and/or a biphasic effect of TGF-β1 
on fibroblast proliferation that is dose-dependent (0.025 ng/ml vs 12.5 ng/ml in this 
study). TGF-β1 concentrations used in this study were based on a previous report in DD 
identifying 12.5 ng/ml as the maximum concentration required to induce myofibroblast 
formation without having negative inhibitory effects [33].  As enhanced fibroblast 
proliferation and myofibroblast differentiation have been previously described as 
mutually exclusive outcomes in some fibroblast models [43], and TGF-β1 is an 
established inducer of myofibroblast differentiation [42,48], myofibroblast differentiation 
may be the dominant phenotype under these culture conditions.  The increased TGF-β1 
expression and enhanced basal contractility of DD cells [44–46] suggest that DD cells 
have differentiated further toward a myofibroblast phenotype than PF cells.  
Our analyses of DD and PF cells treated with TGF-β1 or IGF-II revealed some interesting 
and distinct behaviors in these genetically matched cells at differing stages of 
differentiation. TGF-β1 treatment significantly enhanced DD cell contractility (p < 0.01) 
but no significant treatment/time interactions were evident, suggesting that the 
procontractile effects of TGF-β1 treatment were induced prior to, and not after, lattice 
release. In contrast, no significant TGF-β1 treatment effects on PF cells were detected, 
and a significant (p < 0.01) time/treatment interaction was evident, suggesting that most 
of the contractility induced by TGF-β1 in PF cells occurred during the lattice contraction 
phase after release. These differences are visually evident in the parallel versus divergent 
contraction curves in Figure 3-4C and D. In contrast, IGF-II induced treatment and 
treatment/time interactions in DD cells, indicating effects of treatment both pre- and post-
release. IGF-II also induced treatment and treatment/time interactions in PF cells; 
however simple main effects analyses revealed that IGF-II treatment did not significantly 
affect lattice contraction until 2 h after release. These data suggest that IGF-II can act 
both pre- and post-release to enhance DD contraction, while acting mostly post-release to 
increase PF cell contraction. Thus, IGF-II and TGF-β1 may activate or potentiate distinct 
89 
 
 
 
pro-contractile signaling pathways in DD and PF cells. We were unable to detect 
significant additive effects of TGF-β1 and IGF-II treatment in our analyses; however it is 
unclear if that is because the pro-contractility pathway(s) were fully activated by each 
factor in isolation or if our assays were too insensitive to detect modest additive effects of 
treatment in cells with enhanced levels of contractility.  
The molecular mechanisms activated by IGF-II to enhance the contractility of DD and PF 
cells are currently unclear. Consistent with their contractile myofibroblast-like 
phenotype, untreated DD cells contracted rFPCLs to a greater extent than PF cells over 
24 h. DD cell contraction of rFPCLs was significantly (p < 0.05) enhanced by IGF-II, 
whereas PF cells were insensitive to IGF-II treatment under identical conditions. These 
data suggest that IGF-II can induce lattice contraction by DD cells without modifying the 
differentiation state of these cells, a process that typically requires a 48–72 h pre-
incubation period under isometric tension. We speculate that IGF-II enhances the three-
dimensional migration of DD cells in these rFPCLs, an effect previously shown for 
normal fibroblasts treated with PDGF [33]. PDGF treatment significantly enhanced 
rFPCL contraction by both DD (p < 0.01) and PF (p < 0.05) cells (Figure 3-4A), whereas 
TGF-β1, which significantly enhanced DD cell contraction in sFPCLs (Figure 3-4B), had 
no discernible effects on the contractility of DD or PF cells in rFPCLs (data not shown). 
That IGF-II enhanced rFPCL contraction by DD cells but not PF cells suggests that DD 
cells have enhanced sensitivity to IGF-II signaling, and that there may be a functional 
link between IGF-II sensitivity and the differentiation state of these cells. If future studies 
are able to substantiate this link, local administration of IGF signaling inhibitors [61–63] 
may have utility as novel treatment approaches to attenuate the contractility of 
myofibroblasts in DD patients post-surgery. Alternatively, novel therapies that restore 
IGFBP-6 levels to those evident in normal palmar fascia may be sufficient to attenuate 
IGF-II signaling and myofibroblast contractility. 
IGFBP-6 attenuated DD proliferation, while exogenous IGF-II potently enhanced the 
contractility of DD cells. Future studies will focus on elucidating the IGF-II-independent 
mechanisms regulated by IGFBP-6 and the mechanisms by which IGF-II signaling 
enhances DD cell contractility. These findings implicate IGFBP-6 and IGF-II as novel 
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regulators of DD cell proliferation and contractility that may have utility as targets to 
inhibit DD progression and recurrence. Additionally, these results support our hypothesis 
that the attenuation of IGFBP6 expression and enhancement of IGF2 expression promote 
DD development. Investigation into the molecular mechanisms that increase IGF2 
expression in DD will be the subject of chapter 4. 
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Chapter 4  
4 An analysis of transcriptional dysregulation of IGF2 
expression in Dupuytren’s Disease  
4.1 Introduction 
The Insulin-like Growth Factor (IGF) family is comprised of 2 ligands, IGF-I and –II, 6 
high affinity binding proteins (IGFBP-1 to -6) and 2 receptors, the Type I and Type II 
IGF receptors [1]. IGFBPs regulate the bioavailability of their ligands to their signalling 
receptor, the Type I IGF receptor (IGFIR) [1–3]. The Type II IGF Receptor (IGFIIR), 
which is also a cation-independent mannose-6-phosphate receptor, is a negative regulator 
of IGF-II signalling in most tissues. The IGFIIR can internalize IGF-II, and molecules 
with a mannose-6-phosphate moiety, for lysosomal degradation [4]. 
IGF signalling through the IGFIR can regulate proliferation, differentiation, and survival 
in a variety of systems (reviewed in [5,6]). As their names suggest, IGFs can also signal 
through the insulin receptor (InsR) to elicit metabolic or proliferative effects (reviewed in 
[7]). While isoform B of InsR has much higher affinity for insulin than for either IGF, 
IGF-II can interact with the isoform A of the InsR, (which lacks exon 11) with high 
affinity at physiologically relevant concentrations [8]. Additionally, subunits of IGFIR 
and InsR can create heterodimers and act as an additional set of signalling receptors for 
IGFs and insulin [9]. A key difference between the two IGFs is that IGF-I is largely 
regulated by growth hormone [10,11] while IGF-II is largely growth hormone 
independent and subject to multiple layers of complex genomic regulation and processing 
instead [12]. IGF-II levels are at their highest in the fetus, where it is believed to play an 
integral role in embryonic development [13–16]. Following birth, IGF-II levels decline 
and then increase again in adult humans until IGF-II becomes the predominant IGF in the 
circulation [14].  
The gene that encodes IGF-II, IGF2, is located within a 30 kb DNA region on 
chromosome 11p15.5. This gene contains 10 exons and can be transcribed from 4 distinct 
promoters; however the functional peptide is only encoded by the last 3 exons [17]. 
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Unlike most autosomal genes, which are expressed or transcriptionally silent irrespective 
of the parent from which they were derived, IGF2 is genomically imprinted and 
expressed only from the paternally-derived allele in most mammalian tissues [18]. Like 
many imprinted genes, IGF2 is located within a “cluster” of other genes that are also 
imprinted in various tissues. IGF2 is located adjacent to the insulin gene, INS, which is 
imprinted in yolk sack [19], and H19 [20].  H19 encodes a non-coding RNA that is 
reciprocally expressed with IGF2 i.e. H19 is only expressed from the maternally derived 
allele in most mammalian tissues [20]. IGF2 and H19 are separated by a CG-rich motif 
known as the H19 imprinting control region (ICR). In tissues where IGF2 is imprinted, 
the H19 ICR is methylated on the paternally derived allele and unmethylated on the 
maternally derived allele.  ICR methylation prevents CCCTC binding factor (CTCF) 
interactions and maintains transcriptional silencing of H19 by allowing transcriptional 
enhancers to drive IGF2 expression [21,22]. In addition to being regulated by the H19 
ICR, IGF2 contains another differentially methylated region (DMR) that is unmethylated 
on the paternally derived allele where IGF2 is expressed. The H19 ICR is unmethylated 
on the maternally derived allele, allowing CTCF to bind and prevent transcriptional 
enhancers from activating IGF2 expression [21,23]. The IGF2 DMR is methylated on the 
maternally derived allele and is believed to act as an additional mechanism to prevent 
IGF2 transcription from this allele (Figure 4-1).  
In Wilm’s tumour [24] or other cancers [25], the imprinting control mechanism can be 
disrupted and IGF2 can be expressed from both alleles. This is usually, but not 
exclusively, associated with loss of H19 expression from both alleles [26]. Unlike most 
tissues, IGF2 is biallelically expressed in adult human liver and in some areas of the brain 
[27,28]. The biological significance of genomic imprinting of genes in some tissues and 
not in others is still being elucidated. 
In addition to its transcriptional regulation by imprinting, tissue-specific regulation of 
IGF2 transcription can be imposed by the use of any or all of 4 distinct promoter regions 
designated P1, P2, P3, and P4 [17].  Transcription from these promoters can result in up 
to 5 distinct IGF2 mRNA transcripts, each of which encodes the same peptide [17]. In 
adult humans, transcription from P2 – P4 varies between subsets of tissue or organs, and  
99 
 
 
 
 
Figure 4-1: Allele-specific human IGF2 and H19 gene map 
The human IGF2 gene is genomically imprinted and reciprocally expressed with the 
maternally expressed H19 gene, which encodes a non-coding RNA. On the paternal 
allele, the IGF2 differentially methylated region (IGF2 DMR) is unmethylated while the 
H19 imprinting control region (H19 ICR) is methylated. Methylation of the H19 ICR 
prevents CTCF from binding, and allows enhancer elements to initiate IGF2 expression. 
On the maternal allele, the H19 ICR is unmethylated allowing CTCF to bind and block 
enhancer activity. This prevents IGF2 expression from the maternally-derived allele. 
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P3 and P4 appear to be the most active [17,29,30]. P1 transcripts are usually associated 
with the subset of tissues that biallelically express IGF2, such as the liver and some parts 
of the brain [27,31], while P2 transcripts have been shown to be associated with 
transformed or neoplastic cells [30]. The increased expression of IGF2 in some cancers 
can be the result of multiple promoter usage that results in multiple IGF2 transcripts, or 
the enhanced activity of individual promoters. For example, the P3 promoter is 
hypomethylated in a subset of human osteosarcomas and results in increased IGF2 
transcripts from P3 [32], while imprinting is lost (LOI) in other osteosarcoma cells [24] 
and IGF2 is expressed from several promoters on both alleles [29]. The potential for 
additional and/or enhanced IGF2 promoter usage contributing to increased IGF2 mRNA 
levels in benign fibrosis such as Dupuytren’s disease (DD) has not been reported. 
 Dupuytren’s Disease 4.1.1
DD is a benign fibromatosis affecting the palmar fascia that is characterized by the 
development of permanent finger contractures. The palmar fascia thickens and hardens as 
the result of excess collagen deposition by fibroblasts and contractile myofibroblasts 
within the disease cord [33–35]. This fibroproliferative disorder is one of the most 
common inherited connective tissue disorders affecting Caucasian males over 60 years 
[36,37] and there is a lack of truly effective treatment options. The “gold standard” 
treatment option, surgical resection of the disease cord [38,39], is associated with 
extensive post-operative rehabilitation and at least 1 in 3 patients will experience 
recurrence of contractures [40]. There is an obvious need for a better understanding of the 
molecular mechanisms that drive Dupuytren’s Disease development so that more 
effective and non-surgical therapeutic alternatives can be made available to these 
patients. 
Like virtually all fibroses, DD is characterized by excessive fibroproliferation, the 
increased presence and persistence of contractile myofibroblasts, and excess collagen 
deposition [41].  While relatively little is known about the roles of IGF-II in fibrosis 
development, it has been shown to induce collagen expression in systemic sclerosis-
associated pulmonary fibrosis [42] and to increase the contractility of DD cells [43]. 
IGF2 expression is also increased in DD cells relative to fibroblasts derived from non-
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fibrotic palmar fascia whereas IGF1 expression is unaffected [43]. The mechanisms that 
induce increased IGF2 expression in DD have not yet been investigated.  
4.2 Materials and Methods 
 Sample Collection: tissue and cells 4.2.1
Surgeons at the Roth | McFarlane Hand and Upper Limb clinic resected small palmar 
fascia tissue samples from patients with Dupuytren’s Disease (DD) and from patients 
undergoing carpal tunnel release (CT) with the approval from the University of Western 
Ontario Research Ethics Board for Health Sciences Research involving Human Subjects 
(HSREB protocol # 08222E, Appendix C). An additional tissue sample was taken from 
Dupuytren’s Disease patients as adjacent, phenotypically normal palmar fascia (PF). All 
three samples were also cultured for primary fibroblasts. Patients signed consent forms, 
received a letter of information prior to surgery, and their samples were de-identified to 
ensure patient confidentiality. 
 Primary cell culture 4.2.2
Primary fibroblasts were grown for a week in alpha-minimum essential media (α-MEM) 
containing 10% fetal bovine serum (FBS), 1% antibiotic-antimycotic and 1% L-
Glutamine (all from Invitrogen Corporation, Carlsbad, CA) (growth media).  Cells were 
passaged by first rinsing with 5 ml of phosphate buffered saline (PBS), and then 
incubating them with 2 ml 0.05% trypsin-EDTA (Invitrogen Corporation, Carlsbad, CA) 
at 37°C for 5 minutes to allow the cells to detach from the surface. Inactivation of the 
trypsin was accomplished by adding 2 ml of growth media with FBS. Cells, media and 
trypsin were then collected into a 15 ml conical tube by centrifugation (Hettich 
Zentrifugen Universal 32) at 2000 rpm for 5 minutes. The supernatant was then aspirated 
and the pellet was resuspended in 6 ml of media, split, and fresh growth media was 
added. The dishes were then incubated for 3-5 days. Fibroblasts were assessed up to a 
maximum of 6 passages.  
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 RNA isolation and Real Time PCR 4.2.3
Total RNA samples were isolated from primary DD, PF and CT cells using the RNeasy 
Mini Kit (Qiagen, Mississauga, ON, Canada) according to the manufacturer’s protocol. 
The quality and concentration of RNA were assessed on a NanoDrop Spectrophotometer 
ND-1000 (Thermo Scientific, Waltham, MA). cDNA was made from 2 μg of high quality 
total RNA using the High-Capacity cDNA Archive Kit (Life Technologies, Burlington, 
ON, Canada) in accordance with the manufacturer's instructions. TaqMan gene 
expression assays were used to measure IGF2 (Hs01005963_m1) and H19 
(Hs00262142_g1) expressions relative to the RPLP0 endogenous control 
(Hs99999902_m1) after validation of parallel PCR amplification efficiencies. PCR 
reactions employing the ΔΔCT method were carried out under the following conditions: 
Initial denaturation at 95 °C for 5 min followed by cycles of denaturation (95 °C for 15 
s), primer annealing (60 °C for 1 min) and transcript extension (50 °C for 2 min) for 45 
cycles on a Real-Time PCR ABI Prism 7500. 
 Loss of imprinted expression 4.2.4
Loss of imprinting (LOI) was assessed using nested PCR as described previously [24,44]. 
Genomic DNA was isolated from patient-derived fibroblasts using the DNeasy Blood and 
Tissue Kit (Qiagen, Mississauga, ON, Canada) according to the manufacturer’s 
instructions. The DNA samples were screened for heterozygosity of a restriction 
fragment length polymorphism (RFLP) in the 3’ untranslated region of the IGF2 gene 
which creates an ApaI restriction enzyme site. The first round of PCR with primers PA 
and PC was performed on 20-50 ng of genomic DNA and the amplified products were 
used as the template for a second round of PCR using primers PB and PC. The PCR 
amplicon from the second PCR round was subjected to restriction digestion with ApaI 
(New England Biolabs, Whitby, ON, Canada) at room temperature overnight. Primer 
sequences were: PA: 5’ TCCTGGAGACGTACTGTGCTA-3’, PB: 5’-
CTTGGACTTTGAGTCAAATTGG-3’ and PC: 5’-GGTCGTGCCAATTACATTTCA-
3’ based on  previous studies [24,44]. The positions of the primers are depicted in Figure 
4-2. Cells were deemed “informative” if they were heterozygous for the ApaI 
polymorphism and their alleles could be distinguished by agarose gel electrophoresis.  
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Total RNA was isolated from informative patient-derived cells using the RNase-free 
DNase set with the RNeasy Mini kit (Qiagen, Mississauga, ON, Canada) in order to 
avoid genomic DNA contamination. First-strand cDNA was synthesized using 
Superscript II RT (Invitrogen Corporation, Carlsbad, CA) according to the 
manufacturer’s protocol with 500 ng of total RNA using the PC primer. The nested PCR 
protocol and restriction enzyme digest analyses described from genomic DNA samples 
was repeated on ~50 ng cDNA from these cells and a reverse transcriptase negative 
control was included to detect any chromosomal DNA contamination.  
 IGF2 Promoter Usage 4.2.5
The protocol for identifying specific IGF2 promoter usage was adapted from Grbesa et 
al. [29]. Promoter-specific primers were used to amplify reverse-transcribed RNA 
(cDNA) immediately downstream of specific IGF2 promoters in DD, PF and CT cells. 
Primers are listed in Table 4-1 and locations in Figure 4-2. The reverse primer (PR) was 
common to all promoter-specific forward primers. Touchdown PCR was carried out with 
initial denaturation at 95°C for 5 min followed by 4 cycles of 95°C for 30 s, 68°C for 1 
min and 72°C for 1 min, then again for 13 cycles except the annealing temperature 
decreased by 1°C each cycle from 68°C, followed by 25 cycles of 95°C for 30 s, 55°C for 
1 min and 72°C for 1 min, with the final extension at 72°C for 10 min in the Px2 Thermal 
Cycler (Thermo Scientific, Waltham, MA).  
Table 4-1: Primers used during touchdown PCR to determine IGF2 promoter usage 
in DD, PF and CT cells. The reverse primer was common to all 4 promoter-specific 
PCR reactions. 
Promoter Primer (5’to 3’) Expected Band Size 
P1 CGAATTCTGGGCACCAGTGACTCCCCG 376 bp 
P2 ACCGGGCATTGCCCCCAGTCTCC 254 bp 
P3 CGTCGCACATTCGGCCCCCGCGACT 186 bp 
P4 TCCTCCTCCTCCTGCCCCAGCG 134 bp 
PR (reverse) CAAGAAGGTGAGAAGCACCAGCAT -- 
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Figure 4-2: Primer map for IGF2 gene 
Primer map depicting position of primers used for promoter usage analysis (P1-
P4, PR) and loss of allele-specific expression (PA, PB, PC). There are 4 distinct 
promoters that can initiate transcription of the IGF2 gene. The ApaI restriction 
fragment length polymorphism used for the loss of allele-specific expression 
analyses is located in the 3’ untranslated region. 
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 Epigenetic effects on IGF2 expression 4.2.6
DD, PF and CT cells were cultured on type I rat tail collagen (~1.8 mg/ml stock 
concentration) to better replicate in vivo conditions. Neutralization solution (3 parts 10X 
Waymouth media (Sigma Aldrich, St. Louis, MO), 2 parts 0.34 M NaOH) was added to 
the collagen solution in a 1:4 ratio and 1 ml of this solution was added to coat the bottom 
of each well in a 6-well tray. The collagen was allowed to set in these trays at 37°C for 30 
min. 1x10
5 
cells were seeded in each well of the collagen-coated tray and grown for 2 
days in growth media. After 2 days, cells were rinsed twice in PBS and incubated with 
serum-free media overnight. Treatments were added to media containing 2% FBS, and 
incubated at 37°C with 5% CO2. Each day, fresh media, containing new inhibitor was 
added until each treatment regime was completed. Treatments were as follows: 
decitabine, a DNA methyltransferase (DNMT) inhibitor (Cedarlane, Burlington, ON, 
Canada) was used at 10 µM for 72 hrs and trichostatin A (TSA), a histone deacetylase 
inhibitor (Cedarlane, Burlington, ON, Canada) was used at 300 nM for 48 hrs. Cells were 
then washed in PBS and incubated with 1 mL of 0.25 mg/ml collagenase XI (Sigma 
Aldrich, St. Louis, MO) in Hank’s Balanced Salt Solution media (Sigma Aldrich, St. 
Louis, MO) at 37°C for 25 min with rocking. Once the cells were detached, the trays 
were placed on ice to inactivate the collagenase. The cells were collected and centrifuged 
(Hettich Zentrifugen Universal 32) at 2000 rpm for 5 minutes. The supernatant was 
removed, and the pellet was rinsed in 1X PBS and stored at -20ºC prior to RNA isolation 
and subsequent real-time PCR analysis of IGF2 and H19 expression. Experiments were 
performed on 4 patients (N = 4, n = 1). Paired t tests were used to determine significant 
changes in IGF2 or H19 expression when p < 0.05. 
4.3 Results 
 Loss of imprinting in Dupuytren’s Disease cells 4.3.1
IGF2 expression is increased in primary DD fibroblasts relative to controls, but the 
mechanisms involved in this induction are currently unknown. Loss of imprinting (LOI) 
results in biallelic expression and increased IGF2 transcript levels in cancers; however 
there is no evidence of LOI expression of IGF2 in benign fibroses to our knowledge. To 
106 
 
 
 
assess IGF2 imprinting, DD, PF and CT cells were screened to determine whether they 
were “informative” for these analyses. The 3’ untranslated region (3’UTR) of the IGF2 
gene contains a restriction fragment length polymorphism (RFLP) that introduces an 
ApaI restriction enzyme site. An ApaI restriction digest of genomic DNA amplified from 
the IGF2 3’UTR allowed for the identification of individuals with one or more of these 
RFLPs. In those individuals with an RFLP in only one allele (deemed “informative”), the 
two alleles could be distinguished by restriction digest analyses with ApaI and routine 
agarose gel electrophoresis. If normal IGF2 imprinting is occurring, only one of these 
alleles (with or without the RFLP) will be identified in cDNA derived from reverse 
transcribed mRNA. If IGF2 imprinting is lost and both alleles are transcribed, restriction 
mapping of cDNA derived from reverse transcribed mRNA is predicted to yield two 
DNA species, one with and one without an ApaI restriction site. 
Eight PF/DD (N = 8, n = 1) and 7 CT patients (N = 7, n = 1) were screened for 
heterozygosity of the IGF2 alleles. 3 PF/DD patients (#188, #265 and #274) were found 
to be informative based on the presence of two bands after the ApaI restriction digest of 
the IGF2 3’UTR PCR product derived from the genomic DNA by agarose gel 
electrophoresis (Figure 4-3A). Unfortunately, none of the 7 CT patient cell lines were 
informative (data not shown), with 4/7 containing- and 3/7 lacking the polymorphic ApaI 
site in both alleles. When mRNA samples derived from the informative DD cell lines 
were reverse transcribed into cDNA, 2 of the 3 informative patient samples yielded 
restriction patterns similar to their genomic DNA samples, indicating loss of IGF2 
imprinting. Restriction digest analysis of cDNA derived from patient #274 yielded a 
single band indicating the expression of a single allele that lacked an ApaI restriction site. 
Interestingly, evidence of LOI of IGF2 was also evident in the PF cells derived from 
patients #188 and #265, whereas maintenance of IGF2 imprinting was evident in PF cells 
derived from patient #274 (Figure 4-3B).  
Biallelic expression of IGF2 or LOI at the IGF2 locus is usually associated with a 
reciprocal loss of H19 expression [26]. To assess this in DD, IGF2 and H19 mRNA 
levels were assessed by real-time PCR in the 3 informative patients identified in the LOI 
studies. Consistent with previous analyses, all 3 DD cell lines exhibited higher IGF2  
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Figure 4-3: Loss of imprinting at the IGF2 locus is detected in DD cells. 
A) Genomic DNA samples from fibroblasts derived from patients with DD were 
screened for heterozygosity of an ApaI restriction site in the 3’ UTR of the IGF2 
gene by PCR. U = uncut DNA, C = restriction digested with ApaI. Three patients 
(*, #188, #265 and #274) were found to be “informative” as indicated by the 
presence of two bands in the “C” lane (orange arrows) corresponding to one allele 
with and one without an ApaI restriction site. B) Reverse transcribed mRNA 
(cDNA) of these 3 patient-derived cells were analyzed by PCR to determine 
whether ApaI restriction digests of this region in IGF2 gene resulted in 2 bands 
(confirming LOI) or  a single band (maintenance of imprinting). C) QPCR 
analysis of IGF2 and D) H19 expression in PF (grey bars) and DD (black bars) 
cells derived from the 3 informative patients (N = 3, n = 1) 
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expression than their corresponding PF cells (Figure 4-3C). H19 expression was 
undetectable after 45 PCR cycles in the DD cells derived from the two patients which 
displayed loss of imprinting (#188 and #265), indicating that the H19 transcript levels 
were either absent or below detectable limits (Figure 4-3D).  In contrast, H19 mRNA was 
readily detectable in DD cells derived from patient #274, consistent with maintenance of 
normal IGF2/H19 imprinting. In comparison to DD cells derived from the same patients, 
H19 expression was readily detectable in all three sets of PF cells.  
 Histone deacetylase and DNA methyltransferase inhibitors 4.3.2
increases IGF2 and H19 expression, respectively 
Previous reports have shown that histone deacetylases (HDACs) regulate many imprinted 
genes, including IGF2 in human fibroblasts [45]. To determine if HDACs and other 
epigenetic modifiers were having distinct effects in PF and DD cells, the effects of broad 
spectrum inhibitors of HDACs and DNA methyltransferases (DNMTs) on IGF2 and H19 
expression were assessed. Trichostatin A, an established HDAC inhibitor [46,47], was 
shown to significantly induce IGF2 expression (Figure 4-4A) and in PF (p < 0.05) and 
DD (p < 0.01) cells, and significantly attenuate H19 expression (Figure 4-4B) in PF cells 
(p < 0.01), relative to vehicle treatment. Decitabine, an established DNMT inhibitor [48], 
induced H19 expression (Figure 4-4B) in PF cells (p < 0.05) only.   
 Multiple promoters are active in Dupuytren’s Disease 4.3.3
IGF2 transcripts can be derived from 4 different promoters (P1-P4) and their activities 
are reported to vary with tissue type, developmental stage and disease state [17,27,49]. 
To identify the IGF2 promoters that were active in DD, PF and CT cells, promoter-
specific primers were designed based on previous studies [29] and the expression levels 
of promoter-specific transcripts were assessed by qualitative reverse transcription PCR. 
RNA transcribed from HepG2 cells was used as a positive control for these analyses. 
Unexpectedly, despite P1 activity normally being highest in the liver [27], P1 transcripts 
were not detected in these liver carcinoma cells, which is in accordance with a previous 
study reporting that IGF2-P1 is silent in HepG2 cells [50]. As shown in Figure 4-5, IGF2 
transcripts from P3 and P4 were consistently expressed in all of the DD, PF and CT cell  
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Figure 4-4: Inhibition of histone deacetylases induces IGF2 expression in DD 
and PF cells and attenuates H19 expression in PF cells. 
The effects of trichostatin A (TSA, 300 nM for 48 hrs), a histone deacetylase 
inhibitor, and decitabine (Dec, 10 uM for 72 hrs), a DNA methyltransferase inhibitor 
were assessed on A) IGF2 and B) H19 expression in PF (grey bars) and DD cells 
(black bars) cultured on type I collagen (N = 4, n = 1). Treatment were refreshed each 
day in media containing 2% FBS. Significant treatment effects were determined by 
paired t test and are denoted as * p < 0.05 and ** p < 0.01. (Data is plotted as mean ± 
SE) 
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Figure 4-5: DD cells express IGF2 transcripts derived from P2, P3 and P4. 
PCR analysis of A) P1, B) P2, C) P3 and D) P4 promoter-derived IGF2 transcripts in 
primary DD, PF and CT cells (N = 4 each, n =1) . Reverse transcribed RNA from HepG2 
cells was used as a positive control in this analysis. As shown in A) IGF2 transcripts 
originating at P1 were only evident in 2 PF cells isolates. B) IGF2 transcripts originating 
at P2 were evident in a subset of DD, PF and CT cells.  In contrast, IGF2 transcripts 
originating at P3 (C) and P4 (D) were evident in all 3 cell types. (* denotes patient 
identified to display loss of imprinting).  
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lines assessed (N = 4/group, n = 1). In contrast, 3/4 of the DD cells, 2/4 of the PF cells 
and 1/4 of the CT cells utilized P2 to transcribe IGF2. Transcripts from P1 were 
identified in 2/4 PF patients (including patient #265, identified to have LOI of IGF2) 
whereas no evidence of P1 activity was evident in any of the DD or CT cell lines 
assessed. 
4.4 Discussion 
In this study, loss of imprinted IGF2 expression and aberrant IGF2 promoter usage were 
investigated as possible explanations for the increased IGF2 expression in DD. Loss of 
imprinting was detected in a subset of DD patients and multiple IGF2 promoters were 
activated in DD cells, both of which are likely to contribute to the increased IGF2 
expression in DD cells. Loss of imprinting of IGF2 has been demonstrated in a variety of 
cancers [24] and the functional consequences of this are typically: increased IGF2 
expression and cell proliferation [51,52], presumably due to increased IGF-II signalling. 
LOI of IGF2 was detected in two of the three “informative” patients with Dupuytren’s 
Disease identified in this pilot study. Many more informative patients would need to be 
identified to gain further insight into how prevalent LOI of IGF2 is in DD.   
Interestingly, LOI of IGF2 was also detected in PF cells derived from the non-fibrotic 
palmar fascia of these patients. While the palmar fascia from which PF cells are derived 
is phenotypically normal, it is immediately adjacent to fibrotic DD cord tissue and may 
be in an activated “pre-disease state”.  Genetic predisposition to DD development is also 
evident in many patient families, and thus PF cells may be predisposed to fibrosis relative 
to normal palmar fascia fibroblasts (CT cells). These PF cells exhibited LOI of IGF2 but 
maintained detectable H19 expression, unlike the DD cells derived from these patients.  
While preliminary, these data may be suggestive of progressive changes in the IGF2/H19 
axis during disease development.  Additional studies will be necessary to determine if 
loss of IGF2 imprinting precedes loss of H19 expression during DD development.  
The proportion of the population that are heterozygous for the ApaI polymorphism in the 
3’UTR of IGF2 was reported to be ~44% [53], which correlates well with our findings of 
37.5% of DD patients being heterozygous for this RFLP. 62.5% of DD patients and 57% 
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of CT patients were homozygous for the ApaI polymorphism, which is higher than the 
48.3% reported in larger population studies [53]. In contrast to CT patients, none of the 
DD patients that were screened in this analysis lacked the RFLP, a genotype which is 
reported to represent only ~8% of the population [53]. Taking all cell groups together, of 
the 15 patients screened for heterozygosity of the ApaI polymorphism, 20% were 
heterozygous, 60% were homozygous for the site, while 20% lacked the polymorphism. 
While the different frequencies of the genotypes observed in this study are likely to be 
skewed by the small sample size, it is also plausible that the frequencies differ between 
disease and normal populations. Larger scale studies would be required to establish more 
accurate genotype frequencies within Dupuytren’s Disease populations relative to 
normal.  
Since no heterozygous (informative) CT patients were identified in this study, no 
conclusions can be drawn in the context of a “baseline” for LOI of IGF2 in the normal 
population. Previous studies have indicated that 20 to 25% of Caucasians with a mean 
age of 60 years demonstrate LOI of IGF2 [54]. LOI of IGF2 may be inherited or 
congenitally acquired and be stable over time in these patients [54]. It is unclear if the 
findings of this study, indicating LOI of IGF2 in 2/3 informative patients, indicate chance 
findings or if LOI of IGF2 is a risk factor for DD development. Additional, much larger 
scale studies will be required to address these possibilities. 
The use of IGF2 promoter P1was identified in 50% of the PF cells assessed in this study, 
but not in any of the DD or CT cells assessed. P1 transcripts are normally evident in the 
liver and in those parts of the brain where biallelic expression of IGF2 is the norm. Two 
of the four patients from whom these PF cells were derived also demonstrated LOI of 
IGF2, however only one expressed P1 transcripts. These P1 transcripts were expressed in 
PF cells, but not in DD cells derived from the same patients with increased IGF2 
expression.  This is not the first study in which the presence of IGF2 transcripts from P1 
has failed to correlate with LOI of IGF2 [29] and further analyses will be required to 
determine the relevance of these findings. 
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Further studies will be required to gain a better understanding of LOI of IGF2 in DD. 
These studies should include investigations of CCCTC binding factor (CTCF) 
interactions with the H19 imprinting control region (ICR), assessments of the methylation 
status of the H19 ICR and of the IGF2 differentially methylated region (DMR). 
Methylation at the H19 ICR would prevent CTCF from binding and allow enhancers to 
activate IGF2 expression while silencing H19. The current dogma would predict that the 
H19 ICR will be methylated in patients demonstrating LOI of IGF2 while the IGF2 DMR 
may be unmethylated.  Previous studies in other systems would suggest that the 
methylation status of these loci are integral to maintaining imprinting at the IGF2-H19 
axis [21,26,55]. The addition of a DNMT inhibitor to PF cells significantly increased H19 
expression and a non-significant trend (p = 0.123) towards increased H19 expression was 
evident in DD cells. These findings are consistent with hypomethylation of the H19 ICR, 
which allows CTCF to bind and activate H19 transcription. Unexpectedly, treatment of 
DD and PF cells with the DNMT inhibitor had no discernible effects on IGF2 expression. 
Based on previous studies [56,57], decitabine (5-aza-2-deoxy-cytidine) treatment was 
predicted to initiate expression of IGF2 from the maternal allele and to potentially 
increase P2-P4 promoter usage. One possible explanation is that decitabine only inhibits 
DNA methylation in newly replicated DNA [48]. Thus, it may be necessary to treat cells 
over a multiple passages to induce the increases in IGF2 expression reported in other 
systems [57]. As P2 was activated more frequently in DD cells, it is possible that the 
IGF2-P2 promoters are in a less methylated state in these cells relative to the same sites 
in CT cells. Future studies should focus on determining the relative methylation status of 
the P2 and P3 promoter regions in DD, PF and CT cells.  
Histone acetylation is an epigenetic mark that promotes opening of the chromatin 
structure and the activation of gene transcription [58]. Trichostatin A (TSA) has been 
shown to inhibit histone deacetylases (HDACs), the enzymes that inhibit gene 
transcription by removing these acetylation marks [46,47]. HDACs can regulate 
imprinted genes in human fibroblasts and HDAC inhibition by TSA has been previously 
demonstrated to induce LOI of IGF2 [45].  TSA treatment of PF and DD cells increased 
IGF2 expression in both groups, suggesting that histone acetylation is likely to have a 
role in regulating IGF2 gene expression in these cells. Future studies could confirm 
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whether HDAC inhibition increased IGF2 expression in PF and DD cells by inducing 
biallelic IGF2 expression.  
Both loss of imprinting and activation of the IGF2-P2 promoter are likely to contribute to 
the increased IGF2 expression evident in DD cells. This increase in IGF2 expression is 
predicted to cause increased IGF-II signalling and promote the contractility of DD cells. 
IGF-II inhibitors or factors that regulate IGF2 expression may have potential as 
therapeutic targets to attenuate DD progression and recurrence. Additionally, if loss of 
imprinting is confirmed to be a relatively common component of DD development, 
biallelic IGF2 expression may have utility as one of several markers to differentiate 
between the general population and those individuals who are predisposed to develop 
Dupuytren’s Disease. 
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Chapter 5  
5 General Discussion and Conclusion 
5.1 Thesis Summary 
Dupuytren’s Disease (DD) is a heritable and benign fibromatosis that affects the palmar 
fascia. While the name specifically refers to contractile fibrosis of this particular tissue, 
this disease displays characteristics that are common to other connective tissue fibroses 
[1]. Two of these characteristics are increased β-catenin levels and the repressed 
expression of IGFBP6. In chapter 2 of this thesis, β-catenin was shown to associate with 
the promoter region of IGFBP6 in PF and CT cells, which are derived from non-fibrotic 
tissues, but not fibrosis-derived DD cells. These findings correlated with increased 
IGFBP6 expression levels in PF and CT cells relative to DD cells and were consistent 
with causative link between loss of β-catenin interactions with the IGFBP6 promoter and 
IGFBP6 expression. In addition to IGFBP6, more than 2 000 additional and novel genes 
were identified that have interactions with β-catenin that were specific to DD, PF or CT 
cells.  
In chapter 3, the functional consequences of depleting IGFBP6 expression was examined 
in the contexts of cellular proliferation, contractility and migration. Exogenous addition 
of IGFBP-6 was shown to inhibit the proliferation of DD, PF and CT cells. The major 
IGFBP-6 ligand, IGF-II, was found to be upregulated in DD, and distinct functional roles 
for this peptide were identified in CT, PF and DD cells. These novel roles included IGF-
II induced increases in the cellular contractility and migration of DD cells, increased 
contractility of PF cells and increased proliferation of CT cells.  
Lastly, the mechanisms that promote the overexpression of IGF2 in DD cells were 
explored in chapter 4. Loss of IGF2 imprinting was identified in a subset of DD patients, 
and cell-type specific aberrations in IGF2 promoter usage were identified in DD, PF and 
CT cells.  The findings reported in Chapters 2, 3 and 4 suggest that a complex array of 
transcriptional modifications and signalling events promote DD development. Some of 
these events can be envisaged as contributing to a potential feedback loop, where loss of 
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β-catenin interactions with the IGFBP6 promoter region in DD cells leads to 
downregulation of IGFBP6 expression and IGFBP-6 secretion, thereby enhancing IGF-II 
signalling, contraction of ECM by DD cells and, based on previous literature [2,3], IGF-
II and mechano-transduction induced changes in the accumulation of β-catenin in palmar 
fascia fibroblasts.  
5.2 Dupuytren’s Disease and cancer development 
The previous studies from our laboratory that identified β-catenin accumulation in DD 
cells [4] correlated with the increased levels of β-catenin interactions with the genome in 
DD cells relative to CT and PF cells reported in this thesis. In addition to the findings 
discussed in detail in Chapter 2, the Ingenuity analysis revealed that many of the genes 
specifically associated with β-catenin in DD cells have been previously reported to have 
roles in cancer development. These findings may have relevance to the increased 
incidence of cancer development in patients with a history of DD [5–7].  Correlations 
between types of abnormal wound repair including fibrosis and cancer development have 
been extensively reviewed in the literature [8], and there is evidence that some of the 
molecular mechanisms that promote fibrosis can lead to cancer development [9,10]. The 
stroma microenvironment around epithelial tumours has many similarities to the 
extracellular matrix in fibrosis, including the increased deposition of collagens and other 
ECM molecules, and these changes have been correlated with increased cancer risk [11–
13] and enhanced myofibroblast differentiation [14]. 
The findings of loss of IGF2 imprinting and aberrant IGF2 promoter usage in DD and PF 
cells described in Chapter 4 may provide additional insights into the links between DD 
and tumour development. Loss of IGF2 imprinting is a relatively common occurrence in 
cancers and has been implicated in tumour development [15–17].  While loss of IGF2 
imprinting is associated with overgrowth syndromes [18], a subset of the apparently 
normal population can also exhibit loss of IGF2 imprinting in some tissues [19]. It is 
unclear whether these individuals are predisposed to cancer development, and/or from the 
findings in Chapter 4, DD development relative to the majority of the population 
exhibiting normal IGF2 imprinting.  Much larger scale studies will be required to 
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determine if loss of IGF2 imprinting is over-represented in a subset of patients with DD, 
and if so, if those patients have an increased incidence of cancer development. 
5.3 Origin of DD myofibroblasts 
Cancer-associated fibroblasts (CAFs) have been shown to enhance epithelial-
mesenchymal transition (EMT) and tumour progression by releasing growth factors and 
cytokines into the stroma [20,21]. β-catenin-mediated trans-regulation of gene 
transcription has a well-documented role in promoting EMT [2,22–24], and IGF-II is one 
of the growth factors shown to induce β-catenin nuclear translocation and EMT [2]. It is 
plausible that keratinocytes from the epidermis or endothelial cells from adjacent blood 
vessels may undergo epithelial or endothelial transition to fibroblasts or myofibroblasts 
(Figure 5-1) to promote DD progression. DD-associated fibroblasts have been shown to 
secrete factors, such as TGF-β, IGF-II and EGF, with established roles in promoting 
EMT through β-catenin-mediated processes [2,25–28]. As shown in Figure 5-2, TGF-β 
can downregulate IGFBP6 expression and IGFBP-6 secretion, effects that are predicted 
to increase IGF-II signalling. Increased IGF-II signalling may promote nuclear 
translocation of β-catenin  and facilitate EMT in DD. TGF-β signalling can also increase 
β-catenin levels in DD [3], however whether this increase in total cellular β-catenin 
induces nuclear localization of β-catenin in DD cells is yet to be explored. It is currently 
unclear if TGF-β can induce EMT independently of IGF-II or if synergistic interactions 
are required to activate this process. Future studies should address the possibility that 
TGF-β and/or IGF-II can induce EMT in a β-catenin-dependent manner and enhance DD 
progression. If this is shown to be the case, the palmar epidermis of individuals with DD 
may be compromised by the local fibrosis, and therapeutic interventions to EMT in the 
palmar epithelium may inhibit DD recurrence. 
Interestingly, many of the genes shown to associate with β-catenin in DD and PF cells 
have established roles in cells of neuronal origin (See Appendices F and G). The neural 
crest has been hypothesized as a source of mesenchymal stem cells (MSCs) [29], and 
increased numbers of MSCs have been reported in DD relative to controls [30,31].  These 
cells were postulated to have been derived from both perinodular fat and disease cord 
tissues in DD patients and were not evident in palmar fascia samples derived from  
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Figure 5-1: Origin of myofibroblasts. 
Myofibroblasts can potentially be derived from many sources, 
including resident fibroblasts, hepatic stellate cells (HSCs), smooth 
muscle cells (SMCs), epithelium or endothelium (through epithelial- 
or endothelial- mesenchymal transition (EMT), or from the bone 
marrow, or from stem cells. (Reprinted with permission from Hinz et 
al. [32]).  The source(s) of the myofibroblasts that induce finger 
contractures in DD are yet to be determined.   
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patients undergoing carpal tunnel surgeries [30]. Unfortunately, it is unclear if this 
increase in MSC numbers in DD tissues was truly associated with DD development or 
simply a consequence of a wound healing event in the palmar fascia that was not evident 
in the unwounded palmar fascia used as controls.  Increased numbers of MSCs are a 
normal finding during the repair of many tissues [33–35]. Another possibility is that DD 
cells are derived from pericytes, a type of perivascular cell that is derived from the neural 
crest, exhibit neural epitopes including NG2, are α-SMA-positive and are highly 
contractile [36,37]. Future studies should include the analyses of DD cells for NG2 and 
other neural crest markers to confirm the origins of these cells. 
5.4 Is IGFBP6 a “fibrosis suppressor gene”? 
The findings reported in Chapter 3 demonstrated that IGFBP-6 can inhibit basal 
proliferation and IGF-II induced contraction of DD cells. As IGFBP6 expression and 
IGFBP-6 secretion are attenuated in DD, this molecule could represent a “fibrosis 
suppressor” that is turned off by the loss of β-catenin interactions during DD 
development. Thus, re-expression of IGFBP6 in DD cells to the levels evident in CT cells 
may drive palmar fascia fibroblasts towards conditions approaching normal homeostasis 
where fibrosis is inhibited.  
Bexarotene (trade name Targretin, LGD1069) is a retinoid X receptor agonist (rexinoid) 
that has been shown to increase IGFBP-6 levels in other systems [38]. This therapeutic 
intervention may potentially inhibit connective tissue fibroses including DD.  Bexarotene 
is an FDA approved cutaneous T cell lymphoma treatment [39] that is currently being 
assessed for its efficacy against other cancers [40,41] and neurological diseases [42,43].  
Previous studies in breast cancer indicate that the enhanced expression and secretion of 
IGFBP-6 is a primary mechanism by which bexarotene inhibits breast cancer cell growth 
through an AP-1/c-fos/c-jus-mediated mechanism [38,44].  Additionally, bexarotene has 
been shown to repress CCND1 [45], encoding the proliferation-associated cell-cycle 
protein cyclin D1, and to inhibit cyclooxygenase-2 (COX-2) [44], which is reported to 
increase stromal fibrosis in colorectal cancer [46]. COX-2 inhibitors have been shown to 
reduce fibrosis in other systems [47]. It is plausible that bexarotene would increase 
IGFBP-6 secretion in fibroblasts and repress CCND1 to limit fibroproliferation in DD.  
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Figure 5-2: TGF-β1 treatment of PF and DD cells represses A) IGFBP6 
expression and B) IGFBP-6 secretion. 
PF and DD cells were treated with TGF-β1 (12.5 ng/ml) for 48 hours. RNA 
was extracted and reverse transcribed for analysis by real-time PCR for 
IGFBP6 expression. Media was collected and assessed by Luminex 
Multiplex assay for IGFBP-6 protein levels. TGF-β1 further repressed both 
mRNA and protein levels relative to vehicle treated cells. 
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Enhanced IGFBP-6 levels would also be predicted to inhibit IGF-II signalling, thereby 
attenuating IGF-II induced myofibroblast contractility. While outside of the main scope 
of this thesis, pilot studies were performed to assess the effects of bexarotene treatment of 
DD cells in vitro. The preliminary findings indicate that treatment with 1 µM bexarotene 
induces IGFBP6 expression by approximately 2-fold and inhibits the proliferation of DD 
fibroblasts by approximately 30% over 7 days without affecting PF cell proliferation 
(data not shown). These preliminary findings support the hypothesis that bexarotene may 
have utility as an inducer of endogenous IGFBP6 expression and inhibitor of 
fibroproliferation in DD, and these studies are ongoing in our laboratory.  
5.5 Mechanisms of IGF-II induced contraction 
A novel role for IGF-II as an inducer of DD myofibroblast contractility was identified in 
Chapter 3. Intriguingly, IGF-II induced contraction of DD and PF cells without inducing 
any significant effects on α-smooth muscle actin (α-SMA) expression or levels, 
suggesting that this increased contractility was independent of the differentiation state of 
these cells. In addition, IGF-II was shown to induce the ability of DD cells to contract 
unstressed collagen lattices.  This effect was interpreted as likely to be due to an increase 
in three-dimensional migration within the collagen lattice based on the similarities 
between the effects of IGF-II and platelet derived growth factor (PDGF), shown to induce 
migration in these lattices in previous studies [48,49]. While the signalling pathways 
induced by IGF-II to elicit these effects are yet to be elucidated, an intriguing possibility 
is that they are mediated through the activation of focal adhesion kinase (FAK). FAK 
activation is an established component of integrin signalling and cell migration (reviewed 
in [50,51]).  Links between ligand-induced activation of the IGFIR and FAK activity 
have been reported in cancer cell models [52]. These studies reported IGF-I induced 
migration of breast cancer cells through RACK1 (receptor for activated C kinases), a 
scaffold protein which links the IGF and integrin pathways [53,54]. IGF-I signalling 
through the IGFIR can recruit RACK1 to induce an association with the β1 integrin 
subunit through FAK to facilitate cell migration [53].  It is currently unclear if IGF-II 
signalling can induce similar effects through the IGFIR, and this should be a priority for 
future studies.  
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In addition to its effects on DD migration in three dimensional collagen matrices, pilot 
studies beyond the scope of this thesis have provided preliminary evidence that IGF-II 
can induce the expression of CDH11, encoding OB-cadherin, in stressed FPCLs. 
Increases in CDH11 expression and OB-cadherin levels have been correlated with 
increased myofibroblast contractility in previous studies [55].  The inclusion of OB-
cadherin in adherens junctions has been shown to enhance myofibroblast contractility by 
increasing the strength of cell-cell contacts [55], and this may suggest an additional 
potential mechanism by which IGF-II might be inducing these effects. Interestingly, β-
catenin has been shown to interact with the 3’ untranslated region (UTR) of CDH11 to 
stabilize CDH11 expression [56]. Future studies would be required to determine if this β-
catenin associates with CDH11 in DD and if IGF-II can induce CDH11 expression in a β-
catenin-dependent manner.  
5.6 Toward novel therapeutic interventions in 
Dupuytren’s Disease 
In contrast to its well-established roles in fetal and tumour development, very little is 
known about IGF-II in the context of fibrosis. IGF-II signalling has been shown to induce 
collagen expression in systemic sclerosis-associated pulmonary fibrosis [57] and future 
studies should focus on determining if IGF-II plays a similar role during DD 
development.  Excessive collagen induction is a hallmark of DD, as it is of most other 
fibroproliferative disorders [58–60]. While the findings reported in this thesis support 
distinct roles for IGF-II in promoting fibroblast migration and myofibroblast contraction 
in DD, it is important that future studies assess the combinatorial roles of IGF-II with 
other growth factors and cytokines that contribute to the DD microenvironment. The 
suppression of IGF-II signalling may help to ameliorate DD severity or recurrence, but it 
is unlikely that inhibition of IGF-II signalling in isolation will be sufficient. Therapeutic 
interventions that increase endogenous IGFBP-6 levels, such as bexarotene, may inhibit 
fibro-proliferation through IGF-II dependent and IGF-II independent mechanisms and be 
more effective than targeting IGF-II alone. However, the most effective therapeutic 
approach may be to inhibit fibroproliferation by attenuating β-catenin-mediated trans-
regulation of gene transcription in DD.  
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Resveratrol (3,4’,5-trihydroxystilbene) is a natural phytoalexin which has been 
demonstrated to decrease survival of colorectal cancer and Wnt-stimulated cells. Its 
mechanism of action appears to be dependent on inhibiting β-catenin interaction with 
TCF3, thereby suppressing the expression of c-Myc, Axin2 and cyclin D1 and potentially 
other targets of the Wnt signalling pathway [61]. Additionally, Nefopam (5-methyl-1-
phenyl-1,3,4,6-tetrahydro-2,5-benzoxazocine) has recently been identified as having 
utility in reducing β-catenin levels in aggressive fibromatosis. This drug can inhibit 
proliferation of fibroblasts derived from aggressive fibromatosis and hypertrophic scars 
without discernible effects on control cells, and has been shown to reduce scar size in 
vivo [62]. It may be possible to combine multiple treatments to target both the IGF-II and 
β-catenin signalling pathways in Dupuytren’s Disease to inhibit disease progression 
and/or recurrence.  It is hoped that the findings presented in this thesis will provide an 
incremental advance in our knowledge of the pathophysiology of DD and facilitate the 
development of more effective therapeutic interventions for these patients.   
  
129 
 
 
 
5.7 References 
[1] H. Denys, A. Jadidizadeh, S. Amini Nik, K. Van Dam, S. Aerts, B. a Alman, J.-J. 
Cassiman, S. Tejpar, Identification of IGFBP-6 as a significantly downregulated 
gene by beta-catenin in desmoid tumors, Oncogene, 23 (2004) 654–64. 
[2] O.G. Morali, V. Delmas, R. Moore, C. Jeanney, J.P. Thiery, L. Larue, IGF-II 
induces rapid beta-catenin relocation to the nucleus during epithelium to 
mesenchyme transition, Oncogene, 20 (2001) 4942–50. 
[3] L. Vi, A. Njarlangattil, Y. Wu, B.S. Gan, D.B. O’Gorman, Type-1 Collagen 
differentially alters beta-catenin accumulation in primary Dupuytren’s Disease 
cord and adjacent palmar fascia cells, BMC Musculoskelet. Disord., 10 (2009) 72. 
[4] V.M. Varallo, B.S. Gan, S. Seney, D.C. Ross, J.H. Roth, R.S. Richards, R.M. 
McFarlane, B. Alman, J.C. Howard, Beta-catenin expression in Dupuytren’s 
disease: potential role for cell-matrix interactions in modulating beta-catenin levels 
in vivo and in vitro, Oncogene, 22 (2003) 3680–4. 
[5] K.G. Gudmundsson, R. Arngrímsson, N. Sigfússon, T. Jónsson, Increased total 
mortality and cancer mortality in men with Dupuytren’s disease: a 15-year follow-
up study, J. Clin. Epidemiol., 55 (2002) 5–10. 
[6] S. Wilbrand, A. Ekbom, B. Gerdin, Cancer incidence in patients treated surgically 
for Dupuytren’s contracture, J. Hand Surg. Br., 25 (2000) 283–7. 
[7] S. Wilbrand, A. Ekbom, B. Gerdin, Dupuytren’s contracture and sarcoma, J. Hand 
Surg. Br., 27B (2002) 50–2. 
[8] M. Schäfer, S. Werner, Cancer as an overhealing wound: an old hypothesis 
revisited, Nat. Rev. Mol. Cell Biol., 9 (2008) 628–38. 
[9] M.C. Wallace, S.L. Friedman, Hepatic fibrosis and the microenvironment: fertile 
soil for hepatocellular carcinoma development, Gene Expr., 16 (2014) 77–84. 
[10] G.M. Stella, S. Inghilleri, Y. Pignochino, M. Zorzetto, T. Oggionni, P. Morbini, M. 
Luisetti, Activation of Oncogenic Pathways in Idiopathic Pulmonary Fibrosis, 
Transl. Oncol., xx (2014) 1–6. 
[11] G. Kharaishvili, D. Simkova, K. Bouchalova, M. Gachechiladze, N. Narsia, J. 
Bouchal, The role of cancer-associated fibroblasts, solid stress and other 
microenvironmental factors in tumor progression and therapy resistance, Cancer 
Cell Int., 14 (2014) 41. 
[12] V. Seewaldt, ECM stiffness paves the way for tumor cells, Nat. Med., 20 (2014) 
332–3. 
130 
 
 
 
[13] A. Pathak, S. Kumar, Transforming potential and matrix stiffness co-regulate 
confinement sensitivity of tumor cell migration, Integr. Biol. (Camb)., 5 (2013) 
1067–75. 
[14] B. Hinz, Tissue stiffness, latent TGF-beta1 Activation, and mechanical signal 
transduction: Implications for the pathogenesis and treatment of fibrosis, Curr. 
Rheumatol. Rep., 11 (2009) 120–126. 
[15] O. Ogawa, M.R. Eccles, J. Szeto, L.A. McNoe, K. Yun, M.A. Maw, P.J. Smith, 
A.E. Reeve, Relaxation of insulin-like growth factor II gene imprinting implicated 
in Wilms’ tumour, Nature, 362 (1993) 749–51. 
[16] I. Grbesa, M. Ivkic, B. Pegan, K. Gall-Troselj, Loss of imprinting and promoter 
usage of the IGF2 in laryngeal squamous cell carcinoma, Cancer Lett., 238 (2006) 
224–9. 
[17] S. Rainier, C.J. Dobry, A.P. Feinberg, Loss of imprinting in hepatoblastoma, 
Cancer Res., 55 (1995) 1836–1838. 
[18] R. Weksberg, D.R. Shen, Y.L. Fei, Q.L. Song, J. Squire, Disruption of insulin-like 
growth factor 2 imprinting in Beckwith-Wiedemann syndrome, Nat. Genet., 5 
(1993) 143–50. 
[19] M. Cruz-Correa, R. Zhao, M. Oviedo, R.D. Bernabe, M. Lacourt, A. Cardona, R. 
Lopez-Enriquez, S. Wexner, C. Cuffari, L. Hylind, E. Platz, H. Cui, A.P. Feinberg, 
F.M. Giardiello, Temporal stability and age-related prevalence of loss of 
imprinting of the insulin-like growth factor-2 gene, Epigenetics, 4 (2009) 114–8. 
[20] Y. Yu, C.-H. Xiao, L.-D. Tan, Q.-S. Wang, X.-Q. Li, Y.-M. Feng, Cancer-
associated fibroblasts induce epithelial-mesenchymal transition of breast cancer 
cells through paracrine TGF-β signalling, Br. J. Cancer, 110 (2014) 724–32. 
[21] J.C. Porretti, N. a Mohamad, G. a Martín, G.P. Cricco, Fibroblasts induce 
epithelial to mesenchymal transition in breast tumor cells which is prevented by 
fibroblasts treatment with histamine in high concentration, Int. J. Biochem. Cell 
Biol., 51 (2014) 29–38. 
[22] V. Stemmer, B. de Craene, G. Berx, J. Behrens, Snail promotes Wnt target gene 
expression and interacts with beta-catenin, Oncogene, 27 (2008) 5075–5080. 
[23] J. Duan, C. Gherghe, D. Liu, E. Hamlett, L. Srikantha, L. Rodgers, J.N. Regan, M. 
Rojas, M. Willis, A. Leask, M. Majesky, A. Deb, Wnt1/βcatenin injury response 
activates the epicardium and cardiac fibroblasts to promote cardiac repair, EMBO 
J., 31 (2012) 429–42. 
[24] S.-Y. Shin, O. Rath, A. Zebisch, S.-M. Choo, W. Kolch, K.-H. Cho, Functional 
roles of multiple feedback loops in extracellular signal-regulated kinase and Wnt 
131 
 
 
 
signalling pathways that regulate epithelial-mesenchymal transition, Cancer Res., 
70 (2010) 6715–6724. 
[25] J. Zavadil, L. Cermak, N. Soto-Nieves, E.P. Böttinger, Integration of TGF-
beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition, 
EMBO J., 23 (2004) 1155–1165. 
[26] M. Davies, M. Robinson, E. Smith, S. Huntley, S. Prime, I. Paterson, Induction of 
an epithelial to mesenchymal transition in human immortal and malignant 
keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signalling pathways, 
J. Cell. Biochem., 95 (2005) 918–931. 
[27] A. Eger, A. Stockinger, J. Park, E. Langkopf, M. Mikula, J. Gotzmann, W. 
Mikulits, H. Beug, R. Foisner, beta-Catenin and TGFbeta signalling cooperate to 
maintain a mesenchymal phenotype after FosER-induced epithelial to 
mesenchymal transition, Oncogene, 23 (2004) 2672–2680. 
[28] M. Grände, A. Franzen, J.-O. Karlsson, L.E. Ericson, N.-E. Heldin, M. Nilsson, 
Transforming growth factor-beta and epidermal growth factor synergistically 
stimulate epithelial to mesenchymal transition (EMT) through a MEK-dependent 
mechanism in primary cultured pig thyrocytes, J. Cell Sci., 115 (2002) 4227–4236. 
[29] M.L. Labat, G. Milhaud, M. Pouchelet, P. Boireau, On the track of a human 
circulating mesenchymal stem cell of neural crest origin, Biomed. Pharmacother., 
54 (2000) 146–62. 
[30] S.A. Iqbal, C. Manning, F. Syed, V. Kolluru, M. Hayton, S. Watson, A. Bayat, 
Identification of Mesenchymal Stem Cells in Perinodular Fat and Skin in 
Dupuytren’s Disease: A Potential Source of Myofibroblasts with Implications for 
Pathogenesis and Therapy, Stem Cells Dev., 21 (2012) 609–622. 
[31] S. Hindocha, S.A. Iqbal, S. Farhatullah, R. Paus, A. Bayat, Characterization of 
stem cells in Dupuytren’s disease, Br. J. Surg., 98 (2011) 308–315. 
[32] B. Hinz, S.H. Phan, V.J. Thannickal, A. Galli, M.-L. Bochaton-Piallat, G. 
Gabbiani, The myofibroblast: one function, multiple origins, Am. J. Pathol., 170 
(2007) 1807–1816. 
[33] H. Nakagawa, S. Akita, M. Fukui, T. Fujii, K. Akino, Human mesenchymal stem 
cells successfully improve skin-substitute wound healing, Br. J. Dermatol., 153 
(2005) 29–36. 
[34] S. Maxson, E. a Lopez, D. Yoo, A. Danilkovitch-Miagkova, M. a Leroux, Concise 
review: role of mesenchymal stem cells in wound repair, Stem Cells Transl. Med., 
1 (2012) 142–9. 
[35] J. Cha, V. Falanga, Stem cells in cutaneous wound healing, Clin. Dermatol., 25 
(2007) 73–8. 
132 
 
 
 
[36] M. Kapoor, S. Liu, K. Huh, S. Parapuram, L. Kennedy, A. Leask, Connective 
tissue growth factor promoter activity in normal and wounded skin, Fibrogenesis 
Tissue Repair, 1 (2008) 3. 
[37] S. Liu, R. Taghavi, A. Leask, Connective tissue growth factor is induced in 
bleomycin-induced skin scleroderma, J. Cell Commun. Signal., 4 (2010) 25–30. 
[38] I.P. Uray, Q. Shen, H.-S. Seo, H. Kim, W.W. Lamph, R.P. Bissonnette, P.H. 
Brown, Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent 
permissive cooperation of retinoid receptors and AP-1, J. Biol. Chem., 284 (2009) 
345–53. 
[39] M. Duvic, K. Hymes, P. Heald, D. Breneman, a G. Martin, P. Myskowski, C. 
Crowley, R.C. Yocum, Bexarotene is effective and safe for treatment of refractory 
advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results, 
J. Clin. Oncol., 19 (2001) 2456–71. 
[40] W.-C. Yen, W.W. Lamph, A selective retinoid X receptor agonist bexarotene 
(LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced 
prostate cancer, Prostate, 66 (2006) 305–16. 
[41] W. Yen, W.W. Lamph, The selective retinoid X receptor agonist bexarotene 
(LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced 
breast carcinoma, Mol. Cancer Ther., 4 (2005) 824–34. 
[42] G. Aicardi, New hope from an old drug: fighting Alzheimer’s disease with the 
cancer drug bexarotene (targretin)?, Rejuvenation Res., 16 (2013) 524–8. 
[43] K. McFarland, T. a Spalding, D. Hubbard, J.-N. Ma, R. Olsson, E.S. Burstein, Low 
dose bexarotene treatment rescues dopamine neurons and restores behavioral 
function in models of Parkinson’s disease, ACS Chem. Neurosci., 4 (2013) 1430–
8. 
[44] H.-T. Kim, G. Kong, D. Denardo, Y. Li, I. Uray, S. Pal, S. Mohsin, S.G. 
Hilsenbeck, R. Bissonnette, W.W. Lamph, K. Johnson, P.H. Brown, Identification 
of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast 
cells using oligonucleotide arrays, Cancer Res., 66 (2006) 12009–18. 
[45] Y. Li, Q. Shen, H.-T. Kim, R.P. Bissonnette, W.W. Lamph, B. Yan, P.H. Brown, 
The rexinoid bexarotene represses cyclin D1 transcription by inducing the DEC2 
transcriptional repressor, Breast Cancer Res. Treat., 128 (2011) 667–77. 
[46] S. Kasamaki, K. Suda, T. Kamano, T. Kumasaka, T. Ochiai, Y. Haraguchi, COX-
2+ myofibroblasts may play a key role in marked stromal fibrosis in strictured 
colorectal carcinomas, Histopathology, 44 (2004) 445–52. 
[47] S. Sae-Jung, K. Jirarattanaphochai, Prevention of peridural fibrosis using a 
cyclooxygenase-2 inhibitor (nonsteroidal anti-inflammatory drug) soaked in 
133 
 
 
 
absorbable gelatin sponge: an experimental comparative animal model, Spine 
(Phila. Pa. 1976)., 38 (2013) E985–91. 
[48] F. Grinnell, W.M. Petroll, Cell motility and mechanics in three-dimensional 
collagen matrices, Annu. Rev. Cell Dev. Biol., 26 (2010) 335–61. 
[49] F. Grinnell, C.H. Ho, Y.C. Lin, G. Skuta, Differences in the regulation of 
fibroblast contraction of floating versus stressed collagen matrices, J. Biol. Chem., 
274 (1999) 918–23. 
[50] X. Zhao, J.-L. Guan, Focal adhesion kinase and its signalling pathways in cell 
migration and angiogenesis, Adv. Drug Deliv. Rev., 63 (2011) 610–5. 
[51] D.D. Schlaepfer, C.R. Hauck, D.J. Sieg, Signalling through focal adhesion kinase, 
Prog. Biophys. Mol. Biol., 71 (1999) 435–78. 
[52] S. Andersson, P. D’Arcy, O. Larsson, B. Sehat, Focal adhesion kinase (FAK) 
activates and stabilizes IGF-1 receptor, Biochem. Biophys. Res. Commun., 387 
(2009) 36–41. 
[53] P. a Kiely, G.S. Baillie, R. Barrett, D. a Buckley, D.R. Adams, M.D. Houslay, R. 
O’Connor, Phosphorylation of RACK1 on tyrosine 52 by c-Abl is required for 
insulin-like growth factor I-mediated regulation of focal adhesion kinase, J. Biol. 
Chem., 284 (2009) 20263–74. 
[54] P. a Kiely, D. O’Gorman, K. Luong, D. Ron, R. O’Connor, Insulin-like growth 
factor I controls a mutually exclusive association of RACK1 with protein 
phosphatase 2A and beta1 integrin to promote cell migration, Mol. Cell. Biol., 26 
(2006) 4041–51. 
[55] B. Hinz, P. Pittet, J. Smith-Clerc, C. Chaponnier, J.-J. Meister, Myofibroblast 
development is characterized by specific cell-cell adherens junctions, Mol. Biol. 
Cell, 15 (2004) 4310–20. 
[56] A.K. Farina, Y.-S. Bong, C.M. Feltes, S.W. Byers, Post-transcriptional regulation 
of cadherin-11 expression by GSK-3 and beta-catenin in prostate and breast cancer 
cells, PLoS One, 4 (2009) e4797. 
[57] E. Hsu, C. a Feghali-Bostwick, Insulin-like growth factor-II is increased in 
systemic sclerosis-associated pulmonary fibrosis and contributes to the fibrotic 
process via Jun N-terminal kinase- and phosphatidylinositol-3 kinase-dependent 
pathways, Am. J. Pathol., 172 (2008) 1580–90. 
[58] T.A. Wynn, Common and unique mechanisms regulate fibrosis in various 
fibroproliferative diseases, J. Clin. Invest., 117 (2007) 524–9. 
[59] J.D. Saar, P.C. Grothaus, Dupuytren’s disease: an overview, Plast. Reconstr. Surg., 
106 (2000) 125–34; quiz 135–6. 
134 
 
 
 
[60] S. Rehman, F. Salway, J.K. Stanley, W.E.R. Ollier, P. Day, A. Bayat, Molecular 
phenotypic descriptors of Dupuytren’s disease defined using informatics analysis 
of the transcriptome, J. Hand Surg. Am., 33 (2008) 359–72. 
[61] H.-J. Chen, L.-S. Hsu, Y.-T. Shia, M.-W. Lin, C.-M. Lin, The β-catenin/TCF 
complex as a novel target of resveratrol in the Wnt/β-catenin signalling pathway, 
Biochem. Pharmacol., 84 (2012) 1143–53. 
[62] R. Poon, H. Hong, X. Wei, J. Pan, B. a Alman, A high throughput screen identifies 
Nefopam as targeting cell proliferation in β-catenin driven neoplastic and reactive 
fibroproliferative disorders, PLoS One, 7 (2012) e37940.  
 
 
 
 
135 
 
 
 
Appendices 
Appendix A: License to use figure from Bowley et al. 2007 
 
 
136 
 
 
 
Appendix B: Creative Commons License allowing use of figure from Rehman et al. 
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Appendix C: Western University Research Ethics Board for Health Sciences 
Research involving Human Subjects (HSREB protocol # 08222E) 
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Appendix D: PERL script used to process raw ChIP Seq data and align to genome 
 
for d in $( ls ./ | grep _lib ); do 
 echo $d 
 mkdir md5 
 mv $d/*.md5 md5/ 
 for f in $( ls $d/ | grep -v md5 | grep fastq ); do 
  echo $d/$f 
  gunzip $d/$f 
 done 
done  
 
for f in $( ls ./ | grep fastq ); do 
 echo $f 
 cat $f >> $SAMPLE.all.fastq 
  
 echo "removing $f" 
 rm $f 
done  
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Appendix E: PERL Script used to map common peaks back to human genome 
#!/usr/bin/env perl -w 
use strict; 
 
#open the sorted bed file and create an array 
#of positions for a chromosome (specified on the command line) 
#containing accesssion numbers 
 
#ARGV[0] is sorted bed file 
#ARGV[1] is the chromosome 
#ARGV[2] is the filtered file 
print "to run:\n./merge_tabular_bed_efficient.pl 
../Downloads/Galaxy47-\[Sorted_RefSeq_Upstream_50kb\].bed 
../Downloads/Galaxy147-\[Filter_on_data_145\].tabular chr1 > 
test_chr1.txt \n" if ! $ARGV[0]; 
exit if ! $ARGV[0]; 
#print out accession for start and stop positions in filtered 
file 
my @start = my @stop; my %id; 
open (IN, "< $ARGV[0]") or die; 
 while(my $l = <IN>){ 
  my @l = split/\t/, $l; 
  chomp $l; 
  if ($l[0] eq$ARGV[2]){ 
   push @start, $l[1]; 
   push @stop, $l[2]; 
   my @nm = split/_/, $l[3]; 
   $id{$l[1]} = $nm[0] . "_$nm[1]";  
  } 
 } 
close IN; 
 
my %seen; 
open (IN, "< $ARGV[1]") or die; 
 while(my $l = <IN>){ 
  chomp $l; 
  my @l = split/\t/, $l; 
  if ($l[0] eq $ARGV[2]){ 
   for (my $i=0; $i < @start; $i++){ 
    if ($l[1] >= $start[$i] && $l[2] <= 
$stop[$i]){ 
 
    print "$id{$start[$i]}\n" if !defined 
$seen{$start[$i]}; 
    $seen{$start[$i]} = ""; 
      
    } 
   } 
  } 
 } 
close IN; 
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Appendix F: Select β-catenin associations within intronic regions of a gene in PF 
cells, but not corresponding DD cells 
RefSeq 
Accession 
Number 
Gene 
Symbol 
Gene Description 
Chromosomal 
Location 
NC_000005.10 
ADAMTS
19 
ADAM metallopeptidase with thrombospondin type 1 
motif, 19 
5q23.3 
NC_000012.12 
ADAMTS
20 
ADAM metallopeptidase with thrombospondin type 1 
motif, 20 
12q12 
NC_000007.14 ADCY1 adenylate cyclase 1 (brain) 7p13-p12 
NC_000008.11 ADCY8 adenylate cyclase 8 (brain) 8q24 
NC_000005.10 AFAP1L1 actin filament associated protein 1-like 1 5q32 
NC_000015.10 APBA2 
amyloid beta (A4) precursor protein-binding, family A, 
member 2 
15q11-q12 
NC_000004.12 APBB2 
amyloid beta (A4) precursor protein-binding, family B, 
member 2 
4p13 
NC_000004.12 
ARHGEF3
8 
Rho guanine nucleotide exchange factor (GEF) 38 4q24 
NC_000010.11 ARMC3 armadillo repeat containing 3 10p12.31 
NC_000002.12 BMP10 bone morphogenetic protein 10 2p13.3 
NC_000020.11 BMP7 bone morphogenetic protein 7 20q13 
NC_000009.12 
CACNA1
B 
calcium channel, voltage-dependent, N type, alpha 1B 
subunit 
9q34 
NC_000003.12 
CACNA1
D 
calcium channel, voltage-dependent, L type, alpha 1D 
subunit 
3p14.3 
NC_000003.12 CADM2 cell adhesion molecule 2 3p12.1 
NC_000012.12 CD163L1 CD163 molecule-like 1 12p13.3 
NC_000001.11 CD247 CD247 molecule 1q24.2 
NC_000001.11 CD48 CD48 molecule 1q21.3-q22 
NC_000005.10 CDH12 cadherin 12, type 2 (N-cadherin 2) 5p14.3 
NC_000016.10 CDH13 cadherin 13 16q23.3 
NC_000020.11 CDH4 cadherin 4, type 1, R-cadherin (retinal) 20q13.3 
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NC_000003.12 CNTN4 contactin 4 3p26.3 
NC_000011.10 CNTN5 contactin 5 11q22.1 
NC_000006.12 COL19A1 collagen, type XIX, alpha 1 6q12-q13 
NC_000007.14 COL26A1 collagen, type XXVI, alpha 1 7q22.1 
NC_000002.12 CTNNA2 catenin (cadherin-associated protein), alpha 2 2p12-p11.1 
NC_000010.11 CTNNA3 catenin (cadherin-associated protein), alpha 3 10q22.2 
NC_000007.14 EGFR epidermal growth factor receptor 7p12 
NC_000022.11 FAM19A5 
family with sequence similarity 19 (chemokine (C-C 
motif)-like), member A5 
22q13.32 
NC_000009.12 FAM219A family with sequence similarity 219, member A 9p13.3 
NC_000013.11 FGF14 fibroblast growth factor 14 13q34 
NC_000007.14 FOXP2 forkhead box P2 7q31 
NC_000002.12 GPR155 G protein-coupled receptor 155 2q31.1 
NC_000007.14 GPR37 
G protein-coupled receptor 37 (endothelin receptor 
type B-like) 
7q31 
NC_000011.10 GRIK4 glutamate receptor, ionotropic, kainate 4 11q22.3 
NC_000012.12 GRIP1 glutamate receptor interacting protein 1 12q14.3 
NC_000006.12 GRM1 glutamate receptor, metabotropic 1 6q24 
NC_000001.11 HHAT hedgehog acyltransferase 1q32 
NC_000009.12 JAK2 Janus kinase 2 9p24 
NC_000018.10 LAMA3 laminin, alpha 3 18q11.2 
NC_000011.10 METTL15 methyltransferase like 15 11p14.1 
NC_000016.10 
MIR3680-
2 
microRNA 3680-2 
 
NC_000023.11 MIR548F5 microRNA 548f-5 Xp21.1 
NC_000015.10 MYO1E myosin IE 15q21-q22 
NC_000002.12 MYO3B myosin IIIB 2q31.1-q31.2 
NC_000010.11 PCDH15 protocadherin-related 15 10q21.1 
NC_000005.10 PCDHA1 protocadherin alpha 1 5q31 
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NC_000005.10 PCDHA10 protocadherin alpha 10 5q31 
NC_000005.10 PCDHA11 protocadherin alpha 11 5q31 
NC_000005.10 PCDHA12 protocadherin alpha 12 5q31 
NC_000005.10 PCDHA13 protocadherin alpha 13 5q31 
NC_000005.10 PCDHA2 protocadherin alpha 2 5q31 
NC_000005.10 PCDHA3 protocadherin alpha 3 5q31 
NC_000005.10 PCDHA4 protocadherin alpha 4 5q31 
NC_000005.10 PCDHA5 protocadherin alpha 5 5q31 
NC_000005.10 PCDHA6 protocadherin alpha 6 5q31 
NC_000005.10 PCDHA7 protocadherin alpha 7 5q31 
NC_000005.10 PCDHA8 protocadherin alpha 8 5q31 
NC_000005.10 PCDHA9 protocadherin alpha 9 5q31 
NC_000006.12 PKIB 
protein kinase (cAMP-dependent, catalytic) inhibitor 
beta 
6q22.31 
NC_000006.12 PLG plasminogen 6q26 
NC_000007.14 RELN reelin 7q22 
NC_000009.12 SLC24A2 
solute carrier family 24 (sodium/potassium/calcium 
exchanger), member 2 
9p22.1 
NC_000002.12 SLC25A12 
solute carrier family 25 (aspartate/glutamate carrier), 
member 12 
2q24 
NC_000008.11 SLC30A8 solute carrier family 30 (zinc transporter), member 8 8q24.11 
NC_000002.12 SP3 Sp3 transcription factor 2q31 
NC_000019.10 ZNF431 zinc finger protein 431 19p12 
NC_000007.14 ZNF716 zinc finger protein 716 7p11.2 
NC_000007.14 ZNF804B zinc finger protein 804B 7q21.13 
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Appendix G: Select β-catenin associations within intronic regions of a gene in DD 
cells, but not corresponding PF cells 
RefSeq 
Accession 
Number 
Gene 
Symbol 
Gene Description 
Chromosomal 
Location 
NC_000008.11 ADAM18 ADAM metallopeptidase domain 18 8p11.22 
NC_000008.11 ADAM2 ADAM metallopeptidase domain 2 8p11.2 
NC_000007.14 ADAM22 ADAM metallopeptidase domain 22 7q21 
NC_000002.12 ADAM23 ADAM metallopeptidase domain 23 2q33 
NC_000008.11 ADAM28 ADAM metallopeptidase domain 28 8p21.2 
NC_000004.12 ADAM29 ADAM metallopeptidase domain 29 4q34 
NC_000008.11 ADAM32 ADAM metallopeptidase domain 32 8p11.22 
NC_000008.11 ADAM5 ADAM metallopeptidase domain 5, pseudogene 8p11.22 
NC_000005.10 
ADAMTS
16 
ADAM metallopeptidase with thrombospondin type 1 
motif, 16 
5p15 
NC_000016.10 
ADAMTS
18 
ADAM metallopeptidase with thrombospondin type 1 
motif, 18 
16q23 
NC_000005.10 
ADAMTS
19 
ADAM metallopeptidase with thrombospondin type 1 
motif, 19 
5q23.3 
NC_000007.14 ADCY1 adenylate cyclase 1 (brain) 7p13-p12 
NC_000005.10 ADCY2 adenylate cyclase 2 (brain) 5p15.3 
NC_000002.12 ADD2 adducin 2 (beta) 2p13.3 
NC_000008.11 ADRA1A adrenoceptor alpha 1A 8p21.2 
NC_000002.12 ALK anaplastic lymphoma receptor tyrosine kinase 2p23 
NC_000015.10 APBA2 
amyloid beta (A4) precursor protein-binding, family A, 
member 2 
15q11-q12 
NC_000018.10 APCDD1 adenomatosis polyposis coli down-regulated 1 18p11.22 
NC_000002.12 ARHGEF4 Rho guanine nucleotide exchange factor (GEF) 4 2q22 
NC_000010.11 ARMC3 armadillo repeat containing 3 10p12.31 
NC_000010.11 ARMC4 armadillo repeat containing 4 10p12.1-p11.23 
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NC_000006.12 BAI3 brain-specific angiogenesis inhibitor 3 6q12 
NC_000020.11 BMP7 bone morphogenetic protein 7 20q13 
NC_000001.11 BRINP3 
bone morphogenetic protein/retinoic acid inducible 
neural-specific 3 
1q31.1 
NC_000003.12 CADM2 cell adhesion molecule 2 3p12.1 
NC_000018.10 
CCDC102
B 
coiled-coil domain containing 102B 18q22.1 
NC_000018.10 CCDC11 coiled-coil domain containing 11 18q21.1 
NC_000001.11 CD244 CD244 molecule, natural killer cell receptor 2B4 1q23.3 
NC_000001.11 CD247 CD247 molecule 1q24.2 
NC_000002.12 CD302 CD302 molecule 2q24.2 
NC_000011.10 CD3E CD3e molecule, epsilon (CD3-TCR complex) 11q23 
NC_000003.12 CD86 CD86 molecule 3q21 
NC_000003.12 CD96 CD96 molecule 3q13.13-q13.2 
NC_000005.10 CDH12 cadherin 12, type 2 (N-cadherin 2) 5p14.3 
NC_000016.10 CDH13 cadherin 13 16q23.3 
NC_000005.10 CDH18 cadherin 18, type 2 5p14.3 
NC_000018.10 CDH19 cadherin 19, type 2 18q22.1 
NC_000020.11 CDH4 cadherin 4, type 1, R-cadherin (retinal) 20q13.3 
NC_000018.10 CDH7 cadherin 7, type 2 18q22.1 
NC_000016.10 CDH8 cadherin 8, type 2 16q22.1 
NC_000013.11 CDK8 cyclin-dependent kinase 8 13q12 
NC_000001.11 CHRM3 cholinergic receptor, muscarinic 3 1q43 
NC_000015.10 CHRNA7 cholinergic receptor, nicotinic, alpha 7 (neuronal) 15q14 
NC_000006.12 COL19A1 collagen, type XIX, alpha 1 6q12-q13 
NC_000008.11 COL22A1 collagen, type XXII, alpha 1 8q24.3 
NC_000005.10 COL23A1 collagen, type XXIII, alpha 1 5q35.3 
NC_000007.14 COL28A1 collagen, type XXVIII, alpha 1 7p21.3 
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NC_000002.12 COL4A4 collagen, type IV, alpha 4 2q35-q37 
NC_000003.12 COL6A5 collagen, type VI, alpha 5 3q22.1 
NC_000006.12 COL9A1 collagen, type IX, alpha 1 6q13 
NC_000002.12 CTNNA2 catenin (cadherin-associated protein), alpha 2 2p12-p11.1 
NC_000010.11 CTNNA3 catenin (cadherin-associated protein), alpha 3 10q22.2 
NC_000005.10 CTNND2 catenin (cadherin-associated protein), delta 2 5p15.2 
NC_000011.10 DRD2 dopamine receptor D2 11q23 
NC_000014.9 ESRRB estrogen-related receptor beta 14q24.3 
NC_000001.11 ESRRG estrogen-related receptor gamma 1q41 
NC_000015.10 
FAM189A
1 
family with sequence similarity 189, member A1 15q13.1 
NC_000003.12 FAM19A1 
family with sequence similarity 19 (chemokine (C-C 
motif)-like), member A1 
3p14.1 
NC_000003.12 FGF12 fibroblast growth factor 12 3q28 
NC_000013.11 FGF14 fibroblast growth factor 14 13q34 
NC_000004.12 GABRA2 gamma-aminobutyric acid (GABA) A receptor, alpha 2 4p12 
NC_000015.10 GABRA5 gamma-aminobutyric acid (GABA) A receptor, alpha 5 15q12 
NC_000004.12 GABRB1 gamma-aminobutyric acid (GABA) A receptor, beta 1 4p12 
NC_000001.11 GBP7 guanylate binding protein 7 1p22.2 
NC_000005.10 GHR growth hormone receptor 5p13-p12 
NC_000010.11 GPR158 G protein-coupled receptor 158 10p12.1 
NC_000005.10 GPR98 G protein-coupled receptor 98 5q13 
NC_000011.10 GRIA4 glutamate receptor, ionotropic, AMPA 4 11q22 
NC_000010.11 GRID1 glutamate receptor, ionotropic, delta 1 10q22 
NC_000011.10 GRIK4 glutamate receptor, ionotropic, kainate 4 11q22.3 
NC_000016.10 GRIN2A 
glutamate receptor, ionotropic, N-methyl D-aspartate 
2A 
16p13.2 
NC_000001.11 HHAT hedgehog acyltransferase 1q32 
NC_000004.12 HHIP hedgehog interacting protein 4q28-q32 
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NC_000004.12 IL15 interleukin 15 4q31 
NC_000001.11 IL23R interleukin 23 receptor 1p31.3 
NC_000002.12 IL36B interleukin 36, beta 2q14 
NC_000002.12 ITGA4 
integrin, alpha 4 (antigen CD49D, alpha 4 subunit of 
VLA-4 receptor) 
2q31.3 
NC_000016.10 ITGAD integrin, alpha D 16p11.2 
NC_000009.12 KGFLP2 keratinocyte growth factor-like protein 2 9p12 
NC_000006.12 LPA lipoprotein, Lp(a) 6q26 
NC_000001.11 LRRC52 leucine rich repeat containing 52 1q24.1 
NC_000014.9 LRRC74 leucine rich repeat containing 74 14q24.3 
NC_000017.11 MAP2K4 mitogen-activated protein kinase kinase 4 17p12 
NC_000015.10 MAP2K5 mitogen-activated protein kinase kinase 5 15q23 
NC_000017.11 MAP2K6 mitogen-activated protein kinase kinase 6 17q24.3 
NC_000019.10 MBD3L2 methyl-CpG binding domain protein 3-like 2 19p13.2 
NC_000012.12 METTL25 methyltransferase like 25 12q21.31 
NC_000010.11 MGMT O-6-methylguanine-DNA methyltransferase 10q26 
NC_000023.11 MIR548I4 microRNA 548i-4 Xq21.1 
NC_000007.14 MIR548N microRNA 548n 7p14.3 
NC_000004.12 MIR548T microRNA 548t 
 
NC_000016.10 MIR548W microRNA 548w 
 
NC_000007.14 
MIR5692
A1 
microRNA 5692a-1 
 
NC_000014.9 MIR5694 microRNA 5694 
 
NC_000006.12 MYLK4 myosin light chain kinase family, member 4 6p25.2 
NC_000013.11 MYO16 myosin XVI 13q33.3 
NC_000022.11 MYO18B myosin XVIIIB 22q12.1 
NC_000010.11 MYO3A myosin IIIA 10p11.1 
NC_000011.10 NCAM1 neural cell adhesion molecule 1 11q23.1 
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NC_000021.9 NCAM2 neural cell adhesion molecule 2 21q21.1 
NC_000001.11 NEGR1 neuronal growth regulator 1 1p31.1 
NC_000008.11 NRG1 neuregulin 1 8p12 
NC_000010.11 NRG3 neuregulin 3 10q22-q23 
NC_000020.11 PAK7 p21 protein (Cdc42/Rac)-activated kinase 7 20p12 
NC_000010.11 PCDH15 protocadherin-related 15 10q21.1 
NC_000013.11 PCDH9 protocadherin 9 13q21.32 
NC_000016.10 PRKCB protein kinase C, beta 16p11.2 
NC_000001.11 PTGER3 prostaglandin E receptor 3 (subtype EP3) 1p31.2 
NC_000002.12 RAPGEF4 Rap guanine nucleotide exchange factor (GEF) 4 2q31-q32 
NC_000007.14 RAPGEF5 Rap guanine nucleotide exchange factor (GEF) 5 7p15.3 
NC_000007.14 RELN reelin 7q22 
NC_000020.11 SLC24A3 
solute carrier family 24 (sodium/potassium/calcium 
exchanger), member 3 
20p13 
NC_000014.9 SLC25A21 
solute carrier family 25 (mitochondrial oxoadipate 
carrier), member 21 
14q11.2 
NC_000003.12 SLC25A26 
solute carrier family 25 (S-adenosylmethionine 
carrier), member 26 
3p14.1 
NC_000012.12 SLC2A13 
solute carrier family 2 (facilitated glucose transporter), 
member 13 
12q12 
NC_000004.12 SLC2A9 
solute carrier family 2 (facilitated glucose transporter), 
member 9 
4p16.1 
NC_000008.11 SLC30A8 solute carrier family 30 (zinc transporter), member 8 8q24.11 
NC_000013.11 SMAD9 SMAD family member 9 13q12-q14 
NC_000012.12 SOX5 SRY (sex determining region Y)-box 5 12p12.1 
NC_000007.14 SP4 Sp4 transcription factor 7p15.3 
NC_000011.10 SPON1 spondin 1, extracellular matrix protein 11p15.2 
NC_000006.12 TFAP2B 
transcription factor AP-2 beta (activating enhancer 
binding protein 2 beta) 
6p12 
NC_000002.12 TFCP2L1 transcription factor CP2-like 1 2q14 
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NC_000002.12 TGFA transforming growth factor, alpha 2p13 
NC_000001.11 TNFSF4 tumor necrosis factor (ligand) superfamily, member 4 1q25 
NC_000001.11 WLS wntless Wnt ligand secretion mediator 1p31.3 
NC_000008.11 ZFAT zinc finger and AT hook domain containing 8q24.22 
NC_000008.11 ZMAT4 zinc finger, matrin-type 4 8p11.21 
NC_000007.14 ZNF277 zinc finger protein 277 7q31.1 
NC_000019.10 ZNF28 zinc finger protein 28 19q13.41 
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